The role of heparan sulfates in fibroblast growth factor action by Brown, Kathryn
The Role of Heparan Sulfates in Fibroblast 
Growth Factor Action 
A thesis submitted for the degree of Doctor of Philosophy 
at the Australian National University 
by 
Kathryn Brown 
Cell-Cell Interaction Group 
Division of Cell Biology 
John Curtin School of Medical Research 
Australian National University 
September 1993 
I 
; 
11 
I 
I 
' 
,, 
,, 
:i 
11 
Statement 
I certify that, except for the experiments presented in section 4.2. 7 and 
Figures 4.8 and 4.9 which were performed by Dr David Ornitz, all experiments 
described in this thesis represent my own work and have not previously been 
submitted for a degree at this, or any other university. 
Kathryn J.I. Brown 
September 1993 
111 
Acknowledgements 
I would like to thank my supervisor, Dr Chris Parish, for his enthusiastic 
supervision of my experimental and written work and for his willingness to 
discuss it at any time. 
My warmest thanks to Dr Ian Hendry for being an invaluable friend and 
advisor. 
I would also like to thank Dr Craig Freeman for helpful advice during the 
isolation of HSPGs, Dr John Morisson for doing the scatchard analyses of the 
data, Mr Colin Mclachlan for his generous help with computing, Dr Michael 
Crouch for supplying me with BALB/c 3T3 cells, and Dr Arnie Leon for help 
with the curve fitting program. 
I must also thank the photography unit at JCSMR, particularly Mr Marc 
Fenning for his excellent help with the Macintosh computer, and Mr Geoff 
Osborne and Ms Sabine Gueninger for their help with the FACScan. 
My thanks must also go to Ms Karen Jakobsen for technical help and to Ms 
Susan Maynes for providing me with HUVE cells and extracellular matrices. 
Many thanks to my fellow students, Mark Bartlett and Lyz Hindmarsh for being 
such good company and fun. 
I am most grateful to my Mother and Father for their continuous love and 
support. 
A very special thanks to Alistair for always being my loving friend. 
' Ii 
I 
I 
' 
I 
1: 
lV 
Abstract 
The central event in growth factor action is the binding of the growth factor to 
the signal transducing receptor on the plasma membrane of target cells . 
Fibroblast Growth Factors (FGF) bind to specific (high affinity) receptors that 
possess protein tyrosine kinase activity in their cytoplasmic domain and are 
directly involved in FGF signal transduction. Furthermore, as is being 
discovered for an increasing number of growth factors and cytokines, they 
also bind to cell surface heparan sulfate proteoglycans (HSPGs) which are 
indispensible accessories for the binding of the growth factor to the signal 
transducing receptor. 
In this thesis, I have attempted to study the role of HSPGs in the interaction of 
FGFs with their signaling receptor, FGFR. In particular, I have examined why 
bFGF is more potent than aFGF in vitro, why the mitogenic activity of aFGF in 
cell culture is potentiated by heparin while that of bFGF is generally not, and 
the mechanism by which this potentiation occurs. Comparative studies were 
performed with both acidic and basic FGF in an attempt to further understand 
these phenomena and the possible involvement of heparan sulfates. An 
understanding of the requirements for the interaction between FGFs and 
heparan sulfate (HS) chains, and of how acidic and basic FGF activity is 
modulated by HSPGs, may facilitate the development of compounds which 
disrupt this interaction, thereby inhibiting the interaction of FGF with its 
signaling receptors. Such inhibitors of FGF action could be important in the 
inhibition of angiogenesis which becomes a pathological process during 
tumour formation and many other diseases. 
In chapter 3, several aspects of the interaction of FGFs with HSPGs were 
examined. First, reciprocal cross blocking studies demonstrated that aFGF 
and bFGF bind to identical or closely associated heparan sulfate motifs on 
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BALB/c 3T3 cell surface HSPGs. However, the binding affinity of the two 
growth factors for these HSPGs differs considerably, binding-inhibition data 
indicating that aFGF has a 4. 7 fold lower affinity than bFGF for 3T3 HSPGs. 
Studies of the dissociation kinetics of aFGF and bFGF demonstrated that 
bFGF dissociates from the FGFR at least 10-fold slower than aFGF 
(t1;2 >250min versus 25 min) whereas, following removal of cell surface 
HSPGs by heparinase treatment, the dissociation rate of both FGFs is similar 
and rapid (t1;2 12min versus ?min). These results support the concept that 
cell surface HSPGs stabilize the interaction of FGFs with FGFR, possibly by 
the formation of a ternary complex. The lower binding affinity of aFGF for 
HSPGs, compared with bFGF for HSPGs, appears to result in aFGF binding 
to the FGFR being less effectively stabilized by HSPGs. Such a model may 
explain the lower mitogenic activity of aFGF compared with bFGF for 3T3 
cells and suggests that heparin usually potentiates aFGF-induced, but not 
bFGF-induced, mitogenesis because of aFGF's relatively low affinity for cell 
surface HSPGs. In this context, heparin had no effect on the rate at which 
acidic and basic FGF dissociated from FGFR but it did enhance the net 
binding of aFGF and bFGF to FGFR on cells from which HSPGs had been 
removed by treatment with heparinase. These data are discussed in the 
context of the ability of heparin/HSPGs to promote FGF binding to FGFR by 
inducing a conformational change in the growth factor and/or by enabling the 
formation of a ternary complex. 
The studies described in chapter 4 are primarily based upon the finding by 
Belford et al.,(1992) that carboxyl-reduced heparin (CR-heparin), despite 
binding aFGF as effectively as native heparin, is much less potent at 
augmenting aFGF-induced mitogenesis. The chapter describes experiments 
which examined this phenomenon in more detail in the hope that it would 
shed light on the mechanism by which heparin potentiates aFGF activity. 
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Initial studies confirmed the finding of Belford et al.,(1992) and proteolysis 
protection experiments revealed that CR-heparin was as effective as native 
heparin at protecting aFGF from proteolytic degradation. In contrast, CR-
heparin was shown to be considerably less effective than native heparin at 
enhancing the binding of aFGF to either the FGFR on 3T3 cells or to a soluble 
form of recombinant murine FGFR1. Furthermore, CR-heparin only bound to 
a subset (approx. 1/3) of heparin receptors on 3T3 cells and bound weakly to 
a heparin binding site on FGFR 1. Since CR-heparin protected aFGF from 
proteolysis and bound aFGF with high affinity it appeared unlikely that the 
inability of CR-heparin to enhance aFGF binding to the FGFR was due to its 
failure to induce a conformational change in aFGF essential for FGFR 
binding. In contrast, the reduced ability of CR-heparin to interact with heparin 
binding sites suggests that it is much less efficient than heparin at facilitating 
the formation of a ternary complex between aFGF and the FGFR. Such a 
ternary complex would require a heparin-FGF complex to crosslink the FGFR 
with a heparin binding site either on the FGFR itself or on adjacent molecules 
on the cell surface. 
Additional studies demonstrated that CR-heparin interacted with bFGF with a 
binding affinity comparable to native heparin. Nevertheless, unlike native 
heparin, CR-heparin was completely unable to restore binding of bFGF to 
soluble recombinant FGFR 1. However, CR-heparin was quite an effective 
inhibitor of native heparin-induced binding of bFGF to FGFR 1. Such results 
were not obtained with aFGF. These observations suggest that acidic and 
basic FGF have different requirements for binding to FGFR 1 and a model has 
been proposed to explain these differences. 
In chapter 5, three major heparin-binding proteins, histidine-rich glycoprotein 
(HRG), antithrombin Ill (ATIII) and platelet factor 4 (PF4), were tested for their 
ability to act as modulators of FGF activity by competing with the FGFs for 
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binding to cell surface HSPGs. HAG from both chicken and human , and 
human PF4 were demonstrated to compete with each other and with acidic 
and basic FGF for binding to BALB/c 3T3 cell surface HSPGs, whereas ATIII 
did not compete. Thus HAG, PF4, aFGF and bFGF all interact with the same 
HS chains on the 3T3 cell surface, either binding to the same or to adjacent 
saccharide sequences on the chains. In terms of their relative binding affinity 
for cell surface HSPGs, the hierarchy was shown to be PF4 > bFGF > aFGF = 
cHAG > hHAG. HAG was also shown to bind to extracellular matrices 
(ECMs), originating from bovine corneal endothelial cells , in a heparin-
inhibitable manner. Indeed both HAG and PF4 were shown to effectively 
inhibit the binding of 1251-aFGF and 1251-bFGF to ECMs at concentrations 
thought to occur in vivo. Based on these findings, it is proposed that HAG 
and PF4 may act as positive regulators of FGF activity by displacing FGF 
from the ECM or basement membrane and making FGF available to 
responsive cells. Alternatively, they could act as negative regulators by 
masking HSPGs on responsive cells and preventing FGFA activation . 
In conclusion, the results presented in this thesis confirm the importance of 
HSPGs in the interaction of FGFs with the FGFA. It appears that the reason 
for the difference in potency of aFGF and bFGF is due to the lower binding 
affinity of aFGF for the 3T3 cell surface HSPGs which results in the formation 
of fewer ternary complexes between aFGF, HSPGs and FGFA. Basic FGF, 
by having a higher affinity for cell surface HSPGs is able to activate FGFAs at 
much lower concentrations than aFGF. Similarly, the reason why heparin 
potentiates aFGF-induced activity but generally not bFGF-induced activity, 
appears to be due to aFGF's ability to bind heparin better than HSPGs and to 
utilize heparin more effectively in the formation of productive signaling 
complexes with the FGFA. Thus it appears, given the correct FGFA is 
expressed on the cell surface, FGF mitogenic activity is directly related to the 
affinity of the growth factor for cell surface HSPGs. The ability of 
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physiologically relevant concentrations of HRG and PF4 to inhibit the binding 
of acidic and basic FGF to HSPGs present both on the cell surface and in the 
ECM suggests that they may act as regulators (particularly HRG) of FGF 
activity in vivo. 
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[3H]TdR [methyl-3H]thym idine 
aa amino acid 
aFGF acidic fibroblast growth factor 
ATIII antithrombin Ill 
ATP adenosine triphosphate 
bFGF basic fibroblast growth factor 
BM basement membrane 
BSA bovine serum album in 
BSS balanced salt solution 
cAMP adenosine 3' ,5'-cyclic monosphosphate 
CHAPS (3-[(3-Cholamidopropyl)-dimethylammonio]-
1-propanesulfonate 
cHRG chicken histidine-rich glycoprotein 
cpm counts per minute 
CR-heparin carboxyl-reduced heparin 
CSF-1 colony stimulating factor-1 
DMSO dimethylsulfoxid methyl sulfoxide 
ii E9 embryonic day 9 
I 
11 E11 embryonic day 11 
ECGF endothelial cell growth factor 
ECM extracellular matrix 
EDTA ethylene diam ine tetracetic acid 
FAGS fluorescence activated cell sorter 
FCS fetal calf serum 
FGF fibroblast growth factor 
FGFR fibroblast growth factor receptor 
FITC fluorescein-5-isothiocyanate 
FIU fluorescence intensity unit 
FN fibronectin 
FR1AP mFR1 fused to human placental alkaline phosphatase 
GAG glycosaminoglycan 
GalNAc N-acetylgalactosam ine 
GlcA glucuronic acid 
GlcN D-glucosam ine 
GPI glycosyl phosphatidyl inositol 
h human 
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Abbreviations cont. 
HRG 
HS 
HSPG 
HUVE 
ldoA 
lg 
IL 
Kd 
mFR1 
MW 
ND 
OD 
PBS 
PCR 
PDGF 
PF4 
Pl-PLC 
PLC 
PVC 
r 
SD 
SOS-PAGE 
SEM 
t112 
TGF-~ 
TX-100 
VEGF 
histidine-rich glycoprotein 
heparan sulfate 
heparan sulfate proteoglycan 
human umbilical vein endothelial 
iduronic acid 
immunoglobulin 
interleukin 
dissociation constant 
soluble form of m urine FGF receptor 1 
molecular weight 
not determined 
optical density 
phosphate buffered saline 
polymerase chain reaction 
platelet derived growth factor 
platelet factor 4 
phosphatidylinositol-phospholipase C 
phospholipase 
polyvinylch loride 
recombinant 
standard deviation 
sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis 
standard error of the mean 
time required for half of the bound FGF to be released 
from the FGFR 
transforming growth factor-~ 
Triton X-100 
vascular endothelial growth factor 
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Chapter 1 
Literature Review 
1 
Recently, there has been a dramatic increase in the amount of research 
devoted to the Fibroblast Growth Factor family. This has meant that 
considerable progress has been made towards understanding their biological 
activities, physiological roles and clinical application. The Fibroblast Growth 
Factors, with their ubiquitous distribution, are now recognized as a family of 
growth factors whose members play a critical role in a wide range of normal 
and pathological processes. Yet there remains much to be understood about 
them, and in this introductory chapter I have attempted to outline the 
physiological processes in which FGFs are thought to be involved and to 
describe what is known to date, about their mechanism of action. After a brief 
introduction to the FGF family, I will concentrate on acidic and basic FGF for 
these are the two growth factors most pertinent to this thesis. Special 
emphasis has been placed on what is known about their interactions with cell 
surface receptors and, in particular, their interaction with heparan sulfate 
proteoglycans (HSPGs) and heparin. The relevance of these interactions to 
FGFs' mechanisms of action is also discussed. Recently a new nomenclature 
was introduced at a meeting of the New York Academy of Sciences which 
numbered the members of the Fibroblast Growth Factor Family as FGF-1 to 
FGF-7. However, for ease of identification, I have retained the old 
nomenclature of acidic and basic FGF throughout this thesis. 
1.1. Historical Note 
As early as 1939, Trowell et al.,(1939) and Hoffman (1940) detected mitogenic 
activity for fibroblasts in extracts of brain and then later in bovine pituitary 
(Armelin 1973; Gospodarowicz et al., 1974; Gospodarowicz 1975). It was not 
until the mid-1970's, that the polypeptide mitogen for 3T3 cells was purified 
from bovine pituitary (Gospodarowicz et al., 1975) and named fibroblast growth 
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factor and subsequently characterized as a basic polypeptide with mitogenic 
activity for mesoderm- and neuroectoderm-derived cells (Gospodarowicz 
1983). However, high levels of contaminating myelin basic protein in the 
preparation hindered characterization of its structure (Westfall et al., 1978). 
Thomas and coworkers (1980) independently identified a polypeptide with an 
acidic isoelectric point from acid extracts of bovine brain and named it acidic 
fibroblast growth factor. Acidic FGF was mitogenic for endothelial cells 
(Lemmon et al., 1982) and on this criterion was initially distinguished from 
bFGF (Maciag et al., 1979; Lemmon et al., 1982; Thornton et al., 1983). In 1984, 
both aFGF (Thomas et al., 1984) and bFGF (Bohlen et al., 1984) were purified 
and characterized as potent heparin binding polypeptide mitogens for 
endothelial cells (Shing et al., 1984; D'Amore & Klagsbrun, 1984). Structural 
characterization of aFGF (Gimenez-Gallego et al., 1985) and bFGF (Baird et 
al., 1986) demonstrated their high amino acid sequence homology and these 
two growth factors formed the basis of a larger family of polypeptide growth 
factors. 
In 1983, Thornton and her colleagues demonstrated that heparin could 
potentiate the biological activity of crude preparations of aFGF (Thornton et 
al., 1983). The discovery that aFGF (Maciag et al., 1984) and bFGF (Shing et 
al., 1984) have a strong binding affinity for heparin facilitated their purification by 
heparin affinity chromatography (Shing et al., 1983; Maciag et al., 1984). 
Heparin affinity chromatography is now an essential step in the characterization 
and purification of both aFGF and bFGF because aFGF elutes from 
immobilized heparin with 1.0M NaCl whereas bFGF requires at least 1.6M 
NaCl for elution (Shing et al., 1984). Over twenty growth factors that had been 
previously isolated from various tissues and given different names were able to 
be identified as either aFGF or bFGF by heparin affinity chromatography. 
I 
I 
i 
Ii 
j,; 
3 
1.2. The Heparin Binding Growth Factors 
The number of cytokines and growth factors which have been shown to bind 
heparin and HSPGs is rapidly increasing (Table 1.1 ). Although the members of 
the heparin binding growth factor family, described to date, appear to exhibit 
lower affinities for heparin than do the FGFs, the reasons proposed to explain 
the functional significance of such an interaction are similar to those put 
forward to explain FGF binding to HSPGs. Heparin-binding cytokines are 
thought to bind to HSPGs on the cell surface and in the extracellular matrix 
(ECM), enabling their retention near their site of secretion and facilitating the 
regulation and differentiation events of hematopoiesis (Ramsden & Rider 1992; 
Gordon et al., 1987; Roberts et al., 1988; Keating & Gordon 1988). lnterleukin-3 
and granulocyte macrophage-colony stimulating factor have been shown to I 
stimulate receptors on colony-forming cells whilst bound to HSPGs synthesized 
by stromal cells (Roberts et al., 1988). Heparin enhances the binding of 
vascular endothelial cell growth factor (VEGF) to VEGF receptors and it seems 
likely that VEGF may be required to interact with cell-surface HSPGs before it 
can interact with VEGF receptors (Gitay-Goren et al., 1992). While bound to 
HSPG, transforming growth factor-p is held at the cell surface and protected 
from a2-microglobulin. Pleiotrophin is also thought to be sequestered by 
HSPGs in the ECM. Clearly the full significance of HSPGs in the modulation of 
cytokine and growth factor activity is yet to be realised. 
1.3. Introduction to the Fibroblast Growth Factor Family 
Acidic and basic FGF (termed FGF-1 and FGF-2) are ubiquitously distributed 
throughout the body and have been purified from organs such as the adrenal 
gland (Gospodarowicz et al., 1986a), bone (Hauschka et al., 1986) cartilage 
(Sullivan & Klagsbrun 1985) , corpus luteum (Gospodarowicz et al., 1985a) 
hypothalamus (Klagsbrun & Shing 1985), kidney (Baird et al., 1985a), liver 
(Ueno et al., 1986), placenta (Gospodarowicz et al., 1985b), prostate (Nishi et 
al., 1985), retina (Baird et al., 1985b), testis (Ueno et al., 1987) and thymus 
• 
Table 1.1: Heparin Binding Growth Factors 
Common name Acronym Reference 
acidic fibroblast growth factor FGF1 Burgess & Maciag (1989) 
basic fibroblast growth factor FGF2 Burgess & Maciag (1989) 
int-2 FGF3 Yoshida et al.,(1988) 
Kaposi sarcoma FGF FGF4 Yoshida et al.,(1988) 
fibroblast growth factor-5 FGF5 Nguyen et al.,(1988) 
fibroblast growth factor-6 FGF6 Nguyen et al.,(1988) 
keratinocyte growth factor FGF7 Rubin et al.,(1989) 
androgen-induced growth factor FGF8 Tanaka et al.,(1992) 
I glia-activating factor FGF9 Miyamoto et al.,(1993) 
I interleukin 1 a IL-1 a Ramsden & Rider (1992) I! 
I 
' 
Ii 
I interleukin 1 p IL-1 p Ramsden & Rider (1992) 
i\ interleukin 2 IL-2 Ramsden & Rider (1992) 
I 
interleukin 3 IL-3 Roberts et al.,(1988) 
interleukin 6 IL-6 Ramsden & Rider (1992) 
granulocyte & macrophage 
colony stimulating factor GM-CSF Keating & Gordon (1988), 
Gordon et al., ( 1987) 
heparin binding epidermal 
growth factor HB-EGF Higashiyama et al (1990) 
transforming growth factor p TGF-p MCCaffrey & Falcone ( 1992) 
vascular endothelial growth factor VEGF Gitay-Goren et al.,(1992) 
platelet-derived growth factor PDGF Fager et al., ( 1992) 
pleiotroph in Milner et al.,(1989) 
midkine MK Tomomura et al.,(1990) 
t 
1, 
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Table 1.1. continued: 
Common name Acronym Reference 
hepatocyte growth factor HGF Nakamura et al.,(1986) 
insulin-like growth factor I IGF-1 Myers et al.,(1993) 
11 
insulin-like growth factor 2 IGF-2 Myers et al.,(1993) 
amphiregulin Myers et al.,(1993) 
Schwannoma-derived growth factor - Klagsbrun & Baird (1991) 
' 
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(Gospodarowicz et al., 1986b). Highly purified preparations of aFGF and bFGF 
were subjected to amino acid sequencing and cDNAs for aFGF (Gimenez-
Gallego et al., 1985; Thomas et al., 1985; Jaye et al., 1986) and bFGF (Esch et 
al., 1985; Abraham et al., 1986a,b,c; Kurokawa et al., 1987) have been cloned. 
Seven additional members of the FGF family have been identified to date, on 
the basis of amino acid sequence homologies (Tables 1.2 & 1.3). These 
proteins are the product of the int-2 oncogene (FGF3) (Moore et al., 1986); the 
product of the hst oncogene (Kaposi sarcoma FGF or FGF-4) (Taira et 
al., 1987; Bovi & Basilica 1987); FGF-5 (Zhan et al., 1988); FGF-6 (Maries et 
al., 1989); keratinocyte growth factor (KGF or FGF7; Finch et al., 1989; Rubin et 
al., 1989); androgen-induced growth factor (AIGF or FGF-8) and glia-activating 
factor (GAF or FGF-9). lnt-2, hst/KFGF, FGF-5, FGF-6, KGF, AIGF and GAF 
exhibit 30-45°/o sequence homology with aFGF and bFGF and share with aFGF 
and bFGF the ability to bind heparin. In contrast to aFGF, bFGF and GAF, the 
other family members contain signal peptide sequences encoded by their 
mRNA transcripts. 
The int-2 (FGF-3) gene, a proto-oncogene, was discovered through its 
transcriptional activation by mouse mammary tumour virus (Dickson et 
al., 1984; Peters et al., 1983) and its ability to participate in mammary 
tumorigenesis. It seems that it only functions in specialized cell types such as 
in developing embryos at a variety of stages (Jakobovits et al., 1986; Wilkinson 
et al., 1989) and may be a cell-to-cell signaling molecule (Dickson & Peters 
1987). 
The FGF-4 gene, previously known as hst-1 or KFGF, a transforming gene, 
was the second oncogene found to encode a growth factor. It is activated in 
DNAs of a variety of tissues, for example, noncancerous gastrointestinal 
mucosae. The gene is 35kbp downstream from the int-2 gene and in the same 
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-Common name Generally 
accepted 
acronyms 
Acidic Fibroblast Growth aFGF 
Factor, Acidic 
Endothelial Cell Growth FGF, 
Factor, ECGF, 
Heparin-Binding Growth HBGF-1 
Factor-1, 
Basic Fibroblast Growth bFGF, 
Factor, Basic 
Heparin-Binding Growth FGF, 
Factor HBGF-2 
int-2 int-2 
Table 1.2: General Features of the Fibroblast Growth Factors 
Proposed Gene on 
name human 
chromo-
some 
FGF-1 5q31-33 
FGF-2 4q25 
FGF-3 11q13 
Primary 
trans-
lation 
product 
(aa) 
154 
154 
196 
201 
210 
239 
271 
-
Signal [NaCl] 
Sequence for 
present elution 
from 
heparin 
no 1.0 M 
no 1.6M 
yes ND 
.... 
FGF o/o Oncogenic 
Receptor Sequence potential 
identity to 
bFGF 
FGFR1 53 no 
FGFR2 
FGFR3 
FGFR4 
FGFR1 100 no 
FGFR2 
FGFR3 
ND 42 yes 
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Table 1.3: Tissue Distribution of FGFs 
Growth Factor Tissue Reference 
FGF-1 neural, kidney, prostate, Casscells et al., 
(1990), 
cardiac muscle Crabb et al.,(1986), 
D'Amore & 
Klagsbrun (1984), 
Thomas et al.,(1984) 
FGF-2 brain, pituitary, retina, Esch et al., (1985), 
adrenal, corpus luteum, Baird et al.,(1985b, 
testes, skeletal, cardiac, 1986), Bohlen et al., 
some blood vessels, (1985),Gimenez-
in all organs examined Gallego et al.,(1986), 
Gospodarowicz et al., 
(1984, 1985a, 1986a) 
Ueno et al.,(1987), 
Gonzalez et al.,(1990) 
l,c Joseph-Silverstein et 
al.,(1989) 
I 
I ' 
I ' FGF-3 embryo, foetus, cerebellum, Jakobovitis et al., 
sensory region of inner ear, (1986), Wilkinson et 
retina al.,(1989) 
FGF-4 very early embryo, foetus Herbert et al.,(1990) 
FGF-5 most phases of embryonic & Haub & Goldfarb 
foetal growth, adult brain, specific (1991) 
types of mesenchyme & striated 
muscle 
FGF-6 embryo, adult skeletal muscle Delli Bovi et al., 
& heart (1988), Kimelman 
et al.,(1988) 
FGF-7 adult kidney, colon, ilium, Finch et al., ( 1989) 
epithelial eel Is Rubin et al., ( 1989) 
FGF-8 tumour cells Tanaka et al.,(1992) fl 
Ii FGF-9 brain, kidney Miyamoto et 
al.,(1993) 
.--...... -------------------------------,, 
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transcriptional orientation (Wada et a 1988). Both genes are coamplified in 
several types of human cancers (Yoshida et al., 1988; Tsuda et al., 1989; 
Adnane et al., 1989). The FGF-4 gene is expressed in the apical ectodermal 
ridge of the early mouse limb-bud and the secreted protein, FGF-4, stimulates 
the proliferation of the underlying mesenchyme (Niswander & Martin 1992; 
Suzuki et al., 1992). Therefore, FGF-4 is thought to cause limb outgrowth by 
stimulating the proliferation of cells in distal limb mesenchyme (Niswander & 
Martin 1993). 
FGF-5 is thought to mediate a diverse set of events during embryogenesis. 
Although expressed through most phases of embryogenesis (Herbert et 
al., 1990), FGF-5 gene expression is temporally restricted and tissue specific. It 
is also expressed weakly and exclusively in the adult central nervous system 
(Haub et al., 1990). 
The restricted pattern of FGF-6 gene expression suggests a specific acitivity of 
FGF-6 in the embryo and in cardiac and skeletal muscle cells. The role of FGF-
6 in muscle formation is not known. FGF-6 has a transforming capacity 
comparable to, and sequence similarities, with FGF-4 (hst/KFGF) (Sakamoto et 
al., 1988; Miyagawa et al., 1988; Delli-Bovi et al., 1988). Despite this intrinsic 
transforming capacity, the FGF-6 gene has not been detected in transfection 
assays (Sakamoto et al., 1986; Bovi & Basilica 1987) and has never been found 
altered in human tumours, suggesting that the intrinsic oncogenic capacity of 
the FGF genes must be repressed in vivo. 
Keratinocyte growth factor (FGF-7) acts specifically as a paracrine modulator of 
epithelial cell growth (Finch et al., 1989). It has no mitogenic activity on 
fibroblasts, endothelial cells, melanocytes or other non-epithelial targets of FGF 
action. KGF receptors bind aFGF with a high affinity but have a much lower 
affinity for bFGF. 
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Androgen-induced growth factor (FGF-8) is possibly the first hormone-induced 
autocrine growth factor identified. It has remarkable stimulatory effects on a 
mouse mammary carcinoma cell line (SC-3 cells) and is secreted by these cells 
in response to androgen, stimulating them in an autocrine manner (Tanaka et 
al., 1992). 
Glia-activating factor promotes glial cell proliferation (Naruo et al., 1993) and is 
therefore implicated in the development and maintenance of cells of the central 
nervous system. Besides being expressed in the brain, its gene is also 
expressed in kidney, suggesting that this growth factor may also act on other 
organs in an endocrine manner. It consists of a single peptide and there are 
three molecular weight isoforms of 30, 29 and 25kDa, each having an N-linked 
sugar chain of 3kDa. In addition to promoting the proliferation of rat glial cells, 
it also activates 0-2A progenitor cells, PC-12 cells, BALB/c 3T3 cells but not 
human umbilical vein endothelial cells (Naruo et al., 1993). When transfected 
into BALB/c 3T3 cells it exhibits transforming potency and therefore may be 
involved in oncogenesis of NMC-G 1 cells. Although lacking a typical signal 
sequence, it is clearly secreted from cells and it is proposed that it may have a 
functional signal sequence in the N-terminal domain which is uncleavable in the 
secretion step (Miyamoto et al., 1993). 
I will now concentrate on acidic and basic FGF because these are the two most 
relevant to this thesis. 
1.4. Biological Functions of Acidic and Basic FGF 
FGFs are important in proliferation, differentiation and chemotaxis of various 
cell types in culture. These effects in vitro implicate them in the processes of 
angiogenesis which involves endothelial cell proliferation, migration and 
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differentiation, in wound healing which requires migration and proliferation of 
fibroblasts, in nerve regeneration, in cartilage repair and in embryogenesis. 
1.4.1. Cell Proliferation 
Both aFGF and bFGF are potent mitogens in vitro, being active in the 0.1 to 1.0 
ng/ml range, although bFGF is often 10-30 fold more active than aFGF 
(Gospodarowicz 1987). It appears that cells derived from the three embryonic 
germ layers (mesoderm, ectoderm and endoderm) respond to FGF (reviewed 
in Gospodarowicz 1990). Cells which are FGF-sensitive include endothelial 
cells (Folkman & Klagsbrun 1987; Gospodarowicz et al., 1978; Maciag et 
al., 1981 ), adrenal cortex cells (Schweigerer et al., 1987a; Gospodarowicz et 
al., 1977), prostatic cells (McKeehan et al., 1984; Hoshi & McKeehan 1984; 
Chaproniere & McKeehan 1986), retinal epithelial cells (Arruti & Courtois 1978; 
Barritault et al., 1981; Tarsio et al., 1983; Courty et al., 1985; Baird et al., 1985b; 
Courty et al., 1986;), oligodendrocytes (Eccleston & Silberberg 1985) astrocytes 
(Wu et al., 1988), chondrocytes (Kato & Takayama 1984; Kato et al., 1987; Kato 
& Gospodarowicz 1985), myoblasts (Kardami et al., 1985; Hauschka et 
al., 1986; Ecceleston & Silberberg 1985; Wice et al., 1987) and osteoblasts 
(Canalis et al., 1987; Rodan et al., 1987; Canal is & Lian 1988). Human 
melanocytes respond to the mitogenic influence of bFGF but not aFGF 
(Halaban et al., 1987), and most avian and mammalian cell types respond to 
both polypeptides (reviewed by Lobb 1988a). Acidic and basic FGF are also 
potent mitogens for a number of established cell lines including BALB/c and 
Swiss 3T3 cells, LEII cells, BHK21 cells, CHO cells and rhabdomyosarcoma 
cells (reviewed by Thomas & Gimenez-Gallego 1986; Gospodarowicz et 
al., 1986b). In many cases, the mitogenic effect of FGFs on normal diploid 
mammalian cells significantly delays their premature senescence in vitro 
(Maciag et al., 1981; Gospodarowicz & Bialecki 1978) by inducing early Go to 
G 1 cell cycle events (Wice et al., 1987; Gospodarowicz 1983; Maciag 1984) 
and cellular competence (Stiles et al., 1979). 
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1.4.2. Chemotaxis 
Acidic FGF is chemotactic for endothelial cells, fibroblasts and astroglial cells 
(Terranova et al., 1985; Senior et al., 1986). It is not known whether the 
chemotactic activities of FGFs are mediated through the same receptor 
systems involved in the induction of cell proliferation but there is evidence to 
suggest that chemotactic and mitogenic activities are distinct. Linemeyer et al., 
(1987) have shown that cell division and cell migration in response to aFGF 
require mutually exclusive cytoskeletal arrangements and that high 
concentrations of a raFGF(15-154) fragment which inhibited thymidine 
incorporation into BALB/c 3T3 cells stimulated chemokinesis and chemotaxis of 
these cells. It is proposed that high concentrations of aFGF could stimulate 
migration of endothelial cells or fibroblasts to the site of a wound or tumour and 
then diffusion mediated decreases in the concentration of growth factors would 
result in stimulation of proliferation of the "recruited" cells (Burgess &Maciag 
1989). 
1.4.3. Cell Spreading 
In 1978, Folkman and Moscona, demonstrated the importance of cell spreading 
in cell proliferation by showing that DNA synthesis induced by serum correlated 
with the degree of cell spreading. More recently, Ingber (1990a), has shown 
that the mitogenic effect of bFGF depends on cell spreading which may in turn 
be modulated by proteins in the ECM (Elliot et al., 1992). 
1.4.4. Junctional Coupling 
Basic FGF also induces junctional coupling between endothelial cells (Pepper 
& Meda 1992), increasing junctional communication and connexin 43 
expression in microvascular endothelial cells. Adjacent endothelial cells in the 
vascular endothelium are linked by intercellular tight junctions and gap 
junctions. Gap junctions are transmembranous channels which regulate the 
passage of small molecules and ions between adjacent cells (reviewed by 
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Bennett et al., 1991 ). A bFGF-induced increase in coupling may represent a 
physiological mechanism which allows cells on the leading front of a wound's 
edge to communicate with adjacent cells and cells located further back. 
Endothelial cell coupling may also play a role in arteriolar vasodilation (Segal & 
Duling 1986, 1987, 1989) and the maintenance of intercellular contacts is 
probably important in the formation of structurally and functionally competent 
capillary blood vessels during angiogenesis. 
1.4.5. Differentiation 
Both aFGF and bFGF promote the cellular differentiation and survival in vitro of 
a variety of cells that migrate from the neural crest, including hippocampal and 
cortex-derived cells in vitro (Eccleston & Silberberg 1985; Neufeld et al., 1987; 
Walicke et al., 1986; Unsicker et al., 1987; Lipton et al., 1988; Schubert et 
al., 1987; Wu et al., 1988). Basic FGF induces adipocyte differentiation in vitro 
(Serrero & Khoo 1982) and both growth factors promote neurite extension in 
PC12 cells, a rat pheochromocytoma cell line (Togari et al. , 1983, 1985). Both 
FGFs also appear to have a role in both mesoderm differentiation and 
mesoderm patterning throughout gastrulation (Amaya et al., 1991 ). 
1.4.6. Angiogenesis 
Angiogenesis is the process by which new blood vessels are formed (Folkman 
1991) and is essential in reproduction, development and wound repair 
(Folkman & Shing 1992). In these processes, angiogenesis is highly regulated, 
although, many diseases are driven by unregulated angiogenesis. Currently, 
there are eight polypeptides known to be angiogenic, two of which are aFGF 
and bFGF. Basic FGF is angiogenic when injected extravascularly (Whalen et 
al., 1989). The biological activities of aFGF and bFGF which implicate them in 
angiogenesis are: 
1) their mitogenicity for a wide range of cell types. Basic FGF has been shown 
to be a potent angiogenic factor in vivo when tested in the rabbit cornea, chick 
chorioallantoic membrane and hamster cheek pouch assays (Gospodarowicz 
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et al., 1979; 1984; 1985a; 1986a,b). Acidic FGF, although less potent than 
bFGF, is also angiogenic in the chorioallantoic membrane and rabbit cornea 
assays (Thomas et al., 1985; Lobb et al., 1985). Furthermore, vasodilation of 
the parent venule occurs before the emergence of the first capillary sprout and 
it is thought that this may stretch the endothelial cells making them responsive 
to bFGF or other growth factors (Ingber 1990b). 
2) their ability to bind HSPGs (Vlodavsky et al., 1987a). Basic FGF stored in the 
ECM, bound to HSPGs, may be mobilized by collagenases or heparanases 
which have been secreted by endothelial cells or other vessel associated cells. 
3) their ability to bind copper (Shing 1988; Baird & Ling 1987). Certain copper 
complexes, eg, copper/heparin are angiogenic. 
4) their ability to stimulate endothelial cells to migrate and form tubes 
(Montesano et al., 1986) 
5) their ability to increase production of proteases and plasminogen activator 
(Moscatelli et al., 1986; Presta et al., 1986) 
1.4.7. Wound Healing 
Acidic FGF has been shown to promote repair of experimentally damaged rat 
arterial endothelium and to inhibit the accompanying pathological intimal 
thickening (Bjornsson et al., 1991) . After intra vascular injury, a thickening of 
the intimal smooth muscle layer adjacent to the lumen and a subsequent 
decrease in the vascular lumen diameter occurs when smooth muscle cells 
migrate and proliferate into the intima and lay down ECM. Although the 
mechanism by which aFGF inhibits intimal thickening is unknown it is 
suggested that circulating aFGF has direct mitogenic and chemokinetic 
stimulatory effects on vascular endothelial cells. It is proposed that repair of 
damaged endothelium might inhibit intimal thickening by limiting the exposure 
of the underlying smooth muscle cell to stimulatory factors (Bjornsson et 
al.,1991). Such intimal thickening occurs in humans following balloon 
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angioplasty and is a major cause of coronary artery restenosis. Acidic FGF 
could be used therapeutically in such situations. 
The interaction between ECM and growth factors has been shown to be an 
integral component of the wound healing process. It appears that the ECM 
does far more than stabilize the fibrin clot via interaction with fibronectin (FN). 
Soon after injury, the matrix releases bFGF and signals cells to begin 
manufacturing bFGF and expressing FGF receptors on their cell surfaces 
(Baird 1991 Keystone conference). Basic FGF and the other growth factors 
released, cause a variety of cell types to proliferate but the matrix immobilizes 
the growth factors, preventing them from diffusing out of the wounded area and 
therefore ensuring only a local response. Chemical signals guide cells toward 
the wounded area. Growth factors enable keratinocytes to migrate through the 
ECM to get to the wound bed, by stimulating the cells to produce collagenase 
(David Woodley, Keystone conference 1991 ). Fibroblasts also migrate to the 
wound site where their response to FGF is also controlled by the ECM (Grinnell 
1991 Keystone conference). The end of the wound healing process requires 
that cell proliferation is turned off (Grinnell, Keystone conference 1991 ). In 
response to TGF-~, secreted by inflammatory cells, the fibroblasts make 
collagen to restore the damaged matrix, consequently, FGFs are sequestered 
by the ECM and it is proposed that cells cease to proliferate as a result of the 
removal of the FGF stimulus (Skerrett 1991 ). 
1.4.8. Development 
The ability of FGFs to promote proliferation of cells derived from each of the 
germ layers, and to influence the differentiation of a variety of cell types, 
combined with the detection of bFGF in Xenopus eggs (Slack et al., 1987; 
Knochel et al., 1987; Grunz et al., 1988), unfertilized chicken eggs and the chick 
embryo (Seed et al., 1988) suggests a major role for both factors during 
development. In fact, there is experimental evidence to suggest that they may 
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play a major role during the development of the nervous, skeletal, and vascular 
systems (reviewed by Gospodarowicz et al., 1987a). By expressing a dominant 
negative mutant form of the FGF receptor in frog oocytes, Amaya et al., (1991 ), 
have demonstrated the importance of the FGF signaling pathway in 
embryogenesis, ie., its involvement in the early establishment of the posterior 
and lateral structures of the frog embryo. It is yet to be determined which 
regions of the embryo are involved in the FGF signaling pathway. 
1.4.9. Reproductive Biology 
Basic FGF has been shown to be a potent inhibitor of aromatase activity in 
cultured granulosa cells and peripheral fibroblasts (Baird & Walicke 1989) and 
also of testosterone synthesis in vitro. It is also present in the corpus luteum 
and may be associated with the neovascular response that underlies normal 
menses, implantation and fetal development, ie., it could be an ovarian 
angiogenic factor. Basic FGF may well by involved in some types of ovarian 
dysfunction many of which can be traced to problems of vascularization (Baird 
& Walicke 1989). 
1.4.10. Limb Regeneration 
Some amphibian species are able to regenerate lost appendages and there is 
a strong possibility that bFGF is involved in one of the earlier steps of 
amphibian limb regeneration, namely, recruitment of primitive cells leading to 
blastema formation. A neurotrophic effect is necessary for cell proliferation 
involved in blastema formation but not for later events such as differentiation of 
blastema cells into muscle cartilage and other tissues of the new limb (Powell 
et al., 1969; Singer 1974). Basic FGF is a potent mitogen for myoblasts and 
chondrocytes (Gospodarowicz & Mescher 1977), the two cell types from which 
blastema cells are thought to originate (Hay 1974; Gospodarowicz et al., 1976). 
Infused FGF has also been shown to promote the resumption of mitotic activity 
in denervated newt limb blastemas (Mescher & Gospodarowicz 1979). Basic 
FGF has also been demonstrated to maintain total acetylcholinesterase activity 
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in cultured newt triceps muscle above that in untreated controls, (Carlone et 
al., 1981 ), and to promote heterotrophic growth of adult frog (Rana pipiens) 
forelimbs after amputation (Gospodarowicz et al., 1975). 
1.4.11. Modulation of the Endocrine Response 
The anterior pituitary gland contains the highest concentration of bFGF in the 
body (Gospodarowicz et al., 1986c). It has been suggested that bFGF is 
required in the pituitary to promote angiogenesis (Ferrara et al., 1987), to 
stimulate cell growth (Hayashi et al., 1978) and hormonal secretion (Baird et 
al., 1985c), and to inhibit DNA synthesis (Black et al., 1990). However, these 
ascribed functions are controversial and the results of Inoue et al., (1991) 
suggest that bFGF in the pituitary may stimulate pituitary glandular cell 
adhesion to the ECM which may then allow inhibitory control of cell proliferation 
by bFGF. 
1.4.12. Effects of FGF on the Nervous System 
In tissue culture, bFGF has trophic effects on neurons (Walicke 1989), is a 
mitogen for neuroblasts from young embryos and enhances the survival of post 
mitotic differentiated neurons. A neurotrophic function has also been 
suggested for aFGF. Acidic FGF promotes neuronal differentiation and neurite 
outgrowth in cultures of rat PC 12 cells (Rydel & Greene 1987), increases 
neurite initiation and elongation in cultured rat retinal ganglion cells (Lipton et 
al., 1988), promotes neuronal survival in fetal rat hippocampal and fetal chick 
spinal cord cultures (Unsicker et al., 1987; Walicke & Baird 1988) and promotes 
neuronal survival in fetal rat hippocampal and fetal chick spinal cord cultures 
(Unsicker et al., 1987; Walicke & Baird, 1988) as well as in cultures of fetal rat 
and chick peripheral ganglia (Unsicker et al., 1987). Although bFGF is 
generally more potent than aFGF in vitro, retinal ganglion cells appear to 
specifically require aFGF. Both FGFs enhance the growth of neuritic 
processes implicating them in regulation of brain growth. Not only are neurons 
FGF-responsive but astrocytes and oligodendrocytes are also. Research is 
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being carried out to assess the usefulness of bFGF in improving neuronal 
recovery after brain lesions. Infusion of bFGF to the severed sciatic nerve 
enhances the rate of nerve regeneration (Cuevas et al., 1988) and bFGF 
administered to the stump of the severed optic nerve can increase the survival 
of retinal ganglion cells (Cuevas et al., 1988; Sievers et al., 1987). 
1.4.13. Role of FGFs in Pathological Situations 
1.4.13.1. FGFs as Oncogene Proteins 
Several groups have shown that overexpression of FGF by cells can lead to 
transformation which suggests that FGFs can act as proto-oncogenes (Rogelj 
et al., 1988; Jaye et al., 1988). Each of the FGF-related oncogenes, hst, int-2 
and FGF-5 are associated with cell transformation. The steps that lead to over 
expression of FGFs and FGF-dependent tumour growth are yet to be defined. 
1.4.13.2. Presence of FGFs in Tumour Cells 
FGFs have also been isolated from cultured tumour cells and tumour tissue 
(reviewed by Gospodarowicz et al., 1986c). They are proposed to stimulate 
tumour cell growth as autocrine growth factors and also as tumour angiogenic 
factors (Gospodarowicz et al., 1986c; Schweigerer et al., 1987b; Folkman & 
Klagsbrun 1987; Burgess & Maciag 1989; Nagao & Nishikawa 1989). Basic 
FGF has been found in rat Rhodamine fibrosarcomal tissue, (Nagao & 
Nishikawa 1989), human epidermal carcinoma cells (Masuda et al., 1987) and 
human cholangiocellular carcinoma cells (Matsuzaki et al., 1990). Acidic FGF 
has also been found in tumours, for example, a human neuroblastoma cell line 
(Huang et al., 1987) and in human brain tumours (Takahashi et al., 1990). 
1.4.13.3. FGFs and Tumour Angiogenesis 
FGFs may also promote solid tumour growth by vascularizing the invading 
tissue (Folkman & Klagsbrun 1987). The importance of angiogenesis in the 
development of solid tumours has been established by Folkman and 
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colleagues, over the last 20 years. In many cases, FGFs are produced by 
tumour cells and may be a component of the activity attributed to tumour 
angiogenesis factor or alternatively, the tumour may rely on the "host cells' 
FGF" to vascularize the tumour. In addition, tumours may recruit mast cells 
loaded with heparin and upon degranulation heparin may bind FGF (produced 
by tumour cells) and amplify its response. It is therefore extremely important to 
understand the regulation of endogenous FGF synthesis with a view to 
preventing FGFs from being mobilized by the invading tumour cells and 
inducing vascularization of the tumour. For example, in arthritis, new capillary 
blood vessels invade the joint and destroy cartilage and ocular 
neovascularization is the most common cause of blindness. 
1.4.13.4. FGFs and Complications of Diabetes 
There is strong evidence to suggest that some of the complications of diabetes 
are mediated by FGFs. FGFs are angiogenic and many of the complications 
associated with diabetes are associated with microvascular pathology in the 
eye, kidney and peripheral nerves (Baird & Walicke 1989). For example, new 
capillaries in the retina invade the vitreous, bleed and cause blindness 
(Folkman 1987). Furthermore, each of the elements which modify endogenous 
FGF availability, that is, carbohydrates, glycosaminoglycans (GAGs) and ECM 
are also modified in diabetes (Baird & Walicke 1989). Clinical trials are 
underway to assess the effects of aFGF, bFGF, PDGF and TGF-~ on patients 
with non-healing dermal ulcers resulting from diabetes. 
1.4.13.5. Role of FGFs in Gastric Ulcers 
There has been much experimental evidence in support of a role for FGF in the 
healing of gastrointestinal ulcers. The presence of aFGF and the FGF 
receptor, fig, at the wound margin of acetic-acid-induced gastric ulcers in rats 
has been demonstrated (Hansson & Norstrom 1991 ). Oral treatment with an 
acid-resistant mutein bFGF (TGF-580) has been shown to accelerate the 
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healing of both acetic-acid-induced gastric ulcers (Satoh et al. , 1991 ) and 
cysteamine-induced duodenal ulcers in rats (Folkman et al., 1990; Fitzpatrick et 
al. , 1992). Folkman et al., (1991 ), have shown that endogenous bFGF exists in 
the rat and human gastric and duodenal mucosa but is sensitive to acid 
degradation. Sucralfate and sucrose octasulfate both bind bFGF with a high 
affinity and are able to protect bFGF from acid degradation. Consequently, the 
oral administration of sucralfate elevates local levels of bFGF in the ulcer bed, 
enabling bFGF to accelerate ulcer healing by stimulating angiogenesis. 
Folkman et al., (1991) propose that gastric acid encourages ulcer formation by 
degrading and inactivating endogenous bFGF and that administration of an 
acid-resistant form of bFGF (exogenous) could provide a form of replacement 
therapy. 
1.5. General features of Acidic and Basic FGF 
Some of the general features of acidic and basic FGF will be discussed in this 
section and are summarized in Table 1.4. 
1.5.1. Gene Structure and FGF Gene Products 
The high degree of sequence homology, (55°/o), between bFGF and aFGF 
suggests that they are derived from a single ancestral gene and that they have 
become separate gene products through a process of gene duplication and 
evolutionary divergence (Abraham et al., 1986c). Acidic and basic FGF are 
encoded by separate genes, each present as a single copy (Jaye et al. , 1986; 
Abraham et al., 1986a,b,c). The gene for aFGF is found on human 
chromosome 5, between bands Sq 31.3 and Sq 33.3 (Jaye et al. , 1986) 
whereas the gene for basic FGF is present on chromosome 4, at 4q25 (Mergia 
et al., 1986). The genes for epidermal growth factor and interleukin-2 have also 
been mapped to chromosome 4 (McKusick 1985), while the genes for c-fms 
(the receptor for colony stimulating factor-1) and human PDGF receptor are 
localized on the short arm of chromosome 5 (Jaye et al. , 1986). 
Table 1.4: Biochemical Properties of Acidic and Basic FGF 
Properties Acidic FGF Basic FGF 
Target cells endothelial , epithelial, mesenchyme 
& neuronal cell types 
Molecular weight 16 18,22,23,24 
(kDa) 
,, Number of amino acids 154 154,196,201,210 
55°/o sequence homology 
lsoelectric point 5.6 9.6 
Signal sequence for 
secretion absent absent 
Human chromosome 
with FG F gene 5 4 
FGF receptor FGFR1,FGFR2 FGFR 1,FGFR2 
FGFR3, FGFR4 FGFR3 
FGFR sites/cell 5x1 o3-5x1 o4 3x1 o3-8x1 o4 
HSPG binding 
sites/cell 0.5x106-2x106 0.5x106-2x106 
' ; Kd for HSPG (nM) 2-10 2 I 
Elution from heparin 1M NaCl 1.6M NaCl 
Potentiation of 
m itogen ic activity 
by heparin yes no 
' 1: 
30 structure similar: both have 12 antiparallel ~ strands 
' with 3-fold internal symmetry 
Melting temperature 420c 570c 
! 
Effect of copper reduced unaffected 
I, 
mitogenesis & 
11 heparin binding I·, 
I, 
Effect of thrombin degraded & unaffected 
inactivated 
Based on reviews by D'Amore (1990b); Gospodarowicz et al.,(1986b); Rifkin & 
Moscatelli (1989); Lobb (1988b); Burgess & Maciag (1989). 
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Both aFGF and bFGF genes contain three exons separated by two large 
intrans at similar locations (Mergia et al., 1986; Abraham et al., 1986a,b). 
Comparison of the amino acid sequences of the different FGF family members 
has shown that FGFs tend to have sequence similarities in a "core" portion 
coded for by the 3' half of exon 1, exon 2 and exon 3, but differ greatly in the 
portion coded for by the 5' half of exon 1. The gene for bFGF is at least 36kb 
long (Abraham et al., 1986a,b,c), the two intrans each being 16kb long. 
Genomic sequences 5' of exon 1 contain five GC boxes, rather than the typical 
TATA or CAA T boxes, and are thought to represent SP-1 binding sites and one 
potential nuclear transcription factor, AP-1, binding site (Florkiewicz et 
al., 1991 a). The data of Florkiewicz et al.,(1991 a) suggest that the human 
bFGF gene promoter contains two negative regulatory regions. The second of 
these regions shares some homology with a negative regulatory sequence 
motif found in the c-myc gene promoter (Hay et al., 1989). It is yet to be 
determ_ined whether bFGF DNA sequence domains with negative regulatory 
properties act via a factor-dependent or factor-independent mechanism. 
However, the similarity between myc and bFGF in this region raises the 
possibility that fos or fos-like proteins may be a part of the protein(s) complex 
that mediates regulatory activity (Florkiewicz et al., 1991 a). It is not yet known 
whether similar regulatory domains exist within the promoter region of other 
members of the FGF family. 
Following transcription, a single bFGF mRNA transcript is translated into a set 
of four coexpressed isoforms with apparent molecular weights of 24, 23, 22 and 
18kDa (Florkiewicz & Sommer 1989; Prats et al., 1989). In contrast, evidence 
suggests that the various truncated forms of aFGF are artifacts of the 
purification procedures (MCKeehan & Crabb 1987). The translation of the three 
larger molecular weight forms (24,23, 22 kDa), but not the 18kDa form of 
bFGF, are thought to initiate from novel CUG (leucine) codons, rather than 
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from the classical AUG (methionine) codon (Florkiewicz & Sommer 1989). It 
has been suggested that alternative translation initiation could serve as a 
postranscriptional mechanism for regulating bFGF gene expression and 
intracellular localization (Florkiewicz et al., 1991 b). It is not known whether the 
three larger proteins have the same or different bioactivities as the 18 kDa 
protein. However, the data of Florkiewicz & Sommer (1989) show that the 
three higher molecular weight isoforms localize exclusively to the nucleus while 
the 18 kDa isoform is the only isoform exported onto the cell surface as well as 
colocalizing in the nucleus. Thus, it is possible that the different isoforms of 
human bFGF may have different functions depending upon their intracellular 
localization. In addition, truncated forms of bFGF, presumably the result of 
enzymatic degradation, have been purified from various tissues. For example, 
bFGF has been characterized as a 131 amino acid protein from ovary, kidney 
and adrenal tissue and as a 146 amino acid protein from brain and pituitary 
extracts (Burgess & Maciag 1989; Baird & Bohlen 1990). 
Hitherto, the only postranslational modification to be described for aFGF and 
bFGF is the acetylation of the amino terminal alanine of full length human and 
bovine aFGF (1-154) and bFGF (1-154). There is no evidence to suggest that 
glycosylation of the potential N-linked glycosylation sites in human aFGF and 
bFGF actually occurs. 
1.5.2. Binding Sites on FGFs 
FGFs bind to FGF receptors (FGFR) on cell surfaces and Baird et al.,(1988) 
have localized the receptor binding domain on FGF to a peptide spanning 
residues 106-115 of bFGF (Fig.1.1 ). This fragment begins in the middle of the 
9th P strand, forms an open loop on the surface of the bFGF molecule and 
terminates at the beginning of the 10th p strand. One would expect the 
receptor-binding domain to be conserved between aFGF and bFGF since they 
bind to similar receptors. However, aFGF has two additional amino acids 
FIGURE 1.1: Ribbon diagram illustrating the tertiary and secondary 
structure of bFGF. P-Sheet secondary structure is depicted with 
flattened ribbons. The polypeptide segment (residues 105-115) 
implicated in receptor recognition is shown in red. The diagram was 
produced using the computer program RIBBONS by M. Carson, 
University of Alabama, Birmingham. (From Zhang et al. 1991 ). 
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inserted at or near the position corresponding to the 102-113 peptide bond of 
bFGF with the result that the loop in aFGF corresponding to the 106-115 
fragment of bFGF does not have the same backbone conformation . 
Furthermore, modulation of receptor affinity has been observed to occur as a 
result of phosphorylation of bFGF at Thr-112 by protein kinase A. Thr-112 lies 
within this putative receptor-binding domain and upon its phosphorylation , 
which is blocked in the presence of heparin, the affinity of bFGF for its receptor 
is increased by a factor of 3-8 fold (Feige & Baird 1989). This modulation in 
affinity may be the result of electrostatic interactions with Thr(P)-112 or due to 
conformational changes induced by phosphorylation (Zhang et al., 1991 ). Two 
nearby arginine residues, -107 and -109, have been proposed to act as 
potential ligands for the phosphothreonine (Zhang et al., 1991 ). 
FGFs also bind to heparin and x-ray crystallographic analysis indicates that the 
presumed FGF receptor-binding region is about 25 Angstroms from the 
presumed heparin binding domain and that the two sites are on different faces 
of the molecule (Eriksson et al., 1991 ). This suggests that FGF binding to its 
receptor and FGF binding to heparin are likely to be independent events, 
supported by the observation that neutralizing antibodies inhibit the binding of 
bFGF to its receptor but not to heparin (Kurokawa et al., 1989). 
While bound to heparin, aFGF and bFGF are protected from inactivation by 
high temperatures, acidic conditions and proteolysis (Gospodarowicz & Cheng 
1986; Rosengart et al., 1988; Saksela et al., 1988; Mueller et al., 1989; Sommer 
& Rifkin 1989). Without native heparin, aFGF is relatively unstable at 
physiological temperatures at 35-450C undergoing large structural changes 
and loss of mitogenic activity. However, a three-fold weight excess of heparin 
can increase the melting temperature by 200c (Copeland et al., 1991 ). It has 
been suggested that heparin stabilizes aFGF in its native conformation 
(Gospodarowicz & Cheng 1986) rather than altering its conformation. Upon 
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binding to heparin, the thermal stability of bFGF is enhanced, raising the 
melting or transition temperature from 570c to 820c (Prestrelski et al., 1992). 
In contrast to aFGF, the binding of heparin to bFGF causes a conformational 
change in the molecule (Prestrelski et al., 1992). Heparan sulfate (HS), dextran 
sulfate and sucrose octasulfate also bind bFGF and induce a conformational 
change similar to that observed with heparin (Prestrelski, et al., 1992). The 
binding of heparin is thought to decrease the conformational flexibility of the 
bFGF molecule, or the steric hindrance from the bound heparin may lower the 
accessibility of the backbone amide hydrogens (Prestrelski et al., 1992). The 
interaction between FGF and heparin/HSPGs and its importance in the 
interaction of FGF with FGF receptors will be considered in more detail later 
(section 1. 7.4.4 ). 
Basic FGF, but not aFGF (Thomas & Gimenez-Gallego 1986), contains two 
Asp-Gly-Arg or OGR sequences which are the inverse of the cell adhesion 
sequence AGO (Presta et al., 1991 ). Generally peptides containing the AGO or 
OGR sequence can inhibit the interaction of integrins with ligands (Akiyama & 
Yamada 1985; Humphries et al., 1986; Hynes 1987; Ruoslahti & Pierschbacher 
1987) such as FN, laminin, vitronectin and collagen (Ruoslahti & Pierschbacher 
1986). It is hypothesized that bFGF may interact via its OGR sequences with 
an integrin-like molecule to affect bFGF-induced mitogenesis (Presta et 
al.,1991). 
Both aFGF and bFGF interact with copper, enabling their purification by copper 
bioaffinity chromatography (Shing 1988; Yuen et al., 1990). Recombinant 
human forms of the aFGF monomer protein completely convert to aFGF 
homodimers after exposure to copper (Engleka & Maciag 1992). Such 
homodimers fail to induce mitogenesis, an effect reversed by dithiothreitol 
(Engleka & Maciag 1992), and have a reduced affinity for immobilized heparin, 
eluting with 0.4M NaCl. Interestingly, human bFGF's mitogenic activity and 
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affinity for heparin are relatively unaffected after treatment with copper. It is 
suggested that this difference between aFGF and bFGF may be due to 
differences in free thiol content and arrangement (Engleka & Maciag 1992). 
1.5.3. Three Dimensional Structure of FGFs 
The three dimensional structures of bFGF (Fig. 1.1) and aFGF (Fig. 1.2) are 
similar, both structures consisting of 12 antiparallel 0 strands arranged in a 
pattern with approximately 3-fold internal symmetry (Zhu et al., 1990). 0 strands 
1,4,5,8,9, and 12 (numbered sequentially from amino terminus) form a six-
stranded antiparallel 0 barrel, closed at one end by 0 sheet interactions. There 
are extended loops between strands 03 and 04, between 07 and 08, and 
between 011 and 012. The main difference in the structures of aFGF and 
bFGF lies in the ordering of the nine residues at the amino terminus of aFGF 
and the deletion of two residues in bFGF corresponding to residues 105 and 
106 in a turn between two 0 strands (Zhu et al., 1990). The amino terminal 
region of aFGF has been proposed as a nuclear translocation sequence 
(Imamura et al., 1990) and the crystal structures of FGF are consistent with this 
proposal. X-ray crystallography has enabled bFGFs overall structure to be 
described as a trigonal pyramid with a fold very similar to that reported for IL-a, 
IL-10 and soybean trypsin inhibitor (Eriksson et al., 1991 ). The core of the 
bFGF molecule is packed with hydrophobic and aromatic amino acid side 
chains, while the surface of the molecule is rich in the charged amino acids 
arginine and lysine (Zhang et al., 1991 ). Basic FGF has four cysteine residues, 
located at positions 25, 69, 87 and 92 (Eriksson et al., 1991 ). Cysteines -25 
and -92 are conserved throughout the FGF family (Burgess & Maciag 1989) 
and are not involved in disulfide bridges. Examination of the crystal structure of 
bFGF shows that the cysteine residues are not located near enough to form a 
disulfide bond (Eriksson et al., 1991 ). However, bFGF does form oligomers, 
particularly dimers, under nonreducing conditions and thus dimerization may 
occur between Cys-69 and Cys-87 (Fox et al., 1988). 
FIGURE 1.2: Space-filling models of aFGF and a typical heparin 
tetrasaccharide. In the upper panel, the two views are 180° -y-
rotations of aFGF. The charged side-chain nitrogen atoms of basic 
residues are coloured blue; the side-chain acidic oxygen atoms are 
coloured red, and the cysteine sulfur atom is coloured yellow. All 
basic residues are labeled, along with the exposed Cys 117 and 
Trp107. A representative heparin tetrasaccharide is shown below. 
The lower panel is a ray-traced rendering of the above view that 
illustrates the presence of the striking cavities on the surface of 
aFGF (From Volkin et al 1993). 
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Similarly in aFGF, disulfide bonds are not formed between the two cysteines at 
positions 16 and 83 (Linemeyer et al., 1990). In fact the forced formation of a 
disulfide bond between Cys-16 and Cys-83 in aFGF by copper oxidation 
resulted in a complete loss of activity which could be restored upon reduction 
(Linemeyer et al., 1990). However, the two Cys residues in aFGF appear to 
correlate with selective and rapid inactivation of m itogenic activity in the 
absence of heparin but afford a longer half-life in its presence. Therefore, they 
may play a role in the regulation of aFGF activity by promoting the rapid 
inactivation of aFGF when it is not bound to HSPGs on selected cell surfaces 
as in basement membranes (Ortega et al., 1991 ). 
1.5.4. Tissue Distribution of FGFs 
Differences in the qualitative and quantitative profiles of FGF gene expression 
and the tight regulation of its spatial and temporal synthesis would be expected 
to influence its activities during normal cell growth and development. However, 
despite the ubiquitous distribution of aFGF and bFGF, the mRNA required for 
their synthesis is not easily detected in most tissues and alternative means of 
regulation have been proposed. For example, it is suggested that their 
availability is determined by the target cell altering its expression of high affinity 
FGF receptors, rather than by gene expression (Baird & Walicke 1989) and that 
FGFs may be held in a storage form, bound to HSPG, in the ECM or on the cell 
surface until required. Furthermore, damage or degradation of the ECM could 
decrease FGFs affinity for the ECM resulting in increased availability for FGF 
receptors on neighbouring cells. However, Nurcombe et al.,(1993) provide 
evidence that FGF activity during mouse neural precursor development is 
regulated in part, by differential gene expression. Basic FGF mRNA was easily 
detected at embryonic day 9 (E9) and throughout subsequent ages whereas 
aFGF mRNA was only detectable at E11 and later. 
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1.5.5. Secretion of FGF 
Unlike the other members of the FGF family, aFGF and bFGF lack a signal 
sequence normally required for transit through the secretory pathway. This has 
raised the question as to if, and how, aFGF and bFGF are released from living 
cells. Three models have been proposed to explain how FGF is released from 
the cell. 
Firstly, FGF may be released after injury to the cell. Clearly, FGF can be 
released by lethal cell injury, induced for example, by endotoxin and by 
irradiation. Interestingly, irradiation produced an increase in de novo synthesis 
of the growth factor, peaking 72 hours following radiation treatment (Witte et 
al., 1989). An interesting question is whether transient sublethal cell injury is 
sufficient to release significant amounts of FGF. McNeil and Ito (1989) 
proposed that membrane disruption might be a common occurrence in vivo and 
that plasma membrane wounding followed by resealing might enable molecules 
to move in and out of the cytoplasm. Endothelial cell plasma membranes were 
transiently injured by scraping and the conditioned media assayed for FGF-like 
activity (MCNeil et al., 1989). They suggest that transient cell injury is sufficient 
to release FGF but whether or not it occurs in vivo has yet to be demonstrated 
(MCNeil, et al., 1989). 
There is some evidence though, to suggest that bFGF is released from living 
cells which enables it to act as an autocrine factor. Rifkin, et al.,(1991) utilized 
the phagokinetic assay originally developed by Albrecht-Buehler (Albrecht-
Buehler 1977) to show that bFGF is in fact released from living cells and can 
act as a true autocrine factor (Quarto et al., 1991 ). Studies have shown that 
large vessel, small vessel and corneal endothelial cells all synthesize bFGF 
(Schweigerer et al., 1987c; Vlodavsky et al., 1987a,b). In the case of corneal 
endothelial cells, a majority of the FGF remains cell associated or in the ECM 
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(Vlodavsky et al., 1987a,b). Similarly for capillary endothelial cells , nearly all of 
the bFGF is cell associated (Schweigerer et al., 1987c). However, a 
measurable amount of bFGF in the conditioned media of adrenal cortex 
derived capillary endothelial cells has been shown to influence endothelial cell 
growth (Schweigerer et al., 1987a). 
Addition of a signal peptide to bFGF and transfection of cells with this 
construct, results in cells with a transformed morphology along with tumorigenic 
and metastatic potential. It is therefore proposed that bFGF's lack of a signal 
peptide prevents it from being involved in autocrine stimulatory loops leading to 
transformation (Vayon & Klagsbrun 1990). 
A second and alternative mode of FGF release could be similar to that 
described for a lectin from C2 mouse muscle cells which also lacks a signal 
peptide sequence and is also detected in the ECM (Cooper & Barondes 1990). 
This lectin is concentrated in patches beneath the plasma membrane which 
evaginate, producing extracellular vesicles containing the lectin. The 
extracellular vesicles release the lectin and it is proposed that the released 
material would then be able to bind to the cell surface and/or ECM. Such a 
release mechanism could help prevent excessive autocrine stimulation by FGF. 
The third model is based on the observation that migrating cells are known to 
leave behind "bits" of cytoplasm. The continuous deposition of FGF-containing 
cytoplasm could lead to an accumulation of extracellular FGF (D'Amore 
1990a). 
1.6. FGF Receptors 
The mitogenic response initiated by FGFs is mediated by a plasma-membrane 
bound high affinity receptor. Normal diploid cells which are FGF-sensitive have 
a low density of FGF receptors, ranging from 103-1 o4 receptors/cell (Neufeld & 
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Gospodarowicz 1985). In contrast, established cell lines have a much higher 
density of FGF cell surface receptors (Neufeld & Gospodarowicz 1985, 1986). 
For example, on BHK-21 cells aFGF binds its receptor with a Kd of 25 pM and 
there are 87,000 binding sites/cell (Neufeld & Gospodarowicz 1986) whereas 
for the same cell type bFGF has a Kd of 27 pM and 120,000 binding sites/cell 
(Neufeld & Gospodarowicz 1985). Binding of the FGFs to their receptors 
induces receptor down regulation and internalization of the ligand (Schreiber et 
al., 1985; Friese! et al., 1986; Huang et al., 1986; Clegg et al., 1987). 
Surprisingly, once internalized aFGF is relatively resistant to degradation (Kan 
et al., 1988; Friese! & Maciag 1988), the degradation products not appearing 
until two-three hours after internalization (Friese! & Maciag, 1988). 
Cells also express a large number of low affinity binding sites for FGFs, 
determined to be HSPGs located on the cell surface or in the ECM (Moscatelli 
1987, 1988; Bashkin et al., 1989). FGFs bind to these low affinity sites with a Kd 
of between 2 and 1 OnM and can be removed by incubation with heparin, 
washing with 2M NaCl or by treatment with heparinase (Moscatelli 1987). The 
importance of these low affinity sites in the binding of FGFs to their high affinity 
receptor will be discussed later on (see section 1.7.4). 
Initial studies using iodinated FGFs demonstrated that they bound with high 
affinity to receptors with Kds of 50-500pM for aFGF (Schreiber et al., 1985; 
Baird et al., 1986; Libermann et al., 1987) and 10-200pM for bFGF (Neufeld & 
Gospodarowicz 1985; Maenner et al., 1986; Olwin & Hauschka 1986; Moscatelli 
1987). The hypothesis that different members of the FGF family shared a 
common receptor was supported when it was shown that hst/KFGF caused a 
down regulation of high affinity binding sites for bFGF, indicating that bFGF and 
hst/KFGF can cross react with the same receptor (Moscatelli & Quarto 1989). 
Crosslinking experiments with aFGF and bFGF led to the detection of receptor 
species in the molecular weight range of 125-165 kDa (Neufeld & 
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Gospodarowicz 1985, 1986; Friesel et al., 1986; Moenner et al., 1986; Olwin & 
Hauschka 1986, 1989; Liebermann et al., 1987; Courty et al., 1988) with the two 
most prominent bands seen being 125kDa and 145kDa proteins. Acidic and 
basic FGF were able to bind to both the 125kDa and 145kDa proteins, bFGF 
having a higher affinity than aFGF for the 145kDa receptor species whilst aFGF 
had a higher affinity than bFGF for the 125kDa species (Neufeld & 
Gospodarowicz 1986; Olwin & Hauschka 1986). Although it was initially 
thought that the 125kDa protein represented a proteolytic cleavage product of 
the 145 kDa protein, it is now known that the two proteins are derived from 
different alternately spliced forms of FGF receptor mRNA. 
The FGF receptors belong to the protein-tyrosine kinase superfamily of 
proteins (Fig.1.3). The observation that they contain immunoglobulin-like 
binding domains, also present in Drosophila, suggests that lg-like binding 
domains in cell receptors preceded the immune system in vertebrates. It 
appears that the novel mechanisms which have evolved to generate diversity 
and secreted isoforms, are the same mechanisms which were later improved 
upon to produce the great diversity amongst immunoglobulin genes (Givol & 
Vayon 1992). 
1.6.1. Structural Features of FGF Receptors 
The different FGFR genes and their splice variants have been described in the 
literature under many different names. Table 1.5 should help to clarify some of 
this confusing nomenclature. 
The first complete FGF receptor cDNA, denoted FGFR 1, was isolated in 1989 
by Lee et al., (1989) and since then three more distinct FGF receptor genes 
have been identified, namely, FGFR2, FGFR3 and FGFR4 (Fig.1.4). In 
general, the structures of FGFR3 and FGFR4 are very similar to those of 
FGFR 1 and FGFR2. Although alternative splicing of the genes for FGFR 1 and 
FIGURE 1.3: Receptor tyrosine kinase families. Five classes of 
receptor tyrosine kinase are shown, displaying structural features 
which define each class. The nature of each of these structural 
features is shown below. Classes I, II and Ill are as defined by 
Varden & Ullrich (1988). (From Wilks 1993). 
Class I Class III Class II Class IV Class V 
EGF R 
NEU 
ErbB3 
Xmrk 
DER 
/et23 
PDGFa-R 
PDGFJ3-R 
CSFl-R 
c-kit 
INSULIN-R 
IGFI-R 
IRR3 FGF R 
BEK 
CEK2 
FGFR4 
£PH 
ELK 
ERK 
EEK 
ECK 
HEK 
FLT 
FLT3 
NEK/FLkl 
mmJ = Fibronectin type III repeat 
Q] = Cysteine Rich Domain 
• = Cysteine Rich Domain II 
• = Cysteine Rich Domain m 
~ = lg-like Domain 
fffl = Trans-membrane Domain 
• = Tyrosine Kinase Domain 
1111 = Insert Domain 
-e = Ligand-dependent 
Autophosphorylation Sites 
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Table 1.5: 
Nomenclature of the Different FGF Receptor Genes 
FGFR1 FGFR2 FGFR3 FGFR4 
fig bek Cek2 FGFR4 
bFGFR Cek3 FGFR3 
Cek1 K-sam 
N-bFGFR K-sam' 
h2, h3 TK14 
h4, hS TK25 
FGFR1 KGFR 
FGFR2 
From Johnson & Williams (1993) 
Table 1.6: 
Relative Binding Affinities of FGFs to FGFR1, FGFR2, FGFR3 and FGFR4 
Containing Different Sequences in the Third lg Domain (Ill) 
FGFR1 
Illa bFGF>aFGF 
· lllb . aFGF>bFGF 
Ille aFGF=bFGF 
FGFR2 
lllb aFGF=KGF>bFGF 
Ille aFGF=bFGF (KGF does not bind) 
FGFR3 
Ille aFGF=bFGF 
FGFR4 
Ille aFGF (bFGF does not bind) 
From Johnson & Williams (1993); Keegan et al.,(1991 ); Partanen et al., (1991 ). 
. 
FIGURE 1.4: Schematic diagram of FGF receptor protein 
structures. The figure shows the structure of variant receptor forms 
predicted by published cDNAs. The names of some receptor 
variants as they appear in the literature are written directly above 
the structure. Although cDNAs encoding the receptor variant 
depicted by an asterisk (iii) have not been isolated, PCR and 
Northern blotting experiments have identified mRNA transcripts 
encoding this receptor form (Johnson et al., 1991; Werner et al., 
1992). Furthermore, both 3 lg and 2 lg domain forms of this 
receptor mRNA appear to exist. The following structural features 
are identified in the figure: the 32 unique amino acids at the C-
terminus of the FGFR 1 lg domain 1 secreted form (solid oval), acid 
box domains (open boxes), alternative sequences for the second 
half of lg domain Ill labeled Illa, lllb, or Ille (thick black line), 
transmembrane domains (solid boxes), kinase I and kinase 2 
domains (stippled boxes), and the unique C-tail domains of 2 
FGFR2 proteins (checkered box and striped box). 
(From Johnson & Williams 1993) 
FGFR 1 FGFR 2 FGFR 3 FGFR 4 
h4 
* 
flgibFGFR h2 K-sam' KGFR K-sam BEK/TK14 BEK' TK25 
~ 
P' ,.::J 
• 
(•) (io) (oii) (i v) M (VI) (vu) {VIII) (ix) (x) (xo) (xii) (xiii) 
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FGFR2, gives rise to multiple forms of the receptor, at this stage, only single 
cDNAs have been isolated for FGFR3 and FGFR4, both encoding 3 lg domain 
receptor forms (Keegen et al. , 1991; Partanen et al. , 1991 ). Studies utilizing 
Northern blotting, RNase protection analyses and in situ hybridization have 
shown that FGFR1 and FGFR2 exhibit broad but distinct patterns of expression 
both during development and in adult animals, while FGFR3 and FGFR4 genes 
have more restricted patterns of expression (Johnson & Williams 1993). 
FGFR 1 was first purified from chicken embryos with the aid of biotinylated FGF 
and heparin (Kiefer et al., 1990). Peptides of the purified chicken FGF receptor 
were shown to have amino acid sequences very similar to the predicted amino 
acid sequences of cDNA clones of human fig (Ruta et al., 1988) and mouse bek 
(Kornbluth et al., 1988). At the time of their discovery, the function of fig and 
bek proteins was unknown but it is now known that fig and bek cDNA clones 
represent specific splice variants of the FGFR1 and FGFR2 genes respectively. 
A cDNA encoding the chicken FGFR1 was found to encode a protein with a 
deduced molecular mass of 92 kDa (not including carbohydrate side chains) 
(Lee et al., 1989). Features which it had in common with receptors for other 
growth factors were a single membrane spanning region, an amino-terminal 
signal peptide, and three extracellular lg-like domains (Williams & Barclay 
1988). However, it was unique in that it contained a domain of eight 
consecutive acidic residues, called the "acid box". The FGFR4 protein is 
unique in containing a core of only four consecutive acid residues in the acid 
box, a shorter core sequence than found in the acid box domains of FGFR 1, 
FGFR2 and FGFR3. 
The presence of consensus tyrosine kinase sequences confirmed the receptor 
as a tyrosine-specific protein kinase (Huang & Huang 1986; Coughlin et 
al., 1988). The tyrosine kinase sequence is split by an insertion of 14 amino 
acids and is considerably shorter than those of PDGF-P (Varden et al. , 1988) 
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and CSF-1 (Coussens et al., 1986) receptors but similar to those of insulin and 
insulin-like growth factor-1 receptors (Ullrich et al., 1985, 1986) (Fig.1.5). 
A most interesting discovery has been the isolation of multiple, distinct cDNAs 
encoding variant forms of FGFR1 and FGFR2 (Dionne et al., 1990; Johnson et 
al., 1990; Reid et al., 1990; Champion-Arnaud et al., 1991; Eismann et al., 1991; 
Hou et al., 1991; Miki et al., 1991 ). It now seems that alternative splicing of 
mRNA is responsible for the diverse receptor forms (Champion-Arnaud et 
al., 1991; Johnson et al., 1991 ), many more than seen for any other growth 
factor receptor. Alternative splicing may result in either a) the 
inclusion/exclusion of additional amino acids or b) the use of alternate coding 
exons with no net gain or loss of amino acids, in both cases producing 
structurally different proteins. 
Since the first reported FGFR 1 cDNA was shown to encode a protein with 3 lg 
domains, cDNAs encoding FGFR 1 proteins that are missing lg domain 1 have 
been found (Johnson et al., 1990; Mansukhani et al., 1990; Reid et al., 1990) 
apparently produced by alternative splicing (Fig.1.4). The function of the lg 
domain 1 is currently unknown but it does not appear to be necessary for high 
affinity binding of aFGF and bFGF as the 3 lg domain form of FGFR 1 has been 
shown to have binding affinities for aFGF and bFGF (Dionne et al., 1990; 
Johnson et al., 1990) similar to those of the 2 lg domain form of FGFR1 
(Johnson et al., 1990). cDNAs encoding 3 lg domain and 2 lg domain forms of 
FGFR2 have also been identified (Dionne et al., 1990; Hattori et al., 1990; 
Houssaint et al., 1990; Champion-Arnaud et al., 1991; Crumley et al., 1991; Miki 
et al., 1991) and both forms exhibit similar high affinities for aFGF and bFGF 
(Dionne et al., 1990; Crumley et al., 1991 ). Thus, as is the case with FGFR 1, lg 
domain 1 of FGFR2 does not seem to be required for high affinity binding of 
aFGF and bFGF. 
Signal 
peptide 
lg domain I 
Acid box 
lg domain II 
lg domain III 
Membrane-
proximal 
TM 
JM 
Kinase 1 
Kinase 
insert 
Kinase 2 
C-tail 
(30) 
( 119) 
(149) 
(248) 
~--- (360) 
,._ ___ (376) 
.,_ ___ (397) 
~- (580) 
~- (594) 
..._,:·:-:;..:..i.·:· 4-----
.,._ ___ (822) 
FIGURE 1.5: Structural features of the FGFRI protein. The numbers in 
parentheses indicate the last amino acid of each domain (From Johnson & 
Williams 1993). 
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As was mentioned previously, the early crosslinking studies with aFGF and 
bFGF identified two prominent polypeptides of 125 and 145 kDa. Recent 
studies (Dionne et al., 1990; Johnson et al., 1990; Mansukhani et al., 1990) have 
revealed that cross-linked receptors containing 3 lg domains are about 145 kDa 
in size while cross-linked receptors containing 2 lg domains are approximately 
125 kDa in size. Coexpression of 3 lg and 2 lg mRNA transcripts have been 
detected in a variety of cell lines using PCR (Johnson et al., 1990; Eisemann et 
al., 1991 ), Northern blotting (Reid et al., 1990; Eisemann et al., 1991) and RNase 
protection analyses (Werner et al., 1992). This suggests that the 145 and 125 
kDa bands represent the 3 lg and 2 lg receptor forms respectively. 
Johnson et al.,(1990) have reported a novel protein which represents a 
secreted form of the 2 lg membrane-spanning form of FGFR 1. This secreted 
form is identical to the 2 lg form until halfway through the lg domain Ill 
(Johnson et al., 1990) where it diverges and then terminates in 79 amino acids 
downstream. It also does not contain a hydrophobic membrane-spanning 
domain. A 3 lg domain form of this secreted protein has also been discovered 
and shown to bind bFGF (Duan et al., 1992). It is hypothesized that the 
secreted FGFR could act as an extracellular reservoir of FGF, regulating the 
availability of FGFs to cell surface receptors. 
The secreted form of FGFR 1 was shown to preferentially bind bFGF over 
aFGF which may indicate that it plays a specific role in regulation bFGF 
function. The mouse counterpart of the secreted human form lacks the COOH-
terminal half of the predicted third lg-like domain (Werner et al., 1992) and binds 
both basic and acidic FGF with low affinity, Kds being greater than 1 OOnM 
(Werner et al., 1992). Therefore the COOH-terminal half of the 3rd lg-like 
domain may be required for determining the affinity and specificity for FGF 
ligands. Other secreted growth factor receptors generated by alternative 
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splicing of mRNA are the secreted IL-4 receptor (Mosley et al., 1989) and the 
secreted IL-7 receptor (Goodwin et al., 1990). 
There are three alternative exons for the second half of lg domain Ill in human 
FGFR1 and these have been denoted Illa, lllb and Ille (Johnson et al.,1991). 
The FGFR2 gene has exons corresponding to lllb and Ille but not to Illa, whilst 
FGFR3 and FGFR4 have only exons Ille in their lg domain Ill (Keegan et 
al.,1991, Partanen et al.,1991) (Fig.1.4). Comparisons of the lllb and Ille 
sequences of FGFR1 and FGFR2 show a greater divergence between similar 
exons (lllb and Ille of the same gene, than between corresponding exons of 
different genes), suggesting that the existence of the lllb and Ille exons is what 
enabled the existence of a multigene family (Johnson & Williams 1993). 
Binding experiments have shown that alternative splicing in the third lg domain 
is important for determining receptor binding specificities for those FGFs that 
have been compared namely, aFGF, bFGF and KGF. Table 1.6 shows the 
effect of alternate splicing in the third lg domain of FGFR 1, FGFR2, FGFR3 
and FGFR4 on the relative binding affinity of aFGF, bFGF and KGF. 
1.6.2. FGF Receptor Sequence Homology 
There is a striking degree of similarity in the amino acid sequences of FGFR1 
proteins from different species. The mouse, chicken, and Xenopus FGFR 1 
proteins are 98°/o, 91 °/o and 78°/o identical to the human FGFR 1 protein. The 
most highly conserved regions of the receptor molecule are the kinase 1 and 
kinase 2 domains which exhibit 92°/o and 95°/o identity respectively with human 
and Xenopus whereas the least conserved regions are the signal peptide 
region and the lg domain 1, the membrane proximal domain, the 
transmembrane domain and the kinase insert domain. This is a higher level of 
identity than observed among different members of the FGF family (35 to 55°/o). 
However, the pattern of conservation is similar to that observed when 
comparing FGFR1 domains across species. Table 1.7 shows the overall 
Table 1.7: 
Sequence Homology Between the Different Human FGF Receptor Genesa 
FGFR1 
FGFR2 
FGFR3 
FGFR2 
72°/o 
FGFR3 
62°/o 
66°/o 
FGFR4 
55°/o 
57°/o 
61 °/o 
asequence homology in the 3 lg domain receptor forms containing Ille type 
sequences. 
From Johnson & Williams (1993) 
Table 1.8: 
Tissue Distribution of FGF Receptors in Human Foetal Tissue 
Receptor 
FGFR1 
FGFR2 
FGFR3 
FGFR4 
Distribution 
growth plate of bones , 
skin , brain-neuronal 
populations 
choroid plexus , skin , lung , 
kidney, temporal lobe, 
brain-g lial cells 
intest ine, lung , kidney, 
bone growth plates 
adrena l, lung, kidney, liver 
Reference 
Partanen et al. , ( 1991 ) 
Peters et al. , (1992) 
Partanen et al. ,(1991 ) 
Peters et al.,(1992) 
Partanen et al. ,(1991 ) 
Partanen et al.,( 1991 ) 
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degree of amino acid identity of the Ille type sequences in the 3 lg domain form 
of the different human FGFR genes. 
1.6.3. Tissue Distribution of FGF Receptors 
Multiple members of the FGF family can bind to the same receptor species. 
Both aFGF and bFGF have been shown to bind to 3 lg and 2 lg FGFR 1 forms 
with high affinity (Kd for aFGF of 20-SOpM and 50-1 SOpM for bFGF) (Dionne et 
al., 1990; Johnson et al., 1990) and to activate receptor tyrosine kinase activity 
and receptor mediated signalling (Dionne et al., 1990; Johnson et al., 1990; 
Mansukhani et al., 1990). Hst/KFGF also binds to both receptor forms but with 
lesser affinity than acidic and basic FGFs (Dionne et al., 1990; Mansukhani et 
al., 1990). Similarly, multiple members of the FGF family are able to bind to, 
and activate FGFR2 and FGFR3 proteins. This leads us to the question of how 
cells and tissues can selectively respond to individual members of the FGF 
family. Distinct receptors may be able to generate different cytoplasmic signals 
by differential tissue expression of the receptors and limited mobility of the 
ligands. FGFR1, FGFR2, FGFR3 and FGFR4 expression, when analyzed at 
the RNA level are found to be independently regulated in human fetal (17-18 
week) tissues (Partanen et al., 1991) (see Table 1.8). Differential expression of 
FGFR 1 and FGFR2 in mouse embryos was demonstrated by in situ 
hybridization which showed FGFR1 to be associated with mesenchymal tissues 
and FGFR2 with epithelium (Peters et al., 1992a; Ueno et al., 1992). The same 
pattern of expression has also been observed in embryonic tissues such as 
skin, limb, gut and lung (Peters et al., 1992a). The expression of the three 
FGFRs, cek-1 (FGFR1 ), cek-2 (FGFR2) and cek-3 (FGFR3), has also been 
shown to change during chick embryo development indicating their temporal 
regulation (Patstone et al., 1993). Rather than the distribution of FGFs 
matching a particular receptor, different FGFRs appear to be associated with 
particular cell types and will interact with whichever growth factor is present in 
its vicinity (Patstone et al., 1993). The spatial and temporal expression pattern 
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of the FGF receptors, along with their differential binding specificity is proposed 
as the means by which the function of the FGF receptors is controlled (Ornitz & 
Leder 1992). 
Differential expression of the Illa, lllb and Ille exons by FGFR1 in mouse 
tissues has been demonstrated (Werner et al., 1992). The Ille exon was 
expressed simultaneously with more than one exon, with Ille expression levels 
being much higher than those of Illa or lllb exons. Johnson et al., (1990) also 
found this to be the case in several human cell lines. Werner et al.,(1992) 
found exons Illa and lllb to exhibit more restricted patterns of expression; Illa 
being expressed in brain, skeletal muscle and skin, and lllb predominantly in 
skin but at low levels in brain, kidney, muscle and placenta. 
Removal of the first lg domain by alternative splicing has been shown to occur 
in a tissue-specific fashion. Three lg domain forms of FGFR 1 are the 
predominant form of receptor expressed during mouse embryogenesis (Reid et 
al., 1990; Werner et al., 1992) while 2 lg domain forms are not detected by 
Northern blotting and RNase protection assays until after birth. After birth, 3 lg 
and 2 lg forms are simultaneously expressed in tissues such as heart, lung, 
and muscle (Werner et al., 1992). Three lg domain forms, however, remain the 
predominant form in brain and kidney. 
Tissue specificity of expression of alternatively spliced transcripts has also 
been shown to occur. KGFR and FGFR2 are both encoded by the same gene 
but KGFR, detected by a probe specific for exon lllb, is associated with 
epithelial cells of skin and internal organs or ducts while FGFR2 (exon Ille) is 
confined to bones and nonmesenchymal layers (P.Lonai-personal 
communication to Givol & Vayon 1992). These data are suggestive of a 
mechanism specific to cell-type, utilizing mutually exclusive alternative splicing. 
The different binding properties of keratinocytes and fibroblasts/endothelial 
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as the means by which the function of the FGF receptors is controlled (Ornitz & 
Leder 1992). 
Differential expression of the Illa, lllb and Ille exons by FGFR1 in mouse 
tissues has been demonstrated (Werner et al., 1992). The Ille exon was 
expressed simultaneously with more than one exon, with Ille expression levels 
being much higher than those of Illa or lllb exons. Johnson et al., (1990) also 
found this to be the case in several human cell lines. Werner et al.,(1992) 
found exons Illa and lllb to exhibit more restricted patterns of expression; Illa 
being expressed in brain, skeletal muscle and skin, and lllb predominantly in 
skin but at low levels in brain, kidney, muscle and placenta. 
Removal of the first lg domain by alternative splicing has been shown to occur 
in a tissue-specific fashion. Three lg domain forms of FGFR 1 are the 
predominant form of receptor expressed during mouse embryogenesis (Reid et 
al., 1990; Werner et al., 1992) while 2 lg domain forms are not detected by 
Northern blotting and RNase protection assays until after birth. After birth, 3 lg 
and 2 lg forms are simultaneously expressed in tissues such as heart, lung, 
and muscle (Werner et al., 1992). Three lg domain forms, however, remain the 
predominant form in brain and kidney. 
Tissue specificity of expression of alternatively spliced transcripts has also 
been shown to occur. KGFR and FGFR2 are both encoded by the same gene 
but KGFR, detected by a probe specific for exon lllb, is associated with 
epithelial cells of skin and internal organs or ducts while FGFR2 (exon Ille) is 
confined to bones and nonmesenchymal layers (P.Lonai-personal 
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cells for FGF may well reflect differential expression of lllb and Ille exons in 
these cells. Basic FGF and not aFGF stimulates mitogenesis in human 
melanocytes (Halaban et al., 1987), and while aFGF and bFGF stimulate the 
proliferation of fibroblast and endothelial cells, KGF does not (Rubin et 
al., 1989). In contrast, KGF stimulates keratinocyte proliferation. 
Differences in the affinity of the various FGFs for particular receptors is 
attributed to the differences between the genes, (possibly sequence differences 
between homologous domains), rather than to differential splicing leading to 
heterologous domain structures (Ornitz & Leder 1992). Keegan et al., (1991) 
suggest that each of the FGFRs is likely to have a specific ligand but may be 
able to bind more than one ligand at lower affinity and that each isoform of a 
particular receptor may also have different binding capacities for the same 
ligand (Table 1.6). 
1.6.4. FGFRs in Invertebrates 
Shishido et al.,(1993) have identified two homologues of mammalian FGFR 
genes in the Drosophila genome and denoted them DFR 1 and DFR2. DFR2 
seemingly corresponds to DFGFR identified by Glazer & Shilo (1991 ), because 
it is expressed in endodermal precursors and is virtually identical in nucleotide 
sequence. Initially during embryogenesis, DFR1 is expressed in mesodermal 
primordium and DRF2 in the primordia of the anterior and posterior midguts. 
Later, DFR 1 RNA is expressed in developing tissues derived from mesoderm 
and neuroectoderm while DFR2 RNA is expressed in ectoderm and 
mesoectoderm derived tissues. It is suggested that DFR 1 and DFR2 genes 
may be derivatives of a common ancestral arthropod gene which diverged from 
an ancient vertebrate FGF-R gene when the major phylogenetic branch to the 
arthropods and chordates occurred (Glazer & Shilo 1991 ). DFR1 has been 
shown to have 2 lg-domains and DRF2 to have 5 lg domains and they may 
recognize different ligands. 
'l 
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1.7. Heparin/HSPG Interaction with FGF 
An important feature of acidic and basic FGF is their ability to bind to heparin 
and HS. Recent studies have demonstrated that this interaction is essential for 
the full biological activity of FGF to be expressed (Vayon et al., 1991; Rapraeger 
et al., 1991; Olwin & Rapraeger 1992; Mansukhani et al., 1992). This section 
will consider the heparin/HS -FGF interaction in considerable detail, particularly 
as this interaction is the subject of much of the research work presented in this 
thesis. 
1.7.1. Structural Features of Heparin and Heparan Sulfate 
Before discussing the interaction of heparin and HS with acidic and basic 
FGFs, I will briefly describe and compare the structural features of heparin and 
HS. Heparin and HS are GAGs and they share with the other GAGs namely, 
chondroitin sulfate, dermatan sulfate, keratan sulfate and hyaluronic acid, a 
characteristic disaccharide repeat sequence, one monosaccharide of the 
disaccharide repeat being an amino sugar and the other, except in the case of 
keratan sulfate, a uronic acid residue (Jackson et al., 1991 ). With the exception 
of hyaluronic acid which is not sulfated, they are variably N-and 0-sulfated (see 
Jackson et al., 1991 for review). 
Heparin and HS are the most negatively charged structures produced by 
vertebrate cells. They are ubiquitously distributed throughout the animal phyla 
being present in chordates, mollusks, annelids and arthropods and also in 
animals as ancient as coelenterates (Nader et al., 1988). The most notable 
structural features of heparin and HS are their high negative charge density 
resulting from carboxyl and sulfate groups and their heterogeneous 
composition. Their unbranched carbohydrate backbone consists of either D-
glucuronic (GlcA) or L-iduronic (ldoA) acid and D-glucosamine (GlcN) units 
joined by a1 ,4-glycosidic linkages (Kjellen & Lindahl 1991 ). Figure 1.6 
-0 
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COOH 
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OH 
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FIGURE 1.6: Typical oligosaccharide structures of heparin and heparan 
sulfate. (From Silbert 1982) 
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illustrates the typical disaccharide structures of heparin and HS. Due to the 
variable location of N-acetyl, N-sulfate and 0-sulfate groups on these three 
constituent monosaccharides there are at least ten different monosaccharide 
building blocks which can be combined into a large number of different 
saccharide sequences (Lindahl 1989). Heparin and HS are composed of the 
same monomeric building blocks, the components being present in different 
proportions. In heparin, generally more than 80°/o of the GlcN residues are N-
sulfated. There is much 0-sulfation and a high ldoA/GlcA ratio. In contrast, in 
HS, less than 80°/o of GlcN units are N-sulfated, there is a lower ldoA content 
and a lower overall degree of 0-sulfation (Gallagher & Walker 1985). In 
addition, HS is distinctive in that it has long N-acetyl rich sequences 
interspersed with N-sulfated regions (Fig. 1. 7) (Gallagher & Turnbull 1992). 
Specific combinations of such saccharide units may serve as specific binding 
regions for proteins and thus mediate the various biological activities of the 
polysaccharide. For example, heparin contains a specific pentasaccharide 
sequence to which antithrombin Ill (ATIII) binds, with the effect that heparin 
accelerates the rate at which ATIII inactivates proteinases of the blood 
coagulation system (Marcum & Rosenberg 1989). 
Heparin is synthesized by mast cells and stored within the cytoplasmic granules 
of these cells. In bovine liver capsule heparin occurs as single polysaccharide 
chains of molecular weight greater than 10,000 (Jansson et al., 1975), but in rat 
skin (Horner 1971) and in peritoneal mast cells (Yurt et al., 1977) it has a 
molecular weight of approximately 1x106 and the GAG chains are attached to a 
core protein structure. Apparently, after heparin is released from mast cell 
granules it exists as free GAG chains, not associated with a core protein. 
Some tissues have been found to contain heparin in both forms (Ogren & 
Lindahl 1971) and it is thought that the single chain forms may be the result of 
cleavage of the polypeptide-bound chains by specific endoglycosidases at a 
limited number of sites (Ogren & Lindahl 1971; Horner 1977). 
FIGURE 1. 7: Domain structure of heparan sulfate. Heparan sulfate 
is believed to have a domain structure with N-sulfated regions 
interspersed with long N-acetyl-rich sequences. Heparanase 
cleavage sites are present in the sulfated domains. The most 
proximal (to the protein) heparinase site is -16 disaccharides from 
the core protein, whereas the innermost N-sulfate is -1 O 
disaccharides from the protein. (From Gallagher & Turnbull 1992) 
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Unlike heparin, whose GAG chains have to date only been found in association 
with one type of core protein, HS chains occur bound to several proteins, and 
all mammalian cells studied have been shown to produce HSPGs (Kjellen & 
Lindahl 1991 ). HSPG is also the most ubiquitous of the cell surface 
proteoglycans. In addition, it is located intracellularly within storage vesicles of 
various secretory cells and possibly in the nucleus, and extracellularly in the 
pericellular matrix and basement membrane (Kjellen & Lindahl 1991) (Table 
1.9). A number of HSPGs have been classified according to their core protein. 
For example, syndecans are membrane intercalated cell surface proteoglycans 
which bind growth factors and ECM molecules extracellularly while associating 
with the actin-containing cytoskeleton intracellularly (Rapraeger et al. , 1987; 
Barnfield & Sanderson 1990). Serglycins are mainly located intracellularly in 
storage vesicles, and have core proteins with extended sequences of 
alternative serine and glycine units heavily substituted with chondroitin sulfate 
and/or HS chains (Kjellen & Lindahl 1991 ). 
There are several different ways in which cell-surface-located HSPGs may be 
associated with the plasma membrane. Syndecan is anchored to the plasma 
membrane via a hydrophobic stretch of amino acids that intercalate in the lipid 
bilayer whereas other HSPGs are anchored in the membrane via a covalent 
linkage of the polypeptide core with glycosyl phosphatidylinositol (GPI) 
(Ishihara et al., 1987; Carey & Evans 1989). Such GPl-linked proteoglycans 
can be readily released from membranes by phospholipases. Thus, fifty 
percent of membrane-anchored HSPGs are released from Schwann cells 
derived from neonatal rat sciatic nerves by phospholipase C (PLC) (Carey & 
Evans 1989). Similarly, Brunner et al., (1991) have shown that bFGF can be 
released from human bone marrow cells by incubation with Pl-PLC which 
indicates that bFGF binds to a HSPG linked to the cell surface via a GPl-
anchor. A GPl-linked HSPG might provide a highly selective and efficient 
Table 1.9: Heparan Sulphate and Heparin Proteoglycans 
Glycosam inoglycans 
Proteoglycan MW Chain MW Core Cell/tissue 
type number protein expression 
MW 
Cell surface 
HSPG 7.5x1o4 4 1.4x1 o4 3x1 o4 Liver cell surface 
3.5x1 o5 4-6 per 2x104 9x104 Fibroblast cell 
polypeptide (dimer) surface 
1-2x1 o5 ND ND 1x1Q5 Synaptic 
vesicles 
Basement 
membrane 
HSPG 1.3-2.5x1 o5 4-5 2.sx104 0.9-1. 7x1 o5 Glomerulus 
>7.5x1 o5 6-12 ?x104 3.5x1 o5 Engelbreth-Holm-
Swarm sarcoma 
4x105 10 2.sx104 1.5x1 o5 PYS-2 terato-
carcinoma cells 
Heparin 1x106 9-12 o.s.: 1 x1 o5- 2.0x1 o4 Mast cell 
From Poole (1986) 
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mechanism for releasing active growth factor without otherwise perturbing the 
microenvironment (Brunner et al., 1991 ). 
Alternatively, HSPGs may associate with the cell membrane via cell-surface 
receptors that specifically recognize core proteins or are held at the cell surface 
through noncovalent binding of the glycan side chains to a membrane receptor 
(Hook et al., 1984). Such receptors could participate in the endocytosis of 
extracellular proteoglycans. These heparan sulfates can be released from the 
membrane by inositol hexaphosphate, heparin or high salt concentrations 
which are thought to compete for the electrostatic interactions between the 
negatively charged HS side chains and the positively charged proteins at the 
cell surface (Carey & Evans 1989). Similarly, sulfated GAG molecules which 
are free of their core proteins have been identified as peripheral components of 
3T3 fibroblast plasma membranes. Piepkorn et al., (1989) suggested that 
membrane-associated endoglycosidases may be responsible for the release of 
these peripheral GAGs from their core protein. In fact, Gallagher et al., (1988) 
have isolated and characterized a liver plasma membrane-associated HS 
endoglycosidase which may perform this function. 
1.7.2. Heparin Binding Domain of Acidic and Basic FGF 
In an attempt to further understand the role of heparin/HS in FGF action and 
the specificity of this interaction, as well as the interaction between FGF and its 
receptor, structure-function studies have concentrated on locating and defining 
the heparin-binding and receptor-binding domains of acidic and basic FGF. 
Studies utilizing chemical modification, site-directed mutagenesis and synthetic 
peptides have implicated basic residues, in particular Lysine-118, in the heparin 
binding site of aFGF and bFGF (Baird et al., 1988; Harper & Lobb 1988; Lobb 
1988a; Seno et al., 1990; Burgess et al., 1991) (See Table 1.1 O) Lysine 
residues have also been implicated in the interaction between heparin and 
Table 1.10: 
Regions on FGFs Proposed as Heparin-Binding Domains 
Analysis by: Residues implicated Reference 
Acidic FGF 
reductive methylation Lys-118 Harper & Lobb ( 1988) 
site-directed m utagenesis Lys-132 Burgess et al.,(1991) 
synthetic peptides 49-71 Mehlman & Burgess (1990) 
X-ray crystallography 105-128 Zhu et al.,(1991) 
X-ray crystallography Asn-18, Lys-113, Eriksson et al., ( 1991) 
Lys-118 
X-ray crystallography Lys-112, Lys-118, Volkin et al.,(1993) 
Arg-119, Arg-122 
Basic FGF 
Deletion m utagenesis Thr 105-Pro 141 Seno et al.,(1990) 
Synthetic peptides 24-68, 73-87, Baird et al.,(1988) 
93-120 
X-ray crystallography Lys-119, Arg-120, Zhang et al.,(1991) 
Lys-125, Lys-129 
X-ray crystallography 105-128 Zhu et al.,(1991) 
X-ray-crystallography Asn-27, Arg-120, Eriksson et al., ( 1991) 
Lys-125 
I 
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platelet factor 4 (PF4; Deuel et al., 1977), ATIII (Rosenberg & Dam us 1973), 
heparin cofactor II (Church & Griffith 1984) and between heparin and 
apolipoprotein E (Weisgraber et al., 1986). In fact, it has been proposed for 
many years that clusters of basic residues are important in protein-heparin 
interactions (Deuel et al., 1977). In the case of aFGF, there are two segments 
containing clusters of basic residues; lysines -9,-10, and -12 near the amino 
terminus and the region spanning residues 100 to 122. Chou and Fasman 
(1978) used secondary structure analysis of aFGF to demonstrate that Lys-118 
is contained within a P-turn region encompassing residues 112-123 which 
probably form part of the surface of the protein (Fig. 1.2). A similar loop 
structure is also predicted for human aFGF and for human and bovine bFGF. 
X-ray crystallographic studies of aFGF and bFGF implicate Lys-112, Lys-118 
and Arg-122 (in human aFGF) in the heparin binding site of both FGFs (Zhu et 
al., 1991; Eriksson et al., 1991; Zhang et al., 1991 ). Volkin et al.,(1993) utilized 
the ability of various polyanions to stabilize the conformation of aFGF, in order 
to investigate the nature of its polyanion binding site. Their three dimensional 
model of human aFGF shows Lys-112, Lys-118, and Arg-122 form a tight 
cluster of positively charged sidechains. Close by, and partially solvent 
exposed is Cys-117 and it is likely that polyanions protect the thiol groups from 
metal catalyzed oxidation. The deep cavity in which Cys-117 sits probably 
comprises part of the polyanion binding site and polyanions may stabilize aFGF 
through occlusion of the clefts within this cavity (Fig.1.2). The authors conclude 
that the major polyanion binding site of aFGF probably extends from Arg-119 
across the surface of the molecule to the three clustered positively charged 
residues. In this context, the ability of high concentrations of neutral salts to 
completely inhibit polyanion binding suggests a binding site of electrostatic 
nature (Gospodarowicz et al., 1987a). 
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Sulfate ions have also been shown to bind to the sidechain equivalent of aFGF 
Lys-113 in the crystal structure of bFGF (Eriksson et al. ,1991). There are at 
least 24 basic residues exposed on the surface of bFGF, five of which are 
conserved between bFGF and aFGF and form a prominent cluster within the 
carboxyl-terminal repeat of the molecule (ie. , residues 119, 120, 125, 129 and 
135). The quaternary amino groups of lysines -119, -125 and -129 form a 
nearly equilateral triangle and there are 2 ordered sulfate ions ,one forming 
ionic contacts with Lys-119 and Lys-129 and the second linking Arg-120 and 
Lys-125 which are thought to mimic HS moieties. A contour map of the 
electrostatic potential surface shows the most prominent centre of positive 
charge to correspond to this group of conserved lysines and arginines, and to 
be located adjacent to the putative receptor-binding loop (residues 106 to 115) 
(Zhang et al. , 1991 ). 
1.7.3. Nature of the Heparin/Heparan Sulfate Motif which Interacts with 
FGFs 
In addition to binding to FGF-receptors on the cell surface, acidic and basic 
FGFs bind to HSPGs on the cell surface (Moscatelli 1987) and in the ECM 
(Vlodavsky et al. , 1987a). HSPGs are sites of low affinity (Kd 2-1 OnM) and of 
high capacity [(0.5-2)x1 o6sites/cell] for acidic and basic FGFs (Moscatelli 
1987). An important question to be answered is whether FGFs recognize a 
particular sugar sequence in heparin and HS, as does ATIII, and if so, is this a 
means by which HSPGs can regulate the interaction of FGFs with the FGF 
signaling receptor. Affinity coelectrophoresis of ATIII with heparin produces 
two distinct heparin subpopulations, as would be expected for ATI 11 binding to 
only a specific sequence on a portion of heparin molecules (Lee & Lander 
1991 ). A similar result was seen with FN suggesting that the FN/heparin 
interaction may be due to a distinct GAG sequence. However, analysis of 
aFGF and bFGF showed no evidence for heparin subpopulations (Lee & 
Lander 1991 ), suggesting an extensive interaction of the FGFs with heparin 
molecules. In fact, there is a recent report demonstrating that 10-15 aFGF 
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molecules can bind to a single 16kDa heparin molecule. Such an observation 
implies one aFGF molecule for every 4-5 monosaccharide units on a single 
heparin chain (Mach et al., 1993). 
Furthermore, when a wide range of polyanions were tested for their ability to 
stabilize hraFGF (15-154) against thermal denaturation, the interaction was 
found to be one of very low specificity with a surprising number of polyanions 
being able to induce physical stability (Volkin et al., 1993). Low molecular 
weight heparin, sulodexide, dextran sulfate, fucoidan and pentosan polysulfate 
all stabilized aFGF well and even ATP, inorganic phosphates, phosphorylated 
inositols, polynucleotides and inositol hexasulfate were effective. Similar 
results were obtained with aFGF potentiation (Belford et al., 1993). The 
common feature of all these compounds is the presence of one or more 
regions of high negative charge density such as regions of sulfation or 
phosphorylation. 
Despite these studies suggesting the relatively non-specific binding of 
polyanions to FGF, recent studies indicate that FGF binds to a particular 
heparin/HS motif (see Table 1.11 ). Turnbull et al.,(1992) used bFGF affinity 
chromatography to examine the structural properties of fibroblast HS that 
enable it to bind bFGF with high affinity. They isolated an oligosaccharide 
component from the parent HS molecule, seven disaccharides in length, which 
binds bFGF with the same affinity as undegraded HS. Their data suggest that 
contiguous sequences of ldoA(2-0S03)a1 ,4 GlcNS03 are important in 
mediating high affinity binding between fibroblast HS and bFGF. The 2-0 
sulfate of ldoA (2-0S03) and the N-sulfate of GlcNS03 appear to be essential 
for strong binding to bFGF. 
Habuchi et al.,(1992) also identified a HS oligosaccharide capable of binding to 
bFGF. In agreement with Turnbull et al.,(1992), Habuchi et al.,(1992) suggest 
Table 1.11: 
Saccharide Sequences of Heparin/Heparan Sulfate Implicated in FGF Binding 
Predom in ant disaccharide Fragment size 
Basic FGF 
ldoA(2-0S03)a1 ,4 GlcNS03 tetradecasaccharide 
ldoA(2-0S03)a1 ,4 GlcNS03 octasaccharide 
ldoA(2-0S03)a1 ,4 GlcNS03(6-0S03) 
hexasaccharide 
Acidic FGF 
ldoA(2-0S03)a 1,4 GlcNS03(6-0S03) 
tetrasaccharide 
ldoA(2-0S03)a1 ,4 GlcNS03(6-0S03) 
hexasaccharide 
Reference 
Turnbull et al., 
(1992) 
Habuchi et al., 
(1992) 
Tyrrell et al., 
(1993) 
Mach et al., 
(1993) 
Barzu et al., 
. (1989) 
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that binding to bFGF may be dependent upon specific sugar sequences and 
sulfation patterns in HS. While Turnbull et al., (1992) used heparan sulfate 
from human fibroblasts, Habuchi et al.,(1992) used heparan sulfate from pig 
aorta and the EHS tumour. In their system, the smallest fragment which bound 
bFGF was an octasaccharide composed of clusters of three ldoA (O-OS03)-
GlcNS03 disaccharide units (Habuchi et al., 1992). The fraction of HS from pig 
aorta which had high affinity for bFGF had a molecular weight of 47kDa and 
they suggested that there may be one or two bFGF-binding sites on each HS 
chain. Heparin cofactor II has been shown to bind to a similar cluster of units, 
namely ldoA(S04) GalNAc(4S04) units in skin dermatan sulfate (Maimone & 
Tollefsen 1990). Therefore, it is proposed that clusters of ldoA(2S04)-
containing disaccharide units may be important in controlling the biological 
activity of HS and dermatan sulfate and that they may be regulated by the 
same biosynthetic mechanisms (Bame et al., 1991; Franssen 1987; Lindahl et 
al., 1986; Gallagher et al., 1986). 
The observation that the ability of a HS fraction to protect aFGF from proteolytic 
inactivation corresponded to its ability to bind bFGF, suggests that aFGF and 
bFGF may recognize similar sugar sequences in HS (Habuchi et al., 1992). 
Indeed, oligosaccharides comprising ldoA(2-0S03)a1 ,4GlcNS03(6-0S03) 
bind, stabilize and potentiate aFGF activity (Barzu et al., 1989; Mach et 
al., 1993; Volkin et al., 1993) (see Table 1.11 ). It is not yet clear, however, 
whether the 6-0S03 is relevant to the interaction between aFGF and 
heparin/HS. 
On the other hand, a recent study by Nurcombe et al.,(1993) clearly 
demonstrated that during murine neural cell development, aFGF and bFGF 
preferentially bind HSPG species which are differentially glycosylated. HSPGs 
derived from E9 preparations were found to be over 4-fold more effective in 
binding bFGF than aFGF, while HSPGs from E 11 neuroepithelium bound aFGF 
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6-fold more effectively than bFGF. Examination of the HSPGs from E9 and 
E11 indicated a single, unique species of HSPG which differed only in the size 
and number of their GAG chains. HSPG isolated from E9-conditioned medium 
had an average GAG chain of approximately 20kDa and approximately 20 side 
chains attached per core protein synthesized, and those from E 11 had GAG 
side chains of 35kDa with approximately 12 side chains attached per HSPG 
core protein. The specificity of the interaction between the two growth factors 
and the HSPGs appears to be the result of differential glycosylation of the 
same protein core at the two ages. 
1.7.4. Functional Relevance of Heparin/ Heparan Sulfate Binding by FGF 
Heparin potentiates the biological activity of aFGF, but generally not that of 
bFGF (Thornton et al., 1983; Orlidge & D'Amore 1986; Schreiber et al., 1985), 
by as much as 100-fold in vitro (Thornton et al., 1983). It is not clear whether 
such an enhancement of aFGF activity occurs in vivo, but the results of Kessler 
et al.,(1976) show a correlation between the density of heparin-containing mast 
cells and neovascularization. It is therefore possible that mast cells release 
heparin at sites of neovascularization to stimulate the angiogenic activity of 
aFGF. The mechanism by which heparin potentiates the biological activity of 
aFGF is not fully understood but it is generally thought that the binding affinity 
of the particular heparin species for the growth factor correlates with its 
potentiating ability. However, the results of Belford et al.,(1992) show that a 
carboxyl-reduced form of heparin which has the same binding affinity for aFGF 
as that of native heparin, is less potent at augmenting aFGF-induced 
m itogenesis. These results suggest that mechanisms other than those based 
entirely on a heparin-aFGF interaction, such as one involving the direct action 
of heparin on cell surface heparin-specific receptors, may be required for the 
potentiation of aFGF activity by heparin (Belford et al., 1992). 
/: 
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Several models which are not necessarily exclusive, have been proposed to 
explain the biological relevance of heparin/HS binding by acidic and basic FGF. 
1.7.4.1.Secretion Model 
Since FGFs lack a signal sequence, it has been suggested that bFGF may 
form an intracellular complex with HS found in the cytoplasm and nucleus 
(Ishihara et al., 1987) which is then inserted into the cell surface or deposited in 
the ECM. However, since HSPG synthesis occurs in the Golgi complex and 
exocytosis is via membrane-bound vesicles, it is unlikely that FGF would come 
into contact with the HSPG. 
1. 7.4.2. Protection from Proteolysis Model 
Both basic and acidic FGFs are very sensitive to proteases, which may be due 
to their high arginine and lysine content. Proteases generated in areas of 
neovascularization may therefore inactivate them, and one important role of 
HSPG in the ECM and on the cell surface may be to protect FGFs from 
proteolytic digestion by plasminogen activators and collagenase. An example 
is the ability of heparin to protect aFGF against cleavage by thrombin. After 
incubation of aFGF with SOU/ml of human thrombin for 1 hour at 370c, aFGF is 
degraded and is at least 50-fold less potent at stimulating mitogenesis than the 
uncleaved mitogen (Lobb 1988b). Heparin at 50ug/ml is able to protect aFGF 
against cleavage by thrombin. Interestingly, bFGF exhibits negligible 
degradation and its m itogenic activity is unchanged after incubation with 
thrombin for 6 hours (Lobb 1988b). In addition, in the absence of heparin, 
FGFs particularly aFGF, are relatively unstable at physiological temperature 
and at low pH. Heparin and a variety of sulfated polysaccharides have been 
shown to stabilize aFGF by binding to the native conformation of the protein 
(Gospodarowicz & Cheng 1986). The relatively low specificity required 
suggests that molecules other than heparan sulfates may also be able to 
stabilize the growth factors in vivo (Copeland et al., 1991 ). Although protection 
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from proteolysis is likely to be a component of the mechanism of potentiation of 
aFGF by heparin, it does not account for all the potentiation which can be as 
great as 100-fold (Damon et al., 1988 & chapter 3). 
1.7.4.3. Reservoir Model 
Cell surface HSPGs appear to provide a slow-release reservoir of FGF thereby 
allowing for long term responses after only brief exposure of the cells and ECM 
to bFGF (Flaumenhaft et al., 1989). In terms of potentiation of aFGF by 
heparin, aFGF may be concentrated on the cell surface in greater quantities 
when complexed to heparin which binds to a large number of cell surface 
receptors specific for heparin. This would increase the amount of aFGF 
available to interact with the FGF receptor. Furthermore, acidic and basic 
FGFs are thought to be deposited into the ECM of vascular or corneal cells 
(Vlodavsky et al., 1991 c; Schweigerer et al., 1987c) where they bind to HSPGs 
(Jeanny et al., 1987; Folkman et al., 1988) and are protected from proteolytic 
degradation and inactivation. It is proposed that while the ECM would provide 
a source of FGF which could be utilized during localized endothelial cell 
proliferation and neovascularization, it would also sequester FGFs preventing 
them from acting on the vascular endothelium and thus maintaining a very low 
rate of endothelial cell turnover and vessel growth (Vlodavsky et al., 1991 a,b). 
This model requires a mechanism for the selective release of FGF from the 
ECM and heparanase activity has been implicated. Basic FGF may be 
released from basement membranes and ECMs as a noncovalent complex with 
a HS fragment as a result of heparanase activity provided by platelets, 
neutrophils, and tumour cells when they attach to the subendothelium (Matzner 
et al., 1985). Furthermore, bFGF complexed to HSPG stimulates the production 
of plasminogen activator by endothelial cells (Saksela & Rifkin 1990) which 
generates plasmin and may ultimately lead to further release of bFGF from the 
ECM as may plasminogen activator stimulation of heparanase activity (Bar-Ner 
(. 
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et al., 1986). It is unlikely that FGF would be released, not complexed with 
HSPG as it would probably be quickly inactivated by proteinases. On the other 
hand, enzymatic release of FGF from a HS complex might provide a 
mechanism for the rapid termination of its biological activity (Copeland et 
al.,1991). 
1.7.4.4. Receptor Binding Model 
Evidence is rapidly accumulating which indicates that the binding of FGF to 
heparin or to HSPG is an essential requirement for activation of the FGF 
receptor by FGFs. This has been demonstrated for the binding of bFGF to the 
high affinity Flg/FGFR1 receptor by Ya yon et al.,(1991) where CHO cells 
lacking HSPGs, and transfected with the FGFR 1 receptor, were only able to 
bind bFGF in the presence of heparin. Rapraeger et al.,(1991) and Olwin & 
Rapraeger (1992) also showed that treatment of various cells with heparitinase 
or culturing of cells in sodium chlorate which blocks sulfation, caused a drastic 
reduction in the binding of aFGF, bFGF and Kaposi's sarcoma FGF to their 
receptors and that binding could be restored by addition of heparin. Similarly, 
when murine FGFR2 was transfected into receptor-negative CHO cells and 
320 myeloid cells, exogenous heparin was required for bFGF and Kaposi 
sarcoma FGF to bind FGFR2 and to induce proliferation in 320 cells lacking 
HSPGs. In contrast, when FGFR2 was introduced into CHO cells that express 
HSPGs, binding and activation of FGFs occurred in the absence of exogenous 
heparin, indicating that endogenous HSPG and exogenous heparin can act 
interchangeably. Similarly, when receptor-negative FOC-P1 cells were 
transfected with vectors containing FGFR 1 with the 3 lg-like and 2 lg-like 
domains, the cells bind aFGF and bFGF but only in the presence of heparin 
(Bernard et al., 1991 ). In a related study, Ornitz and Leder (1992) 
demonstrated that with soluble murine FGFR 1 binding of acidic and basic FGF 
was totally heparin dependent, whereas with soluble FGFR3, aFGF did exhibit 
some affinity for soluble FGFR3 in the absence of heparin but its binding affinity 
I· 
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was markedly increased in the presence of heparin. Ornitz and Leder (1992) 
suggested that this aFGF binding, in the absence of heparin, may not represent 
a functional high affinity complex and moreover, an FGFR3-mediated mitogenic 
response to aFGF exhibited an absolute requirement for heparin. 
1.8. Role of HSPGs in FGF receptor binding 
As outlined above, there is now considerable evidence indicating that 
heparin/HS binding is essential for acidic and basic FGF to interact effectively 
with FGF receptors. Hitherto, three models have been proposed, which take 
this requirement for HSPG interaction into consideration, namely a 
conformational change model, a ternary complex model and a dimerization 
model. Each of these will models will be discussed briefly below. 
1.8.1. Conformational Change Model 
Vayon et al.,(1991) suggest that interaction of HSPG or heparin with bFGF 
produces a conformational change in bFGF which allows it to interact with the 
bFGF receptor (Fig. 1.8). In support of the conformational change model, 
Rapraeger et al.,(1991) suggest that the intrinsic affinity of the FGF receptor for 
bFGF is low, but that a complex of FGF, receptor and HSPG results in a high 
affinity interaction. They also propose that FGF undergoes a conformational 
change after interaction with HSPG. Similarly, Ornitz et al.,(1992) suggest that 
bFGF, its receptor and heparin/HSPG form a stable trimolecular complex 
possibly as a result of bFGFs change in conformation after its initial interaction 
with heparin or HS. Heparin has also been proposed to potentiate aFGF 
activity by producing a conformational change in the molecule which enhances 
its affinity for FGFRs. 
1.8.2. Ternary Complex Model 
Analysis of the kinetics of the association and dissociation of bFG F from its 
receptor has led Nugent & Edelman (1992) to propose that bFGF has as low an 
affinity for FGFR as it does for HSPG and it is not until a ternary complex is 
FIGURE 1.8: An induced-fit model for heparin-dependent high 
affinity receptor binding of bFGF. It is proposed that in the absence 
of heparin, bFGF exists in a conformation that is not able to interact 
with its receptor. Interaction with heparin in solution or HSPG on 
the cell surface convert bFGF to a conformation that is recognized 
by the receptor. (From Vayon et al., 1991) 
FGFR 
FGF 
HSPG 
FGFR 
Induced Fit Model 
Yayon et al (1991) 
heparin 
+ -
-· -·-· ~· ~ ~--===--=,,...--.,.,=,,..,; ....... ---......... --
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formed between the three molecules, that the interaction is of sufficiently high 
affinity for receptor activation to occur (Fig. 1.9). They suggest, however, that 
binding of bFGF to the HSPG is not required as a prerequisite for FGF binding 
to the FGFR. This, however, is in direct contrast to the results of Ornitz et 
al.,(1992) and others whose data indicate that FGFs are unable to bind the 
FGF-receptor in the absence of HS or heparin. Perhaps in the Nugent and 
Edelman experiments, there were some residual HSPGs remaining on the cells 
after heparitinase treatment which enabled FGF to bind to the FGFR. Rather 
than bFGF changing its conformation after binding to HSPG, it is proposed to 
undergo a cooperative "high affinity" interaction requiring both HSPG and FGF-
I: receptor which results in a decreased "off" rate for bFGF. Furthermore, for 
I 
I ( 
I 
I I' 
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exogenously added heparin to replace the requirement for HSPG in this model, 
heparin would need to be bound to cell surface heparin receptors to produce a 
ternary complex (Nugent &Edelman 1992) (Fig. 1.9). 
Recent studies by Kan et al.,(1993) demonstrate a heparin binding site in the 
lg-like domain II of FGFR 1. They found that this heparin binding domain and its 
associated heparan sulfates are an essential requirement for the binding of 
FGF to FGFR1. This suggests that complexes of FGF and heparin or FGF and 
HSPG may form a ternary complex by crosslinking the growth factor-binding 
and heparin-binding domains on one FGFR. 
1.8.3. Dimerization Model 
Mascarelli et al., 's (1993) data are consistent with the model of general 
allosteric oligomerization of growth factor receptor tyrosine kinases. They 
propose that heparin/HSPG mediated dimerization of FGF is essential for 
productive FGFR interaction. A 150kDa complex, observed in bovine lens 
epithelial cells, is the result of a very stable aFGF homodimer crosslinking an 
FGFR molecule with a HSPG molecule (Fig. 1.10). Dimers of bFGF have 
I been observed in neurons and astrocytes (Walicke & Baird 1991) and in retinal I 
I 
I 
' I 
! 1 
FIGURE 1.9: Ternary complex model for "high affinity" bFGF 
binding. "High affinity" binding is represented as a ternary complex 
with bFGF bound simultaneously to FGFR and HSPG. In the 
absence of HSPGs, a ternary complex forms in which bFGF and 
soluble heparin crosslink FGFR and a heparin receptor. (From 
Nugent & Edelman 1992). In this model the heparin receptor is 
depicted as a separate molecule on the cell surface but it could 
represent a heparin binding site on the FGFR as suggested by Kan 
et al.,(1993). 
FGFR 
FGF 
HSPG 
FGFR 
Ternary Complex Model 
Nugent and Edelman (1992) 
heparin 
FGF 
heparin-R 
FIGURE 1.10: Dimerization model for aFGF high affinity binding. It 
is proposed that monomeric and oligomeric aFGF may bind to 
HSPG, the low affinity receptor (LAA). Monomeric aFGF may bind 
to FGF-R, the high affinity receptor (HAR). Dimerization of aFGF 
leads to interaction of HAR with LAA forming the very high affinity 
receptor (VHAR). (From Mascarelli et al., 1993) 
HAR 
FGF-R 
VHAR 
Dimerization Model 
Mascarelli et al (1993) 
LAR 
FGF 
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pigmental epithelial cells. Ornitz et al.,(1992) have shown that dimerization of 
bFGF in solution can be induced in the presence of heparin or by heparin 
oligosaccharides 6, 8 and 16 sugar residues in length but that optimal dimer 
formation is highly dependent on the ratio of aFGF to heparin oligosaccharide. 
Mach et al.,(1993) suggest that dimers of aFGF could form as a result of the 
large number of aFGF molecules (10-15) able to bind to a single 16kDa 
heparin molecule. Ligand dimerization has previously been shown to be 
involved in either inducing or stabilizing receptor dimers. Mascarelli et 
al.,(1993) suggest that dimers of aFGF could form as the result of an aFGF 
molecule binding to the FGFR, and another aFGF molecule binding to HSPG. 
Alternatively, an aFGF dimer bound to HSPG could interact with an FGFR, 
producing an aFGF-dimer-FGFR complex of molecular weight 150kDa. In 
either case, the crosslinking of FGFR and HSPG by an aFGF dimer 1s 
proposed to result in a greater affinity of the FGFR for aFGF and this complex 
has been termed the "very high affinity receptor". In support of this idea that 
dimerization of FGF is important for high affinity cell surface binding, high 
concentrations of heparin were found to inhibit formation of multimers of aFGF 
(Mascarelli et al., 1993) and displace high affinity binding complexes. 
1.9. Transmembrane and Intracellular Signalling by Acidic and Basic FGF 
In this section I will highlight some of the important transmembrane and 
intracellular signalling events following engagement of FGFs with FGFRs. 
1.9.1. Receptor Dimerization 
Although FGF-dependent signalling 1s initiated immediately following the 
binding of FGF to its receptor (Johnson & Williams 1993) the intracellular 
signalling mechanisms which give rise to FGF-induced proliferation, 
differentiation or maintenance of a differentiated phenotype are not well 
understood. Similar to other growth factor receptors (Williams 1989; Ullrich & 
Schlessinger 1990), FGFR dimerization is induced upon binding of aFGF or 
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bFGF (Bellot et al., 1991; Ueno et al., 1992) and both homodimeric and 
heterodimeric receptor species involving FGFR 1, FGFR2 and FGFR3 (Bel lot et 
al., 1991; Ueno et al., 1992) have been observed. Homodimers of FGFR are 
thought to be required for signal transduction, although, it may be possible that 
in cells expressing more than one type of FGFR, signalling may occur through 
heterodimers as well as through homodimers. Heterodimers may activate 
cytoplasmic signalling pathways differently than do homodimers (Ueno et 
al., 1991 ). Oligomerization of receptors may be induced by monomeric ligands 
which induce conformational changes (Greenfield et al., 1989) resulting in 
receptor-receptor interactions, or by bivalent ligands that mediate dimerization 
of neighbouring receptors (Seifert et al., 1989; Heldin et al., 1989; Hammacher 
et al., 1989) (see section above). Receptor oligomerization produces a 
conformational change in the extracellular domains, resulting in increased and 
more stable interactions between cytoplasmic domains, and leads to receptor 
autophosphorylation (Huang & Huang 1986; Coughlin et al., 1988; Mansukhani 
et al., 1990) and utimately to elevated protein tyrosine kinase activity, 
1.9.2. Intracellular Messengers Implicated in FGF Activity 
As already mentioned, the intracellular signalling mechanisms induced by FGF 
binding to its receptor are not well understood and there are many 
contradictions in the literature as to whether G-protein mediated signalling 
pathways are involved in FGF-induced DNA synthesis (see Table 1.12). When 
used alone on hamster lung fibroblast cells, bFGF does not appear to utilize 
any of the major G-protein-mediated signalling pathways and its actions are 
thought to be primarily mediated by the intrinsic protein tyrosine kinase of its 
receptors (Paris & Pouyssegur 1991 ). However, these results are in direct 
contrast to those of Logan & Logan (1991) which indicate that pertussis toxin is 
a potent inhibitor of bFGF-induced DNA synthesis implying that G-proteins do 
have a role in the mitogenic pathways for bFGF. The substrate for pertussis 
toxin is Gi which modulates adenylate cyclase activity, and pertussis toxin 
Table 1.12: 
Intracellular Messengers Implicated in FGF-induced DNA Synthesis 
Cell type Messenger Reference 
Hamster lung protein tyrosine-kinase activity, Paris & Pouyssegur 
fibroblasts no G-protein mediated signaling ( 1991) 
Gi couples adenylate cyclase Logan & Logan ( 1 991 ) 
to bFGF-receptor Gp 
3T3 fibroblasts increased intracellular pH Halperin & Lobb (1987) 
increased calcium levels Tsuda et al.,(1985) 
increased phosphorylation Burgess et al.,(1990a) 
of PLC)' 
increased hydrolysis of Brown et al., (1989) 
phosphoinositides 
phosphorylation of MAP-2 kinase Rybak et al.,(1988) 
phosphorylation of raf Rapp et al.,(1991) 
Friese I et al., ( 1989) 
phosphorylation of p60, p85, Zhan et al.,(1993) 
p90, p130 
increased transcription of c-fos, Burgess et al., ( 1990b) 
c-myc and c-jun 
protein kinase C activation Logan & Logan ( 1991) 
inhibition of adenylate cyclase 
activity 
activation of tyrosine kinase by Lee et al., ( 1989) 
PKG-independent phosphorylation 
translocation to the nucleus Bouche et al., ( 1987) 
L6-myoblasts calcium mobilization Peters et al., ( 1992b) 
phosphatidylinositol hydrolysis Peters et al.,(1992b) 
not required 
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treatment inhibited a bFGF-induced fall 1n intracellular cAMP levels. Gi is 
therefore implicated in coupling adenylate cyclase to the bFGF receptor(s). 
Gp, linked to phospholipase C, may also be involved in the intracellular 
signalling pathways for bFGF (Logan & Logan 1991 ). 
The intracellular messengers observed to be activated after stimulation of cells 
with acidic and basic FGF are listed in Table 1.12. However, it is yet to be 
determined which messengers are activated directly as a result of FGF 
stimulation and have a direct role in DNA synthesis. It is not known whether 
modulation of protein kinase C, cAMP and inositol phosphates occur as a result 
of direct coupling to the bFGF receptor(s), to the signalling pathways, or 
whether they occur secondary to activation of other mechanisms (Logan & 
Logan 1991 ). Nor is it understood what changes in signalling patterns allow 
FGFs to regulate cellular differentiation and chemotaxis, to influence cell-shape 
and to maintain cell survival without stimulating DNA synthesis. The cell types 
in which the messengers were observed to be activated are listed in Table 1.12 
because although all cells listed undergo DNA synthesis in response to FGF, 
inconsistencies over which signals are required, seem to arise when different 
cell types are compared. Furthermore, some of the messengers activated may 
well be involved in differentiative responses. For example, a similar set of 
intracellular messengers is produced in neurons and yet these cells do not 
undergo cell division but survive and differentiate in response to FGFs. An 
example of this uncertainty is the controversy over the role of PLC--y in FGF 
receptor mediated signalling. PLC--y is found directly associated with the 
receptor (Mohammadi et al., 1991; Peters et al., 1992b) and Logan & Logan 
(1991) have demonstrated a correlation between FGF mitogenesis and 
production of inositol phosphates. This is in contrast to Peters et al.,(1992b) 
who showed that L6 myoblasts, expressing a mutant receptor which does not 
associate with or phosphorylate PLC--y but does phosphorylate itself and 
several other proteins, are still able to proliferate in response to FGF (Peters et 
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al., 1992b). This result suggests that neither calcium mobilization nor 
phosphatidylinositol hydrolysis are required for FGF-induced mitogenesis in L6 
myoblasts. Furthermore, FGF does not stimulate hydrolysis of 
phosphoinositides in Chinese hamster lung fibroblasts (Magnaldo et al., 1986) 
or only gives a relatively small response when compared to that observed with 
other growth factors (Peters et al., 1992b). These contradictory results have led 
to the suggestion that other signalling pathways must be required for FGF-
induced mitogenesis and that maybe phosphatidylinositol hydrolysis is 
important in non-mitogenic cellular responses, such as, chemotaxis, cell-shape 
changes (Goldschmidt-Clermont et al., 1991) and in the regulation of cellular 
differentiation in early amphibian embryogenesis. However, there is some 
evidence to suggest that cell survival is less independent of phosphatidyl 
inositol hydrolysis (Magnaldo et al., 1986; Chambard et al., 1987; Moenner et 
al.,1987). 
Further controversy over which messengers are important in DNA synthesis 
occurs when FGF is used in combination with other factors. For example, FGF 
stimulation of mouse fibroblasts results in a fall in cAMP levels whereas when 
used in combination with prostaglandin E, forskolin or cholera toxin in hamster 
fibroblasts, cAMP accumulation is potentiated by up to 50°/o (Paris & 
Pouyssegur 1991 ). Since this potentiation is insensitive to pertussis toxin, FGF 
is thought to enhance activation of adenylate cyclase through Gs, the 
stimulatory G protein (Magnaldo et al., 1989) and not through Gi, the inhibitory 
G protein. 
1.10. Localization of FGF in the Nucleus 
Not only do FGFs stimulate intracellular messengers to transmit signals to the 
nucleus but there is increasing evidence to suggest that they may also act 
directly within the cell nucleus (Kardami & Fandrich 1989; Renko et al., 1990; 
Tessler & Neufeld 1990; Suzuki et al., 1991; Brigstock et al., 1991 ). Growth 
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factors may be localized to the nucleus to allow activation of pre-existing 
nuclear receptors resulting in protein kinase activity; or to enable direct 
interaction of growth factor with nuclear receptors or chromatin, ultimately 
leading to increased mRNA efflux, or enhanced chromatin condensation in 
preparation for mitosis (Burwen & Jones 1987). 
It has been proposed that a complex of aFGF and HS could be internalized by 
FGF-receptor mediated endocytosis and targeted to the nucleus with the aid of 
the nuclear translocation sequence on aFGF. This would ensure that the 
growth factor was protected from proteolysis during transport to the nucleus 
(Habuchi et al., 1992). Indeed HS enriched in GlcA(2S04)GlcNS03(6S04) has 
been found in the nuclei of rat hepatoma cells (Fedarko & Conrad 1986). 
Rusnati et al.,(1993) have also speculated that bFGF is internalized via HSPGs 
and transported to the nucleus as a complex. 
However, the lack of evidence supporting the release of bFGF from cells has 
led to the proposal that endogenous bFGF may have a biological function 
within its cell of origin (Logan 1990). The observation that suramin, a molecule 
that inhibits the binding of bFGF to its plasma membrane receptor, did not 
effect the amount of biosynthetically labeled bFGF present in the nucleus 
suggests that the nuclear localization of endogenous bFGF is not the result of 
receptor-mediated uptake of released bFGF (Dell'Era et al., 1991 ). 
It is proposed that FGF is transported into the nucleus by a nuclear targeting 
signal (Imamura et al., 1990; Bugler et al., 1991; Quarto et al., 1991; Florkiewicz 
et al., 1991 b) where it directly regulates the transcription of specific genes. It 
appears not to recognize distinct DNA regions but binds to the DNA in a 
nonspecific manner. Brigstock et al.,(1991) found that bFGF could be 
displaced from chromatin by heparin, suggesting an intra-nuclear interaction 
between bFGF and heparin-like molecules may occur. Alternatively, a heparin-
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sensitive association between bFGF and other anionic substances such as 
DNA is possible. However, preliminary results of Amalric et al.,(1991) indicate 
that bFGF may bind DNA with nucleotide sequence specificity. 
The intracellular localization of bFGF is tightly regulated during the cell cycle 
with bFGF being detected in the nucleus during the final two hours of the G 1 
phase (Hill & Logan 1992; Baldin et al., 1990). Basic FGF's presence in the 
nucleolus is accompanied by the activation of ribosomal RNA transcription and 
in vitro, by stimulation of pre-rRNA synthesis (Bouche et al., 1987), a major 
event in the transition from a quiescent state to full proliferation (Pardee et 
al., 1985). Basic FGF also increases the transcriptional activity of RNA 
polymerase 1 in nuclei isolated from quiescent sparse adult bovine aortic 
endothelial cells by a factor of 5.6 (Bouche et al., 1987). 
Basic FGF has also been shown to inhibit the transcription of Pgk-1 and 
stimulate the transcription of Pgk-2, two spermatogenic genes encoding 
phosphoglycerate kinases (Nakanishi et al., 1992). Basic FGF may compete 
with trans-acting factors for binding to corresponding cis elements and have 
either a stimulatory or inhibitory effect on transcription depending on the mode 
of action of the cis elements (Nakanishi et al., 1992) . 
The establishment of mesodermal and endodermal cell lineages during 
Xenopus embryogenesis has been proposed to depend upon the action of 
hormones and growth factors in the nucleus (Burwen & Jones 1987; Logan 
1990) and the results of Shiurba et al.,(1991) support the idea that FGFs may 
act directly on the genome during embryonic induction. Shiurba et al.,(1991) 
have monitored the spatial localization of aFGF and bFGF within the Xenopus 
laevis embryo at successive developmental stages. Some FGFs appeared to 
be prepositioned within the egg in association with yolk in the vegetal 
hemisphere where they remain during cleavage. However, at the time of 
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mesoderm induction, they shift from the cytoplasm to the nucleus in cells of the 
marginal zone. Although the data provide considerable evidence for the 
translocation of FGFs to the nucleus, the functional relevance of their nuclear 
localization remains to be determined. 
1.11. Aims of the Present Study 
The importance of HSPGs in FGF action is only now beginning to be 
appreciated. Acidic and basic FGF are distributed widely throughout the body 
and yet they must remain inactive for much of the time. It is becoming 
increasingly clear that HSPGs play a major role in regulating FGF activity. 
Thus, the interaction between FGF and cell surface HSPG is now known to be 
essential to the central event in growth factor action, that is, the binding of the 
growth factor to the signal transducing receptor. HS chains may also regulate 
FGF activity by varying the affinity of the interaction between FGF and HSPG. 
This was shown to be the case by Nurcombe et al.,(1993) who showed that 
during murine neural precursor cell development, acidic and basic FGF activity 
was differentially modulated in part, by variations in the glycosylation of a 
particular HSPG. In addition, HSPGs sequester FGFs and store them in a 
stable and protected form in the ECM. Heparin is also able to modulate many 
of the biological activities of the FGFs in an apparently similar manner to 
HSPGs. However, the mitogenic activity of aFGF is potentiated by heparin and 
although not generally regarded as a physiological phenomenon, an 
understanding of the mechanism involved, would further our understanding of 
the requirements for FGF activation and the role of heparin-like molecules in 
th is process. 
An understanding of the requirements for the interaction between FGFs and HS 
chains, and of how acidic and basic FGF activity is modulated by HSPGs, may 
facilitate the development of compounds which disrupt this interaction thereby 
inhibiting the interaction of FGF with its signaling receptors. Such inhibitors of 
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FGF action could be important in the inhibition of angiogenesis which becomes 
a pathological process during tumour formation and many other diseases. 
The major aims of the research presented in this thesis have been to try and 
understand why bFGF is more potent than aFGF in vitro, why the mitogenic 
activity of aFGF in cell culture is potentiated by heparin while that of bFGF is 
not, and the mechanism by which this potentiation occurs. Comparative 
studies were performed with both acidic and basic FGF in an attempt to further 
understand these phenomena and the possible involvement of heparan 
sulfates. These studies are described in the first two experimental chapters. In 
particular, the hypothesis that heparin enhances aFGF activity by forming a 
complex with aFGF which crosslinks both the FGFR and a receptor specific for 
l' t heparin on the cell surface was examined. These studies also examined the 
intriguing observation that CR-heparin , although binding to aFGF as well as 
native heparin, was less effective at enhancing aFGF mitogenicity (Belford et 
al., 1992). All of these studies were performed with the long term aim of 
inhibiting FGF activity by disrupting the interaction of FGF with HSPG, and the 
third experimental chapter describes experiments specifically directed towards 
this goal. In this chapter, the effect of two naturally occurring heparin/HS 
binding proteins on FG F action is described. 
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Chapter 2 
Materials and Methods 
2.1 Growth Factors and Heparin Binding Proteins 
Human recombinant acidic and basic fibroblast growth factors were obtained 
from Bio Source International (Camarillo, CA) and Pepro Tech Inc. (Rocky Hill, 
NJ). Acidic and basic FGFs were reconstituted at 200ug/ml in PBS/0.1 °/o 
CHAPS to prevent adherence to the walls of the tubes and aliquots stored in 
polyethylene tubes (Kartell, Milan, Italy) at -7ooc. Aliquots were not frozen 
more than once and were not used any longer than two weeks after thawing. 
1251-aFGF(1234Ci/mmol) and 1251-bFGF (920Ci/mmol) were obtained from 
Amersham International pie, Amersham, UK. 1251-aFGF was resuspended in 
distilled water to a final concentration of 600ng/ml and aliquots frozen. 1251-
bFGF was resuspended in distilled water to give a final concentration of 
200ng/ml and aliquots frozen . 
Human antithrombin Ill (ATIII) and human platelet factor 4 (PF4) were obtained 
from Sigma Chemical Co, St Louis, Mo. ATIII was reconstituted in distilled 
water to give a final concentration of 143ug/ml. PF4 was desalted and 
resuspended in PBS to give a final concentration of 1 OOug/ml. Chicken and 
human histidine-rich glycoprotein (HRG) were purified by the method of Rylatt 
et al.,(1981). 
2.2. Polysaccharides 
Heparin (bovine lung), HS (bovine kidney), HS-fast moving fraction (bovine 
intestinal mucosa), HS (bovine intestinal mucosa), hyaluronic acid (human 
umbilical cord), chondroitin-4-sulfate (whale cartilage), chondroitin-6-sulfate 
(whale cartilage), chondroitin-4,5-disulfate (whale cartilage), dermatan sulfate 
(porcine skin) and keratan sulfate (bovine cornea) were all obtained from 
Sigma Chemical Co, St Louis, Mo. Sodium sucrose octasulfate was a 
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generous gift from Bukh meditec A/S, Denmark. Heparan sulfate (porcine 
mucosa!, 32kDa) was a generous gift from Organon International bv, Oss, 
Netherlands. 
CR-heparin was prepared according to the method of Taylor et al.,(1976) and 
the number of carboxyl groups remaining on the various preparations of CR-
heparin, relative to the number present on native heparin, was determined by 
the method of Bitter & Muir (1962). The ability of these preparations to 
compete for the binding of aFGF to heparin-agarose (Bio-Rad, Richmond, CA) 
was determined as described by Belford et al.,(1992). The following modified 
heparins: N-desulfated heparin; N-desulfated acetylated heparin; N-desulfated 
acetoacetylated heparin; N-& 0-desulfated heparin and N-& 0-desulfated, N-
resulfated heparin, were provided by Dr C. Parish and prepared as previously 
described by Belford et al.,(1992). 
2.3. Fluoresceination and Iodination of Heparins 
Heparin and CR-heparin were fluoresceinated by cyanogen bromide activation 
and conjugation with fluoresceinamine as previously described (Glabe et al., 
1983). The concentration of the fluoresceinated heparin was estimated by N-
de-sulfation and deamination by nitrous acid and the resulting 
anhydromannose estimated by indole-hydrochloric acid reagent, as described 
by Chandrasekaran & BeMiller (1980). The concentration of native heparin 
was estimated as 6.5mg/ml and the concentration of CR-heparin as 5.4mg/ml. 
The fluoresceinated heparins were then iodinated by adding 3ul of the heparin 
in PBS (20ug of native heparin and 16ug of CR-heparin) to 13. 7ul normal 
saline, 1.5ul of 0.2M borate buffer pH 8.0 and Sul iodine-125 (500uCi) (lodine-
125, carrier free 1 OOmCi/ml, Amersham) in an eppendorf tube and transferring 
the mixture to a small glass tube in which 20ul of 1,3,4,6-tetrachloro-3a,6a-di-
phenylglycouril (lodogen; Sigma), at 0.26mg/ml in chloroform, had been dried 
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under N2 . The reaction mixture was incubated for 30 min on ice with regular 
mixing and the reaction was terminated by dilution of sample to 0.25ml with 
PBS. Sul of sample was removed for counting. The sample was applied to a 
NAP-5 Sephadex G-25, DNA grade column (Pharmacia, Sydney, Australia) 
preequilibrated with PBS and eight fractions of 0.25ml collected and Sul of each 
counted. The 3rd, 4th and 5th fractions were generally found to contain the 
majority of cpm and were pooled and stored at 40c. Specific activity was 
approximately 18000 cpm/ng. 
2.4. Iodination of cHRG 
Chicken HAG (cHAG; 20ug) in a volume of 1 Qui was mixed with 50ul borate 
saline pH 8.0, and 4ul 1251 (200uCi), before being transferred to a small glass 
1 tube containing 20ul lodogen (0.26mg/ml) dried under N2. Incubation was for I· 
• 
I' !I 
' 
I 
I 
I 
' 
30min on ice with regular mixing. The reaction was terminated by the addition 
of 436ul PBS and a Sul sample removed for counting. The sample was applied 
to a NAP-5 column, preequilibrated in PBS, and eluted in 1 ml PBS. The 
specific activity was determined as 3x106 cpm/ug HAG. 
2.5. Effect of Heparins on Digestion of aFGF by Trypsin 
To 12.5ul of each heparin preparation (1 mg/ml in PBS/0.1 °/o BSA) was added 
12.5ul PBS/0.1°/o BSA, followed by 2ul 1251-aFGF (1.8ng). Controls received 
PBS/BSA in place of heparin. After mixing samples, 25ul trypsin (200ug/ml) 
(Cooper Biomedical, Glendale, CA) dissolved in 0.1 M ammonium bicarbonate 
buffer pH 8, or 25ul of ammonium bicarbonate buffer pH 8 for controls, was 
added and samples left to react at 370c. After 3 hours, a further 5ug of trypsin 
was added to each sample and samples left to react at 370c overnight. 
, 
Samples of each treatment were then boiled for 5 min in reducing SOS-PAGE 
sample buffer, applied to an 11 °/o SDS-polyacrylamide gel and electrophoresed 
at a constant current of 20mA for 2.5 hours. After fixation, the dried gel was 
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autoradiographed at -700c on Kodak XAR-5 film using a Cron ex intensifying 
screen. 
2.6. Cell Culturing 
Mouse BALB/c 3T3 cells were maintained in Dulbecco's modified Eagle's 
medium (DMEM; Gibco, Gaithersburg, MD) supplemented with NaHC03, 1 °/o 
L-glutamine, 20mM Hepes pH 7.4 and 10°/o fetal calf serum (FCS; 
Commonwealth Serum Laboratories, Melbourne, Australia) at 370c (5°/o CO2 
incubator) in 80cm2 tissue culture flasks (Nunc, Roskilde, Denmark). Cell 
monolayers were released for subculturing with 0.1 °/o trypsin (Cytosystems, 
Sydney, Australia) and 0.1 °/o EDTA in PBS when cells were subconfluent ( every 
three days) and cells were then resuspended at 1.5x1 o4 cells/ml in culture 
medium. Confluent monolayers used in mitogenic and binding assays were 
prepared by seeding 3x1 o3cells/well in 96-well plates (Nunc) in the same 
medium as used for subculturing, and incubating at 370c for four to five days. 
For mitogenic assays, confluent monolayers were serum starved (DMEM/1 °/o L-
glutamine/20mM Hepes pH 7.4) for 48 hours. 
Human umbilical vein endothelial cells (HUVEC) were isolated from human 
umbilical cords by the method of Jaffe (1984) and cultured in Medium 199 
(Gibco) supplemented with 20°/o FCS, 2°/o L-glutamine, antibiotics, 130ug/ml 
heparin and 1.2mg/ml of endothelial cell growth supplement (Sigma). They 
were grown in tissue culture flasks (Nunc), coated with 0.1 °/o gelatin (Sigma) in 
distilled water. Cells generally reached confluence after seven days and were 
passaged at a density half that reached at confluence. The medium was 
replaced every four days. Only cells at passages two to seven were used in 
experimental work. When used in mitogenic assays, confluent monolayers of 
HUVE cells were released with 0.1 °/o trypsin and 0.05°/o EDTA in PBS, and 
diluted in culture medium to a final concentration of 7.6x1 o5cells/ml. 
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2.7. Heparinase Treatment of 3T3 Cells 
In some experiments BALB/c 3T3 cells were treated with heparinase prior to 
1251-FGF binding (Nugent & Edelman 1992). Heparinase 1 (EC 4.2.2. 7; Sigma) 
in 350 unit lots was resusupended in 205ul of 200mM sodium acetate pH 7, 
527ul of normal saline and 81 ul of 2mg/ml BSA. Aliquots of soul were frozen 
on dry ice and ethanol before being stored at -700c. Confluent BALB/c 3T3 
cells were washed once with 370c binding buffer (DMEM, 1 °/o L-glutamine, 
20mM Hepes, 0.1 °/o BSA pH 7.4) and treated with soul/well of heparinase, 
using 2 units/well for 30min at 370c with 1251-aFGF and 4 units/well for 1 hour 
at 370c with 1251-bFGF. These treatments generally resulted in the removal of 
70-90°/o HSPGs as determined by comparing the number of cpm eluting from 
the cell surface of heparinase treated cells in 1 O sec when washed with 2M 
NaCl in binding buffer with the number of cpm eluted by the same buffer from 
untreated cells. Heparinase and soluble degradation products were removed 
by washing the cells three times with ice cold binding buffer. 
2.8. Isolation of HSPGs from 3T3 Fibroblasts 
Heparan sulfate chains were isolated from BALB/c 3T3 fibroblasts according to 
the method of Turnbull & Gallagher (1991 ). Briefly, BALB/c 3T3 cells (19x106 
cells) in Basal medium Eagle (BME, sulfate-free, Gibco)/10°/o FCS/1 °/o L-
glutamine/20mM Hepes pH 7.4 were seeded into 6 x 175cm2 flasks and grown 
to subconfluence in the presence of 3Sso4 (50 uCi/ml) (25-40Ci/mg; 
Amersham). The conditioned media were collected and frozen for subsequent 
use. After treating cells with 2M NaCl for 30m in to remove salt dissociable 
HSPGs, flasks were rocked in n-octyl-~-D-glucopyranoside (octyl glucoside) 
(Sigma) for 30min at 40c to dissociate detergent soluble HSPG from cell 
membranes. The octyl-glucoside supernatants were pooled and frozen. HS 
chains were isolated from conditioned media and octyl-glucoside supernatant 
as follows: The sample was applied to a DEAE-Sepharose column and GAGs 
eluted with 1 M NaCl, 20mM phosphate buffer pH 6.8. Fractions containing the 
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most cpm were pooled, lyophilized and desalted on a PD-1 o column. After 
digestion of HSPG core proteins with protease (5mg/ml) (from Streptomyces 
griseus; Sigma) overnight at 370c, the sample was applied to a DEAE-
Sepharose column and chondroitin sulfates eluted with 0.3M NaCl and heparan 
sulfates with 1 M NaCl. The HS-containing fractions were desalted and 
digested with chondroitinase ABC (2mg/ml; EC 4.2.2.4; Sigma) for 6 hour at 
37°C to remove contaminating chondroitins. The digest was applied to a 
DEAE-Sepharose column and the 1 M NaCl eluate desalted, lyophilized and 
resuspended in 500ul of 1 O°lo ethanol in distilled water. Glucuronic acid 
determination showed that 17ug of HS was isolated from the conditioned media 
and 1 ug HS from the octyl-glucoside lysate. 
2.9. Binding of Radiolabeled Heparins to BALB/c 3T3 Cells 
Confluent cultures of BALB/c 3T3 cells in 96 well plates were washed twice with 
200ul/well of binding medium (DMEM/ 0.5°/o BSA/ 20mM Hepes) whilst on ice. 
Serial dilutions of radiolabeled heparins (1.56-1 SOug/ml) were added in 
volumes of 1 OOul/well and nonspecific binding determined by including a 50-
fold excess of unlabeled heparin in a replicate set of reaction mixtures. 
Following incubation for 5 hours on ice cell monolayers were washed once with 
200ul/well of binding medium before being detached with 200ul/well 0.1 °/o 
EDTA in PBS. After mixing with a multichannel pipette, cells were harvested 
with a Titertek cell harvester 530 (Flow Laboratories, Sydney, Australia) and 
counted by an Auto-gamma 5650 counter (Packard Instrument International, 
Meriden, CT). Scatchard analysis was performed using "Scatchard Plot" 
written by R.E. Viola. 
In order to determine 3T3 cell number/well in binding assays, Sul of a 1 mM 
stock solution of Hoechst 33342 (Sigma) was added directly to each well and 
incubated for 15 min at 370c. Medium containing the unbound dye was 
removed and the cells washed once with 200ul/well PBS. Cells were detached 
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by adding 1 OOul/well of 0.1 °/o trypsin in PBS and incubated for 1 Omin at 370c. 
Detached cells were transferred to a 96-well flat bottomed microplate (Nunc) 
and their fluorescence determined by an automated fluorescence reader (Micro 
Fluor reader, Dynatech Laboratories Inc., Alexandria, VA). 
In the case of inhibition assays, serial dilutions of unlabeled heparin and CR-
heparin were made and 50ul of each concentration (0.04-5 mg/ml) added to 
triplicate wells. This was followed by the addition of soul/well of a constant 
concentration of either 1251-heparin or 1251-CR-heparin to give a final 
concentration of 1 OOug/ml. Following incubation on ice for 5 hours, cells were 
washed, detached and harvested as above. 
2.10. Binding of Radiolabeled Acidic and Basic FGF to BALB/c 3T3 Cells 
1251-FGF binding was conducted with confluent BALB/c 3T3 cells. Prior to the 
initiation of the 1251-FGF binding, the monolayers were washed once with 
200ul/well of ice cold binding buffer (DMEM/1 °/o L-glutamine/0.1 °/o 8SA/20mM 
Hepes pH 7.4) and then incubated at 40c for 1 Omin to precool the monolayers. 
To determine dissociation rate constants for 1251-aFGF and 1251-bFGF, the 
method described by Nugent & Edelman (1992) was followed. Cells were 
incubated with 1251-bFGF (2ng/ml) or 1251-aFGF (1 Ong/ml) in binding buffer 
for 3 hours at 40c to allow binding to reach equilibrium. When examining the 
effect of heparin on the rate at which aFGF and bFGF dissociated from FGFR, 
FGFs were preincubated with either heparin (0.1 ug/ml) or medium for 1 hour at 
4°C before being added to cells for the 3 hour incubation. The amount of 1251-
FGF bound to nonspecific sites was determined by including an excess of the 
unlabelled growth factor (50ug/ml) in the buffer during the 3 hour incubation. 
After the incubation, the supernatant was aspirated and the monolayers 
washed three times with ice cold binding buffer before adding 1 OOul/well of 
dissociation medium and incubating the cells at 40c for the required period of 
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time. For the dissociation kinetics of 1251-aFGF, the dissociation medium 
contained 1 ug/ml of unlabeled aFGF and for bFGF dissociation kinetics , it 
contained 7ug/ml of unlabeled bFGF in binding buffer. Unlabeled FGF was 
included in the dissociation medium to ensure that released 1251-FGF would 
not rebind to unoccupied receptors (Nugent & Edelman 1992). A higher 
concentration of bFGF than aFGF was used because of bFGF's stronger 
tendency to reassociate with HSPG during the final washing process. After the 
dissociation period, the dissociation medium was removed, the cells washed 
once with ice cold binding buffer and the amount of 1251-aFGF or 1251-bFGF 
that remained bound to the HSPG released by exposing the cells to 2M NaCl in 
binding buffer for 1 O sec. Radiolabeled FGFs bound to FGFR were released 
by incubating the monolayers in low pH buffer (2M NaCl, 20mM sodium acetate 
pH 4) for 5 min, followed by a wash with the same buffer (Nugent & Edelman 
1992). At each time point non-specific binding of 1251-aFGF or 1251-bFGF was 
determined in the salt and acid washes of samples containing 50ug/ml of 
unlabeled FGF and these values subtracted from the experimental points. 
In some experiments the effect of heparin on the rate of association of 1251-
aFGF and 1251-bFGF with FGFR on heparinase-treated cells was also 
examined. Briefly, after preincubation of FGF with heparin, association was 
determined by incubating the cells with 1251-FGF in the presence and absence 
of heparin at 40c for various periods of time up to 4 hours. At the end of each 
incubation period, 1251-FGF was removed by suction and the cells washed 
three times with 200ul/well of ice cold binding buffer, followed by salt and acid 
washes as described above. Nonspecific binding at each time point was 
determined by including an excess of unlabeled FGF (50ug/ml) in the assay 
mixtures and subtracting the 1251-FGF which remained bound, from the 
experimental points. 
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Additional experiments examined the effect of heparin and CR-heparin on the 
binding of 1251-FGFs to heparinase treated cells. Serial dilutions of either 
heparin or CR-heparin in binding buffer were added to an equal volume of 
either 1251-aFGF or 1251-bFGF (final concentration 20ng/m I) and incubated on 
ice with regular mixing for 30-60min. Nonspecific binding of 1251-aFGF and 
1251-bFGF in the presence and absence of heparin or CR-heparin was 
determined by including an excess of unlabelled aFGF or bFGF (final 
concentration 50ug/ml) in the incubation mixtures. Heparin-FGF mixtures were 
added to heparinase treated BALB/c 3T3 cells (100ul/well), incubated for 4 
hours on ice, and after washing once with ice cold medium, 1251-aFGF or 1251-
bFGF bound to residual HSPG or FGFR released by exposing the cells to 2M 
NaCl and pH 4.0 solutions, respectively, as described above. 
To determine the ability of chicken HAG (cHRG), human HAG (hHRG), ATIII, 
PF4, heparin, aFGF and bFGF to inhibit the binding of 1251-aFGF and 1251-
bFGF to the 3T3 cell surface, cells were incubated with 95ul/well of each 
inhibitor at the concentration indicated for 1 hour on ice before adding Sul of 
either 1251-aFGF or 1251-bFGF to each well to give a final concentration of 
1 Ong/ml of 1251-FGF. The plate was incubated for a further 2 hours on ice 
before aspirating unbound 1251-FGF and washing cells three times with ice 
cold Hanks BSS/0.1 °/o BSA. Cells were lysed by incubation with 1 OOul/well of 
PBS/0.5°/o Triton-X100 for 30min, mixed and transferred to counting tubes for 
counting by a gamma counter. 
2.11. Binding of Radiolabeled aFGF, bFGF and cHRG to Extracellular 
Matrices 
Extracellular matrices (ECM) were prepared as follows: bovine corneal 
endothelial cells at passage 6-12 were seeded into 96-well plates (Nunclon) at 
a concentration of 1.25x1 o5 cells/ml. Cells were grown to confluence and 
confluent monolayers denuded of cells by incubating monolayers with 
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150ul/well of 0.02M ammonium hydroxide for 5 min at room temperature, 
followed by a PBS rinse and incubation of each well with 1 SOul of 0.5°/o TX-100 
in PBS for 30m in at 370c. Lysed cells were removed to expose the 
subendothelial matrix. ECMs were stored in PBS/ 0.1 °/o azide at 40c until 
required and washed three times with 200ul/well of PBS just prior to use. To 
determine the relative affinities of 1251-HRG, 1251-aFGF and 1251-bFGF for 
ECM HSPGs, serial dilutions of each radiolabeled molecule, (supplemented 
with unlabeled molecule) were made in Hanks BSS/0.1 °/o BSA and 1 OOul of 
each dilution mixed with 1 OOul of medium or medium containing heparin 
(SOOug/ml). Following incubation for 1 hour on ice, the mixtures (50ul/well) 
were transferred to ECM containing wells and incubated for 2 hours on ice. 
The unbound radiolabeled molecules were removed by aspiration and the wells 
washed three times with 200ul/well of ice-cold Hanks BSS/0.1 °/o BSA. The 
ECMs and bound radiolabeled molecules were solubilized by incubating each 
well with 200ul of 4M guanidine HCI /2°/o Triton-X100, overnight at 40c. The 
amount of radiolabeled aFGF, bFGF and cHRG associated with the ECM was 
then determined by a gamma counter. 
In binding-inhibition experiments, soul of either cHRG, hHRG, PF4, ATIII, 
heparin, aFGF or bFGF were added per well to give the final concentration 
required. The inhibitors were allowed to bind to the ECM for 1 hour at 40c 
before Sul/well of either 1251-bFGF (22ng/ml) or 1251-aFGF (440ng/ml) was 
added to each well. Incubation was for 2 hours at 40c before the reaction was 
terminated with the removal of unbound growth factor by washing and the 
release of radiolabeled growth factor bound to the ECM, as described above. 
2.12. Binding Affinity of Radiolabeled Heparin and CR-Heparin for 
Immobilized aFGF and bFGF 
Acidic and basic FGF were diluted from 200ug/ml to Sug/ml in PBS, and round 
bottom polyvinylchloride microtitration plates (PVC)(Dynatech Laboratories, Inc. 
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VA, USA) were either coated with 50ul/well of aFGF or bFGF, at a constant 
concentration of 5ug/ml, and the plates left at 40c overnight. Unbound FGF 
was removed from the plates by suction and the plates dunked twice in a PBS 
bath. Serial dilutions of radiolabeled heparin (0.003-6.5ug/ml) and CR-heparin 
(0.003-5.3ug/ml) were prepared in PBS/0.1 °/o BSA and 50ul of each , added to 
quadruplicate wells. Control wells received a 100-fold excess of the appropriate 
unlabeled heparin in addition to each concentration of radiolabeled heparin . 
After a 2 hour incubation on ice, unbound radiolabelled heparins were aspirated 
and the wells washed four times with 200ul/well PBS. The wells were removed 
from the plate by a hot wire and counted by an Auto-gamma 5650 counter 
(Packard Instrument International). Specific binding of 1251-heparin to FGF 
was determined by subtracting the mean binding of 1251-heparin in the 
presence of excess unlabeled heparin from the total 1251-FGF binding. 
Scatchard analysis was performed with a computer program, 11 Scatchard Plot 11 • 
2.13. Rose Bengal Cell Adhesion Assay 
A modified version of the cell-adhesion assay developed . by Ishihara et 
al.,(1992) was used to investigate the interaction of BALB/c 3T3 cell surface 
HSPG with FGFs immobilized on plastic. Ninety-six well round bottom 
polyvinylchloride (PVC) Microtiter plates (Dynatech Laboratories, Chantilly, VA) 
were coated with 50ul/well of either aFGF, bFGF, cHRG or hHRG (at the 
concentrations indicated) overnight at 40c. Wells were aspirated, the plate 
dunked twice in a PBS bath, and non-specific binding sites blocked by 
incubation with Hanks BSS/0.1 °/o BSA, pH 7.0 at 370c for 1 hour. BALB/c 3T3 
cells were suspended in Hanks BSS/0.1 °/o BSA at a cell density of 5x106 
cells/ml, 0.1 ml applied to each coated well and incubated at 370c for 1 hour. 
The plate was flicked to remove unbound cells and 1 OOul/well of 0.25°/o Rose 
Bengal dye (Koch-Light Laboratories Ltd, Colnbrook Berks, England) in PBS for 
3min at room temperature. Rose Bengal stains the nuclei and cytoplasm of 
both live and dead cells (O'Neill & Parish 1983). The unadsorbed dye was 
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removed by flicking the plate and dunking it twice in two separate PBS baths. 
The plate was allowed to drain before adding 200ul/well of 50°/o ethanol in PBS. 
Each well received a constant amount of mixing with a multichannel pipette to 
allow liberation of the dye from the cells. Nonspecific binding of the dye to 
FGF-coated and uncoated wells in the absence of cells was also determined 
and subtracted from experimental points. The relative number of cells in each 
well was quantified by determination of each well's optical density (A1 =540nm, 
A2=650nm) using a Thermomax microplate reader (Molecular Devices, Menlo 
Park, CA). 
In order to determine the optimum time and temperature for incubation of cells 
on FGF-coated PVC wells, 1 OOul/well of cells (5x106 cells/ml) were added in 
triplicate to aFGF (5ug/ml)-coated wells and incubated at either room 
temperature or 370c for the times indicated. Control wells were not coated 
with FGF but received cells at the same times as experimental wells. 
To determine the optimal cell concentration to use in this assay, doubling 
dilutions of cells in Hanks BSS/0.1 °/o BSA were prepared, ranging between 
1x106 cells/well and 3.9x1 o3 cells/well and incubated with HAG-coated 
(1 Oug/ml) wells for 1 hour at 370c. To determine the optimal concentrations of 
aFGF, bFGF, cHRG and hHRG with which to coat the wells, wells of a plate 
were coated with a range of concentrations of either aFGF, bFGF, cHRG or 
hHRG in triplicate. 1 OOul/well of cells at a final concentration of 2.5x106 
cells/ml was added to wells coated with FGF and 1 OOul/well of cells at a final 
concentration of 5x106 cell/ml added to HRG coated wells. The assay was 
then performed as described above. To determine whether acidic and basic 
FGF adhere to the PVC plate to an equal extent, quadruplicate wells were 
coated with either 50ul/well of 1251-bFGF or 1251-aFGF, both at 313ng/ml, and 
left overnight at 40c. Unbound FGF was removed by washing twice, the two 
washes being collected. 1 OOul/well of Hanks BSS/0.1 °/o BSA was then added, 
the plate incubated for 1 hour at 370c, supernatants collected and individual 
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wells detached from the plate by a hot wire. The amount of labeled FGF in 
each wash and that which remained bound to the wells was determined by a 
gamma counter. 
The ability of various GAGs (1 OOug/ml) to inhibit the binding of cell-surface 
HSPGs to aFGF, bFGF, cHRG and hHRG was also tested. Fifty ul/well of GAG 
was incubated with FGF- or HAG-coated wells for 1 hour at 40c before 50ul of 
cells (5x106 cells/ml) were added to each well and incubated at 370c for 1 
hour. To titrate the inhibitory activity of some GAGs or proteins doubling 
dilutions of each inhibitor were prepared in Hanks BSS/0.1 °/o BSA pH 7.0 and 
50ul/well of each concentration aliquoted in triplicate into FGF or HRG coated 
wells and the same procedure followed as described above. Control wells 
received medium without inhibitor. 
To determine whether PF4, ATIII, cHRG, hHRG, aFGF and bFGF cross react 
with the same HSPGs on the 3T3 cell surface, each of these factors were 
tested for their ability to inhibit the binding of 3T3 cells to PVC plates coated 
with one of the following: aFGF, bFGF, cHRG or hHRG. Serial dilutions of 
each of PF4, cHRG, hHRG , aFGF and bFGF were prepared and equal 
volumes of each dilution incubated with an equal volume of cells (5x106 
cells/ml) for 2 hours at 40c before aliquotting 1 OOul of each sample to triplicate 
wells coated with FGF or HAG. Control wells received cells which had been 
preincubated with medium in place of growth factor. 
2.14. Fluorescence Flow Cytometry 
In order to confirm the results of the Rose Bengal plate assays, an assay was 
developed which utilized the ability of a FACScan to quantify the binding of a 
fluoresceinated form of cHRG to 3T3 cells. FITC-conjugation of chicken HAG 
was performed by Dr C. Parish as follows: 1 ml cHRG (2.14mg/ml) in PBS was 
dialyzed overnight at 40c against 500ml of 0.05M boric acid, 0.2M NaCl, 
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pH9.2. 10mg of fluorescein-5-isothiocyanate (FITC; Molecular Probes, 
Eugene, OR) were dissolved in 2.0ml DMSO and soul of FITC-DMSO 
immediately added to the cHRG solution. Incubation was for 2 hours at room 
temperature in the dark. The sample was applied to a PD-1 O column and 
fluorescent HAG eluted in PBS to give a final concentration of 1 mg/ml. 
To test the ability of cHRG, hHRG, aFGF, bFGF and PF4 to inhibit the binding 
of FITC-cHRG to 3T3 cells, cells were grown to confluence in DMEM/20°/o 
FCS/1 °/o L-glutam ine/20m M Hepes, detached with PBS/EDT A and adjusted to 
5x106 cells/ml in Hanks BSS/0.1 °/o BSA pH7.0. To wells of a 96-well V-bottom 
plate (Serocluster Costar; Cambridge, Mass.) were added 20ul of cells and 
20ul of inhibitor, spanning the concentration ranges required. The plate was 
mixed gently and incubated on ice for 30min. Two microlitres of FITC-cHRG 
(1 mg/ml) were added to each well and after further mixing, the plate incubated 
on ice for 1 hour. Unbound FITC-cH RG was removed by washing the wells 3 
times with 150ul/well of ice cold Hanks BSS/0.1 °/o BSA pH7.0, the cells being 
pelleted by a GS-6R centrifuge (Beckman, Sydney, Australia) (at 200g force for 
1 min at 40C). Cell pellets were resuspended in 1 OOul of ice cold Hanks 
BSS/0.1 °/o BSA , and the fluorescence intensity of each sample determined by 
a FACScan (Becton Dickinson, Mountain View, CA). Control samples 
contained medium in place of inhibitor, or medium in place of FITC-cHRG. 
To test the ability of heparin to inhibit the binding of FITC-cHRG to 3T3 cells, 
serial dilutions of 20ul FITC-cHRG were made in a V-bottom plate and 2ul 
heparin (2mg/ml) added to each well. After incubating the plate on ice for 
30min, 20ul of 3T3 cells (5x1 o6cell/ml) were added to each well. Control 
samples included HRG in the absence of heparin, and cells in the presence 
and absence of heparin without HAG. The plate was mixed gently and 
incubated for a further 30min on ice. Unbound FITC-cHRG were removed by 
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washing the plate three times in the same manner as described above and 
fluorescence quantified by a FACScan. 
In some experiments, a rabbit anti-cHRG antiserum was also used to quantify 
the binding of cHRG to HSPGs on the 3T3 cell surface. To determine whether 
the medium used affects the ability of cHRG to bind to cells, the assay was 
performed in DMEM/1 °/o L-glutamine/20mM Hepes; F15 (Minimum Essential 
Medium 410-1500, G ibco) /1 °/o L-glutam ine/20m M Hepes, RPM I 1640 ( G ibco) 
/1 °/o L-glutamine/20mM Hepes; and Medium 199 (Gibco) /1 °/o L-
glutamine/20mM Hepes. Cells were prepared in PBS/EDTA, transferred to V-
bottom wells of a 96-well plate, pelleted, the supernatant discarded and cells 
resusupended in 20ul/well of cHRG diluted to 1 OOug/ml in one of the media 
mentioned above. Incubation was for 2 hours on ice. Unbound HRG was 
removed by washing samples three times in the appropriate medium. Rabbit 
anti-cHRG antiserum (prepared and provided by Dr C. Parish) was then added 
(20ul/well) and the plate incubated for 30min on ice. Unbound antibody was 
removed by washing the plate three times as described above and 20ul/well of 
Protein A-FITC (Boehringer-Mannheim, Mannheim, Germany) added. 
Incubation was for a further 30min on ice before unbound FITC-Protein A was 
removed by washing 3 times and cell pellets resuspended in 1 OOul/well of the 
appropriate medium. Samples were then analyzed by a FACScan. 
2.15. Soluble FGF Receptor Binding Assay 
Comparison of the abilities of heparin and CR-heparin to promote the binding of 
1251-aFGF and 1251-bFGF to an FGFR in a cell-free system were tested by Dr 
David Ornitz (Washington University, St. Louis, Missouri) using a soluble form 
of the murine FGF receptor 1 (mFR 1 ). A plasmid containing mFR 1 fused to 
human placental alkaline phosphatase (AP) cDNA (FR 1 AP) was introduced into 
NIH 3T3 cells, and monoclonal antibodies to placental AP coupled to 
Sepharose used to immunoabsorb FR1 AP from the conditioned medium. The 
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components of the soluble binding reaction mixture included FR1 AP-
conditioned medium (0.24 OD units/min), 1251-bFGF or 1251-aFGF, heparin or 
CR-heparin, 20ul of a 2 x slurry of anti-AP monoclonal antibodies coupled to 
Sepharose, DMEM and 0.1 °/o BSA in a volume of 250ul. The components were 
mixed at room temperature and rotated for 2-3 hours at 40c. Bound receptor 
or ligand was recovered by centrifuging ( 1 Os at 6000rpm at 40c in a 
microcentrifuge) and washing two times with 500ul of ice-cold PBS. 1251-FGF 
binding was determined by counting tubes directly in a 'Y counter (Ornitz & 
Leder 1992). 
2.16. Effect of cHRG on Cell Attachment 
Bacteriological petri dishes (Johns Scientific, Sydney, Australia) were incubated 
overnight at 40c with 20ml of either PBS or PBS containing 1 Oug/ml of HRG. 
PBS and unbound cHRG were aspirated and the dishes washed three times 
with 10ml Hanks BSS/0.1 °/o BSA and non-specific binding sites blocked by 
incubation with 10ml Hanks BSS/0.1 °/o BSA pH 7.0 at 370c for 1 hour. After 
removal of the blocking buffer, each petri dish received 10ml of a BALB/c 3T3 
cell suspension (0.6x1 o5 cells/ml), and the cells were left to adhere to the 
dishes for 2 hours at 370c before being examined for spreading under a light 
microscope. 
2.17. Mitogenic assays 
The mitogenic activity of aFGF and bFGF was determined by measuring their 
ability to stimulate DNA synthesis in HUVE cells and in serum starved BALB/c 
3T3 cells, as determined by [methyl-3H]thymidine incorporation. To compare 
the abilities of heparin and CR-heparin to potentiate aFGF activity over time, 
equal volumes of aFGF and medium, aFGF and heparin, and aFGF and CR-
heparin, were incubated together for 1 hour on ice with regular mixing, before 
being added to serum starved 3T3 cells (1 OOul/well) to give final concentrations 
of 1 Ong/ml for aFGF and 50ug/ml for each heparin. [Methyl-3H]thymidine 
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(0.5uCi/well) (60Ci/mmol) (Amersham) was added for the final 24 hours of each 
treatment. Incubation was stopped by freezing and thawing the cultures three 
times, the assay harvested with a 1295-004 Betaplate 96-well harvester 
(Pharmacia, Uppsala, Sweden) and the radioactivity counted with a liquid 
scintillation counter (Pharmacia). 
To compare the effects of heparin on the dose response curves of acidic and 
basic FGF for BALB/c 3T3 cells and HUVE cells, serial dilutions of acidic and 
basic FGF in the culture medium were prepared and equal volumes of each 
FGF dilution mixed with either medium or heparin to give a final heparin 
concentration of 5ug/ml. Samples were mixed and incubated at 40c for 30min. 
A constant volume of HUVE cells (2.5x1 o4 cells/well) was added to each 
sample tube and 1 OOul of sample added to quadruplicate wells of a 96-well 
plate (Nunc) precoated with 0.1 °/o gelatin. Control wells received cells and 
medium without FGF or heparin. In the case of BALB/c 3T3 cells, after 
incubation of the different FGF dilutions with and without heparin, 1 OOul of each 
dilution was added to quadruplicate wells of 3T3 cell monolayers. Control wells 
received medium without FGF or heparin. Incubation was for 24 hours before 
the addition of [methyl-3H]thymidine for a further 24 hours. 
In order to determine whether high concentrations of heparin and CR-heparin 
would inhibit aFGF-induced mitogenesis in cells lacking HSPGs, cells were 
cultured in chlorate and sulfate-free medium (BME) for 48 hours, as described 
by Rapraeger et al.,(1991 ). The cells were treated with heparinase 1 (2 
units/well) to remove residual cell surface HSPGs before receiving treatments. 
Control cultures received BME in place of heparinase and were subjected to 
the same washing procedure. Treatments consisted of aFGF (20ng/ml) in the 
presence and absence of 0.1, 10, and 1 OOOug/m I of heparin and CR-heparin. 
Incubation mixtures for heparinase-treated cells were prepared in BME and 
30mM chlorate while cells not treated with heparinase received the same 
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incubation mixtures prepared in BME and O.SmM sulfate. Incubation was for 
24 hours at 370c before [methyl-3H]thymidine was added for a further 24 
hours. 
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Chapter 3 
Acidic and Basic FGF Bind with Differing Affinity to the Same 
HSPG on BALB/c 3T3 Cells: Implications for Potentiation of 
Growth Factor Action by Heparin 
3.1. Introduction 
Acidic and basic FGF bind to two classes of binding site on the cell surface, the 
FGFR which is regarded as a "high affinity" binding site on the basis of low Kd 
values (Kd=1 o-9-1 o-12M) (Neufeld & Gospodarowicz 1985; Maenner et al 
1986; Olwin & Hauschka 1986) and HSPGs regarded as "low affinity" binding 
sites on the basis of relatively high Kd values (Kd=10-8-1 o-9M) (Moscatelli 
1987). HSPGs on the cell surface generally outnumber FGFRs by 1-3 orders 
of magnitude (Moscatelli 1987; Burgess & Maciag 1989). Furthermore, it is 
generally accepted that the presence of either HSPG or heparin is required for 
the binding of FGFs to the "high affinity" receptor. This study aimed to clarify 
several aspects of the interaction of FGFs with HSPGs. 
First, I have examined whether both acidic and basic FGF recognize similar or 
different motifs within the HS chains of cell surface HSPGs and have 
determined their relative binding affinities for these HS motifs. 
Second, this study examined the importance of HSPG in stabilizing the 
interaction of FGFs with their "high affinity" receptor. Two models have been 
proposed to explain how HSPGs promote the binding of FGFs to their 
receptors. In one model it is proposed that HSPGs induce a conformational 
change in FGF which enables the growth factor to bind with high affinity to its 
receptor (Vayon et al., 1991 ). In a second model, Nugent & Edelman (1992) 
have proposed that formation of a "ternary complex" is required which does not 
involve a conformational change in the molecule, but requires the simultaneous 
binding of FGF to FGFR and HSPG for stable binding to occur. I have 
undertaken a comparative study, using both aFGF and bFGF, to determine the 
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relative importance of HSPG in stabilizing the FGF/FGFR complex. In 
particular, the role of the "ternary complex" model of FGF binding was 
examined for both growth factors. 
Finally, based on these observations an attempt has been made to explain why 
heparin potentiates aFGF action but has little or no potentiating effect on bFGF 
function. Of particular interest was whether differences in the affinity of the two 
FGFs for cell surface HSPGs can explain why acidic but not basic FGF is 
potentiated by heparin. 
3.2. Results 
3.2.1. Binding of Acidic and Basic FGF to Cell Surface HSPGs 
In order to examine the interaction of acidic and basic FGFs with BALB/c 3T3 
cell surface HSPGs, an assay based on that of Ishihara et al.,(1992) was 
developed to determine whether acidic and basic FGFs interact with the same 
HSPGs, and if so, whether they differ in their affinity for these HSPGs. The 
assay utilized the ability of the FGFs to adhere to 96-well PVC plates and of 
cells to bind to the FGF-coated wells via their cell surface HSPGs. Bound cells 
were then quantified using the vital dye, Rose Bengal. 
Initially, the optimum time and temperature for incubation of the cells with the 
FGF coated plate was determined (Fig. 3.1 ). Binding of cells to plates coated 
with aFGF was shown to occur most rapidly at 370c, a little slower at room 
temperature and not at all at 40c. This temperature effect is probably due to a 
rapid redistribution of ligands on the cell surface at 370c which would allow 
more HSPGs to come into contact with the factor on the plate, and thereby 
result in multivalent binding. Subsequent assays were incubated for 1 hour at 
370c with the optimum cell number of 2.5x1 oS cells/well. 
1.0 
0.8 
E 
C 0.6 
0 
v 
LO 
I 
0 
0 0.4 
0.2 
0.0 
20 40 60 80 100 120 140 
Time (minutes) 
FIGURE 3.1: Determination of the optimum time and 
temperature for binding of BALB/c 3T3 cells (5x1 oscells/well) to 
PVC wells coated with aFGF (5ug/ml). Incubation was at 37°C 
(•) and at room temperature (.~) for the times indicated. There 
was no cell binding at 4°C (data not shown). Values represent 
means + SEM (n=3), the number of cells remaining bound to 
each well being quantified by Rose Bengal staining. 
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The optimal FGF concentration to be used for coating the wells was also 
determined (Fig. 3.2) . It was found that for optimum cell binding, an 
approximately 8 fold higher concentration of aFGF, than bFGF, was required 
for coating. This difference was not due to differences in the ability of acidic 
and basic FGF to adhere to plastic as studies with 1251-labeled FGFs showed 
that both growth factors bound equally well to the plates, ie. , approximately 
15°!o of added radiolabeled FGF at 0.3ug/ml. Acidic and basic FGF were 
generally used at concentrations of 2.5ug/m I and 0.313ug/m I, respectively, to 
coat plates in subsequent assays. 
Subsequent studies demonstrated that binding of BALB/c 3T3 cells to the 
immobilized FGFs was heparin inhibitable, although of eleven GAGs tested 
only heparin, fast moving HS and bovine intestinal HS were inhibitory, 
indicating that they share with 3T3 cell surface HSPGs, the structure required 
for FGF binding. The eight non-inhibitory GAGs were, hyaluronic acid, 
chondroitin-4-sulfate, chondroitin-6-sulfate, chondroitin-4,6-disulfate, dermatan 
sulfate, keratan sulfate, bovine kidney HS, and porcine mucosa! HS. The 
complete inhibition curves for heparin, fast moving HS and bovine intestinal HS 
are depicted in Figure 3.3. for bFGF, and Figure 3.4. for aFGF. For both 
growth factors, heparin was the most potent inhibitor. Fast moving HS was, on 
a weight basis, 480 fold less effective at inhibiting aFGF and 600 fold less 
effective at inhibiting bFGF binding than heparin. Bovine intestinal HS, at high 
concentrations, also inhibited bFGF binding but this inhibition was not observed 
with aFGF. This difference suggests that there may be some subtle differences 
in the HS motifs recognized by acidic and basic FGF. 
Figure 3.5. shows that both soluble aFGF and bFGF can totally block the 
binding of immobilized bFGF to HSPGs on BALB/c 3T3 cells. Similarly, both 
FGFs totally inhibited immobilized aFGF from binding to 3T3 cells (Fig. 3.6). 
Thus, acidic and basic FGF cross react with the same species of cell surface 
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FIGURE 3.2: Determination of optimum coating concentration of FGF 
required for the binding of BALB/c 3T3 cells (2.5 x 1 oscells/well) to 
PVC plates. Cell binding was performed for 60m in at 37°C and the 
number of cells bound/well quantified by Rose Bengal staining. 
Values represent means+ SEM (n=3) of one representative experiment. 
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FIGURE 3.3: Comparison of the ability of heparin (•), fast moving 
heparan sulfate (e) and bovine intestinal heparan sulfate (.&.) to 
inhibit the binding of BALB/c 3T3 cells to PVC wells coated with 
bFGF (0.625ug/ml). Heparin and heparan sulfates were incubated 
with plate-bound bFGF for 1 hour on ice before adding cells 
(2.5x1 as cells/well) for 1 hour at 37°C. 100°/o binding represents 
that occurring in the absence of inhibitor. Each value represents 
the mean of triplicate treatments. Standard errors of the means 
Were < 10°/o. 
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FIGURE 3.4: Comparison of the ability of heparin (•), fast moving 
heparan sulfate (e) and bovine intestinal heparan sulfate (A) to 
inhibit the binding of BALB/c 3T3 cells to PVC wells coated with 
aFGF (2.Sug/ml). Assay conditions were as described in the 
legend of Figure 3.3. 
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FIGURE 3.5: Ability of soluble aFGF and bFGF to inhibit the 
binding of BALB/c 3T3 cells to immobilized bFGF. Cells were 
incubated with a range of FGF concentrations for 2 hours on ice 
before being added to bFGF-coated wells for a further 1 hour 
incubation at 37° C. Each value represents the mean of 
triplicate treatments. 1 OOo/o binding is the number of cells 
bound to bFGF in the absence of FGF inhibitor. Standard 
errors of means were < 5%. 
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FIGURE 3.6: Ability of soluble aFGF and bFGF to inhibit the 
binding of BALB/c 3T3 cells to immobilized aFGF. Assay 
conditions and data presentation as described in legend of Figure 
3.5. 
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HSPG on 3T3 cells. However, in both assays aFGF was a less effective 
inhibitor, the difference being 2.5 fold with immobilized bFGF (Fig. 3.5) and 7.8 
fold with immobilized aFGF (Fig. 3.6) in the experiments shown. Subsequent 
replicate inhibition assays gave similar results irrespective of the immobilized 
FGF used, the pooled data showing that aFGF was a 4.7+1.0 (SEM, n=4) fold 
less effective competitor than bFGF. This result indicates that bFGF has a 
higher affinity for 3T3 cell surface HSPGs than does aFGF. 
3.2.2. Role of Cell Surface HSPGs in Binding of FGFs to FGFR 
In order to determine whether aFGF's ability to be potentiated by exogenously 
added heparin is in any way dependent on its affinity for cell surface HSPG and 
its ability to form ternary complexes with them and the FGFR, studies were 
performed which compared the dissociation rates of aFGF and bFGF from 
FGFR and HSPG on BALB/c 3T3 cells. As found by Nugent & Edelman 
(1992), the rates of dissociation of bFGF from the FGFR and HSPG differed 
significantly (Fig. 3. 7 A). There was a biphasic release of bFGF from FGFR. 
Initially, approximately 20°/o of bound bFGF was released relatively rapidly from 
FGFR. This was followed by a second phase of dissociation during which the 
majority (80°/o) of FGFR-bound-bFGF dissociated extremely slowly, with the 
time required for half of the bound bFGF to be released (t1;2) from the FGFR 
being >250 min compared with approximately 9 min for the HSPG. In contrast, 
aFGF dissociated from the FGFR and HSPGs at similar rates, t1;2 being 
determined as 25 min and 16 min, respectively (Fig. 3.78). Thus, aFGF 
dissociates from the FGFR considerably faster than does bFGF and this 
difference is reflected in their t1;2 values, being 25 min for aFGF and >250 min 
for bFGF dissociation from the FGFR. In contrast, the two growth factors 
dissociated from HSPG relatively rapidly and at similar rates, the t1;2 values for 
aFGF and bFGF being 16min and 9min, respectively. 
FIGURE 3. 7: Dissociation of bFGF (A) and aFGF (8) from FGF-R 
and HSPG on intact BALB/c 3T3 cells. Dissociation was performed 
in the presence of an excess of unlabeled bFGF (7ug/ml) or aFGF 
(1 ug/ml) to minimize rebinding of released 1251-FGF. Each data 
point represents the mean + SEM of triplicate treatments. Initial 
binding (100°/o) to FGF-R was 893+38 cpm and 4701 +166 cpm for 
bFGF and aFGF, respectively. Initial binding (1 OO°!o) to HSPG was 
434+60 cpm and 994+120 cpm for bFGF (2ng/ml) and aFGF 
( 1 Ong/m I), respectively. 
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In order to determine whether heparin can act as a substitute for cell-surface 
HSPGs, cells were treated with heparinase to remove cell surface HSPG and 
the effect of heparin on the dissociation of bFGF from the FGFR observed (Fig. 
3.8A). As observed by Nugent & Edelman (1992), in the absence of HSPG, 
bFGF dissociates >20 fold faster from the FGFR, the time required for half of 
the bound bFGF to be released from FGFR being 12min as compared with 
>250min on untreated cells. In fact, bFGF dissociated from FGFR at a rate 
similar to that which bFGF dissociated from HSPG on untreated cells. In the 
absence of cell surface HSPG, aFGF dissociated from FGFR with a t112 of 
approximately ?min (Fig. 3.88). Thus aFGF dissociated from FGFR in the 
absence of HSPG at a rate almost 3.5-fold faster than in their presence. 
Therefore in the absence of HSPG the dissociation rates of aFGF and bFGF 
from FGFR differed by a factor of only 1.7 whereas in their presence, they 
differed by a factor > 10. These results suggest that the difference in the 
dissociation rates of aFGF and bFGF from FGFR is very likely due to a 
difference in their ability to interact with cell surface HSPGs. 
The presence of heparin during FGF binding had very little (Fig. 3.8A) or no 
effect (Fig. 3.88) on the dissociation rate of both FGFs from the FGFR. Since 
heparin has been shown by others to restore FGF binding to heparinase-
treated cells and to mutant cells unable to produce HSPGs, it was expected 
that heparin would restore the dissociation rates of aFGF and bFGF on 
heparinase-treated cells to levels similar to those on untreated cells. However, 
in this system, heparin was unable to act as a substitute for cell surface HSPG. 
For bFGF, in the presence of heparin, the t1;2 was 24min, as compared with 
12min in the absence of heparin on heparinase-treated cells. For aFGF, in the 
presence of heparin, the t112 was ?min which was the same as in the absence 
of heparin on heparinase treated cells. 
FIGURE 3.8: Dissociation of bFGF (A) and aFGF (B) from FGF-R 
on heparinase-treated BALB/c 3T3 cells in the presence and 
absence of heparin (0.1 ug/ml). Dissociation was performed in the 
presence of an excess of unlabeled bFGF (7ug/ml) or aFGF 
(1 ug/ml) to minimize rebinding of released 1251-FGF. Each data 
point represents the mean + SEM of triplicate treatments. Initial 
binding (100°/o) to FGF-R in the absence of heparin was 1170+129 
cpm and 1120+14 cpm for bFGF and aFGF, respectively. Initial 
binding (100°/o) to FGF-R in the presence of heparin was 1092+6 
cpm and 1546+187 cpm for bFGF (2ng/ml) and aFGF (1 Ong/ml), 
respectively. 
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In contrast, heparin was shown to enhance the binding of both bFGF (Fig. 
3.9A) and aFGF (Fig. 3.98) to the FGFR on heparinase treated cells. Heparin 
significantly potentiated the binding of aFGF to FGFR at concentrations ranging 
from 0.001 ug/ml to 1 OOug/ml but had an inhibitory effect on aFGF binding at 
1 mg/ml. Enhancement of bFGF binding by heparin was less marked than with 
aFGF and occurred over a narrower concentration range (0.1-1 ug/ml), although 
again at 1 mg/ml, heparin was highly inhibitory. This observation that heparin 
does not enhance the binding of bFGF to its receptor to the same extent as it 
does aFGF is in agreement with the observation that heparin does not 
generally potentiate bFGF-induced mitogenesis in vitro to the same degree as 
it does aFGF. This further supports the idea that potentiation of aFGF activity 
by heparin is related to its ability to enhance aFGF binding to its receptor. 
In order to determine whether soluble cell surface HSPGs could enhance aFGF 
binding like heparin, HSPGs were isolated from both the BALB/c 3T3 cell 
surface and from the culture medium and assayed for their ability to enhance 
aFGF binding to the FGFR on cells treated with heparinase just prior to the 
assay. HSPGs isolated from the cell surface enhanced aFGF binding to FGFR 
by 42°/o, 45°/o and 23°/o above that observed in the absence of added HSPG on 
heparinase-treated cells, when used at concentrations of 0.1 ug/ml, 0.5ug/ml 
and 1 ug/ml, respectively. HSPGs isolated from the culture medium were more 
potent, enhancing aFGF binding by 72°/o, 70°/o and 43°/o when used at 
concentrations of 0.1 ug/ml, 1 ug/ml and 5ug/ml, respectively. However, these 
HSPGs were not as potent as heparin which when used at 0.1 ug/ml enhanced 
aFGF binding by 116°/o. 
3.2.3. Potentiation of Acidic and Basic FGF Action by Heparin 
Before discussing the data described above it was important to examine the 
effects of heparin on the mitogenic activity of acidic and basic FGF for the 
BALB/c 3T3 cells used in this study. Figure 3.10 compares the effect of a 
FIGURE 3.9: Effect of different concentrations of heparin on (A) 
bFGF (20ng/ml) and (8) aFGF (20ng/ml) binding to FGFR on 
heparinase-treated cells. Values represent means + SEM of 
triplicate values for bFGF and quadruplicate values for aFGF. 
Similar results were obtained on 3 separate occasions. Nonspecific 
binding was <20°/o of cpm bound. 
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FIGURE 3.1 O: Effect of heparin (50ug/ml) on (A) bFGF- and on (B) 
aFGF-induced mitogenesis of BALB/c 3T3 cells. 3H-thymidine 
incorporation is given in cpm x1 o-3. Values represent mean + SEM 
of quadruplicate treatments. BALB/c 3T3 mitogenesis in the 
absence of added heparin gave less than 4x1 o3 cpm, and in the 
absence of FG F and heparin gave 3. 7x1 o3 cpm. 
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constant concentration of heparin (5ug/ml) on acidic and basic FGF-induced 
mitogenesis of BALB/c 3T3 cells. In the absence of heparin, aFGF was 
substantially less active than bFGF at inducing 3T3 cell mitogenesis, at least 
100-fold higher concentrations of aFGF being required to induce a proliferative 
response comparable to bFGF (Fig. 3.1 OA & B). Heparin markedly potentiated 
aFGF activity on BALB/c 3T3 cells (Fig. 3.1 OB) with the result that aFGF in the 
presence of heparin, was more active than bFGF in the absence of heparin, at 
all FGF concentrations. Heparin also potentiated bFGF activity above that 
observed in the absence of heparin but not to the same extent as with aFGF. 
In the presence of heparin, aFGF and bFGF exhibited comparable mitogenic 
activities, aFGF perhaps being a little more active than bFGF. 
The ability of heparin to potentiate aFGF mitogenic activity more than bFGF is 
further illustrated in Figures 3.11 A and 3.11 B with HUVE cells. Heparin 
dramatically potentiated aFGF activity to such an extent that, with the exception 
of the three lowest aFGF concentrations used, aFGF was more active than 
bFGF without heparin, and at all but a few FGF concentrations, more active 
than bFGF in the presence of heparin. Heparin had its greatest potentiating 
effect with the lower concentrations of aFGF, whereas with the highest aFGF 
concentration used (1 ug/ml), potentiation was minimal. In contrast, heparin 
only slightly enhanced bFGF-induced HUVE cell mitogenesis at bFGF 
concentrations >0.16ug/ml and, in fact, inhibited bFGF mitogenic activity at 
concentrations of bFGF <0.01 ug/ml. 
3.3. Discussion 
The three main findings in this study are, firstly, that acidic and basic FGF 
interact with the same HSPGs on the BALB/c 3T3 cell surface, secondly, that 
bFGF binds these HSPGs with a substantially higher affinity than does aFGF 
FIGURE 3.11: Effect of heparin (Sug/ml) on (A) bFGF- and on (8) 
aFGF-induced mitogenesis of HUVE cells. 3H-thymidine 
incorporation is given in cpm x1 o-3. Values, from which 
background cpm have been subtracted, represent mean + SEM of 
quadruplicate treatments. 
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and thirdly, that cell surface HSPGs stabilize the interaction of bFGF with the 
FGFR much more effectively than they do aFGF. 
The ability of acidic and basic FGF to interact with the same HSPGs was 
demonstrated by receptor blocking studies where soluble aFGF and bFGF 
totally blocked binding of immobilized aFGF and bFGF to cell surface HSPGs 
on 3T3 cells (Figs 3.5 & 3.6). Although these results demonstrate that acidic 
and basic FGF bind to the same species of HSPG on the 3T3 cell surface they 
do not enable us to determine whether both FGFs bind to exactly the same 
sequence of saccharides on the HS chains. In the light of recent findings by 
Nurcombe et al.,(1993) who have demonstrated that acidic and basic FGF are 
able to recognize differentially glycosylated HSPGs with differing affinity, it 
would appear more likely that acidic and basic FGF bind to slightly different 
sequences which are either adjacent or overlapping. The differential inhibitory 
effect of bovine intestinal HS on basic and acidic FGF binding supports this 
point (Figs 3.3 & 3.4). Although chemical analysis of the saccharide sequences 
to which acidic and basic FGF bind have not to date demonstrated any 
significant differences in the sequences recognized, it seems likely that subtle 
differences in the sequences recognized will eventually be discovered. Basic 
FGF has been shown to bind sequences in which the predominant 
disaccharide is ldoA(2-0S03)a1 ,4GlcNS03 (Turnbull et al., 1992; Habuchi et al 
1992) while aFGF is thought to bind sequences in which the predominant 
' 
disaccharides are ldoA(2-0S03)a1 ,4GlcNS03(6-0S03) (Barzu et al., 1989; 
Mach et al., 1993). 
The binding inhibition studies also indicate that bFGF has a 4. 7 fold higher 
binding affinity for 3T3 cell surface HSPG than aFGF (Figs 3.5 & 3.6). In 
support of this conclusion was the observation that the PVC plates had to be 
coated with approximately an 8 fold higher concentration of aFGF than bFGF to 
facilitate HSPG-mediated binding of 3T3 cells (Fig. 3.2), despite the fact that 
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radiolabeled FGFs adhered to the plates equally well. Although it is generally 
accepted that aFGF has a lower affinity for heparin than does bFGF, their Kds 
being determined as 91 nM and 2.2nM respectively (Lee & Lander 1991 ), the 
relative affinities of acidic and basic FGF for cell surface HSPGs are less well 
defined, their Kds being reported to lie within the range of 2-1 OnM (Moscatelli 
1987). However, lower salt concentrations have been used to elute aFGF 
(0. 75M) from cell surface HSPG than are used to elute bFGF (>2.0M) 
suggesting that aFGF exhibits a lower affinity for HSPG than bFGF (Olwin & 
Rapraeger 1992). On the other hand, Nurcombe et al.,(1993) have detected a 
HSPG during embryonic development which has a higher affinity for acidic than 
basic FGF. Presumably such a HSPG is not expressed on BALB/c 3T3 cells. 
The kinetic studies which compared the rates of dissociation of acidic and basic 
FGF from FGFR in the presence and absence of endogenous HSPG highlight 
the difference in affinities of acidic and basic FGF for HSPGs and the 
importance of HSPG in stabilizing the interaction of FGF with the FGFR. Basic 
FGF was shown to dissociate from the FGFR >20-fold slower in the presence 
of HSPGs than in their absence, t112's being >250min and 12min, respectively 
(Figs 3. 7 A & 3.8A). These results are in agreement with those of Nugent and 
Edelman (1992) who found bFGF to dissociate from FGFR at a 16 fold faster 
rate in the absence of HSPGs. As Nugent and Edelman (1992) have 
suggested, HSPG may prolong the period that bFGF is bound to the FGFR 
thereby enabling receptor activation which might not occur in the absence of 
HSPGs. In contrast to bFGF, aFGF was found to dissociate relatively rapidly 
from FGFR both in the presence and absence of HSPG, t112 being determined 
as 25min and ?min, respectively (Figs 3.78 & 3.88). Thus, these results 
demonstate that aFGF dissociates from FGFR in the presence of HSPG at 
least 10-fold faster than does bFGF. Since this study has shown bFGF has a 
considerably higher affinity for 3T3 cell surface HSPG than aFGF these results 
/1 
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also suggest that aFGF is not able to utilize 3T3 cell surface HSPGs to form 
ternary complexes as effectively as does bFGF. 
In this study, heparin was shown to potentiate aFGF-induced mitogenesis on 
both BALB/c 3T3 cells and HUVE cells to a significantly greater extent than it 
did bFGF-induced mitogenesis (Figs 3.1 OA & B, 3.11 A & B) which confirms the 
findings of others (Thornton et al., 1983; Schreiber et al. , 1985; Lobb et al. , 1986; 
Orlidge & D1Amore 1986). A possible explanation for this potentiation 
difference may be that aFGF1s low affinity for endogenous HSPG on the 3T3 
cell surface is not sufficient to ensure maximal binding of aFGF to its receptor. 
Acidic FGF very likely has a higher affinity for heparin and is able to utilize 
exogenously added heparin more effectively than endogenous HSPG to 
promote high affinity binding to the FGFR. In contrast, bFGF has a sufficiently 
high affinity for cell surface HSPG to enable it to utilize them in high affinity 
interactions with the FGFR without any requirement for exogenously added 
heparin. 
Unfortunately the data presented in this chapter does not enable me to resolve 
the issue as to how heparin/HSPG enhance the binding of FGF to the FGFR. 
The two most likely possibilities are that heparin/HSPG induce a conformational 
change in the growth factor thus enabling it to bind to the FGFR (Schreiber et 
al., 1985; Kaplow et al., 1990; Vayon et al., 1991) or that HSPGs are required to 
stabilize the binding of FGF to its receptor and form a 11ternary complex 11 with 
them (Nugent & Edelman 1991 ). These two models are, however, not mutually 
exclusive and I have presented data in support of both models. In support of 
the 11ternary complex 11 model, my data strongly suggest that the difference 
between acidic and basic FGFs 1 dissociation rates from FGFR is due to their 
difference in affinity for cell surface HSPGs. Nugent & Edelman (1992) have 
demonstrated that the difference between 11 high affinity 11 binding, traditionally 
defined as FGF binding to FGFR, and 11 low affinity 11 binding, ie. , FGF binding to 
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HSPG, is due only to the slower rate at which bFGF dissociates from the "high 
affinity" site. Since in their study, bFGF dissociated from FGFR on heparinase-
treated cells at a rate 16-fold higher than it did from FGFR in the presence of 
HSPG, they proposed that the presence of HSPGs is required for a high affinity 
binding interaction between FGF and FGFR to occur. An HSPG-induced 
conformational change in the growth factor would not be expected to affect its 
rate of dissociation from FGFR. 
In order for heparin to act as a substitute for HSPG in the formation of a ternary 
complex, it would have to bind heparin receptors located adjacent to the FGFR 
or to a heparin-binding domain on the FGFR itself. Indeed potentiation of 
aFGF-induced mitogenesis by heparin may be the result of the formation of 
more ternary complexes between aFGF and FGFR than aFGF would form in 
the presence of HSPG. If this idea is correct, then in the presence of heparin, 
the rate at which aFGF dissociates from FGFR on heparinase-treated cells 
would be expected to be lower than in its absence. However, in my system, 
heparin did not act to decrease the rate at which acidic and basic FGF 
dissociated from the FGFR. In fact, heparin increased the net amount of acidic 
and basic FGF bound to the FGFR on heparinase treated cells (Fig. 3.9) 
without affecting either association (results not shown) or dissociation rates 
(Fig. 3.8), lending support to the idea of a conformational change. Rather than 
heparin stabilizing the formation of a ternary complex it may be enhancing the 
ability of the growth factor to bind to its receptor with the result that more 
FGFRs are being engaged in the presence of heparin. Certainly, the ability of 
heparin to promote the binding of FGFs to soluble forms of FGFR in a cell-free 
system (Ornitz et al., 1992; Ornitz & Leder 1992) strongly suggests that heparin 
is able to promote FGF binding purely by inducing a conformational change in 
the growth factor. 
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One of the difficulties in interpreting the data from my binding assays is that 
due to the large number of FGFRs on 3T3 cells, it is not possible to distinguish 
which interactions are those of biological relevance. Such interactions are 
likely to comprise a small subset of the total number of binding interactions 
observed in the assay. As the data of Schreiber et al.,(1985) suggests, FGF 
mitogenic activity requires only partial receptor occupancy. Similarly, it is not 
known whether the interaction between FGF and FGFR in the soluble receptor 
assays occurring in the absence of cells, is actually one of biological 
significance. It is possible that only a small number of receptors need to be 
engaged to induce a productive signal and that they require the formation of a 
ternary complex. 
Further support for this idea comes from the observation that in my system, 
higher concentrations of heparin are required to potentiate aFGF-induced 
mitogenesis than are required to potentiate aFGF binding to heparinase-treated 
cells. Perhaps this can be explained in part by ,the likelihood that heparin 
receptors on the BALB/c 3T3 cell surface outnumber FGFRs by a factor of at 
least 300:1 (see chapter 4) and thus many of the heparin receptors would not 
be located in a position favourable for the formation of ternary complexes with 
FGF and the FGFR. Thus a large proportion of the heparin/FGF complexes 
formed would be sequestered by heparin receptors distant from the FGFR. Yet 
the formation of a productive complex may require that FGF is bound either to 
HSPG which is predominantly cell surface bound, or to heparin bound to 
heparin receptors and perhaps relatively few of these ternary complexes are 
needed to produce sufficient activation of receptors. Moreover, the possibility 
that heparin is stabilizing the interaction between FGF and FGFR by binding to 
a putative heparin-binding domain on the FGFR has not yet been considered 
(see chapter 4). If such an interaction was occurring then it would tend to 
support the idea that heparin promotes the formation of a ternary complex. 
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3.4. Summary 
Heparan sulfate proteoglycans (HSPGs) on the cell surface act as low affinity 
binding sites for acidic and basic FGF (Moscatelli 1987) and play an important 
role in the interaction of FGF with the FGF receptor (FGFR). In this study, 
several aspects of the interaction of FGFs with HSPGs were examined. First, 
reciprocal cross blocking studies demonstrated that aFGF and bFGF bind to 
identical or closely associated HS motifs on BALB/c 3T3 cell surface HSPGs. 
However, the binding affinity of the two growth factors for these HSPGs differs 
considerably, binding-inhibition data indicating that aFGF has a 4.7 fold lower 
affinity than bFGF for 3T3 HSPG. Subsequent studies of dissociation kinetics 
demonstrated that bFGF dissociates from the FGFR at least 10-fold slower 
than aFGF (t1;2 >250min versus 25 min) whereas, following removal of cell 
surface HSPGs by heparinase treatment, the dissociation rate of both FGFs is 
similar and rapid (t1;2 12min versus ?min). These results support the concept 
I, 
1 that cell surface HSPGs stabilize the interaction of FGFs with FGFR, possibly 
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by the formation of a ternary complex, with r1e lower binding affinity of aFGF 
for HSPG, compared with bFGF for HSPG, resulting in binding to FGFR being 
less effectively stabilized by HSPG. Such a model may explain the lower 
mitogenic activity of aFGF compared with bFGF for 3T3 cells and suggests that 
heparin usually potentiates aFGF-induced, but not bFGF-induced, mitogenesis 
because of aFGF's relatively low affinity for cell surface HSPGs. In this 
context, heparin had no effect on the rate at which acidic and basic FGF 
dissociated from FGFR but it did enhance the net binding of aFGF and bFGF to 
FGFR on cells from which HSPGs had been removed by treatment with 
heparinase. These data are discussed in the context of the ability of 
heparin/HSPGs to promote FGF binding to FGFR by inducing a conformational 
change in the growth factor and/or by enabling the formation of a ternary 
complex. 
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Chapter 4 
Evidence that Carboxyl-Reduced Heparin Fails to Potentiate 
aFGF Activity via an Inability to Interact with Cell Surface 
Heparin Receptors 
4.1. Introduction 
The potentiation of aFGF activity by heparin was first observed by Thornton et 
al.,(1983) who reported that heparin greatly potentiated the mitogenic effect of 
endothelial cell growth factor (ECGF), a semi-purified aFGF preparation, on 
the proliferation of endothelial cells. They found that maximal growth could be 
induced by 25ug/ml of ECGF in the presence of heparin, but that 100-200ug/ml 
of ECGF was required to support significant growth in the absence of heparin. 
Heparin alone had no effect on endothelial cell replication, indicating that both 
factors were required for optimum growth. It was therefore suggested that 
heparin-like substances may play an important role in regulating cell growth in 
normal and injured vessels (Thornton et al., 1983). Ten years later, although 
cell surface HSPGs and heparin have been clearly implicated in the regulation 
of FGF-induced cell growth, and significant advances have been made towards 
understanding the mechanisms involved, it is still not known exactly how 
heparin potentiates the mitotic (Thornton et al., 1983), chemotactic (Terranova 
et al 1985), neurotrophic (Unsicker et al., 1987) and angiogenic (Lobb et 
al., 1985) activities of aFGF. 
A major aim of my Ph.D. project was to gain a better understanding of how 
heparin potentiates aFGF-induced mitogenesis of BALB/c 3T3 cells. Of 
particular interest in this regard was the demonstration by Belford et al.,(1992) 
that a chemically modified form of native heparin which has had the majority of 
its carboxyl groups reduced, is able to bind aFGF as effectively as does the 
native heparin molecule but is less potent in augmenting aFGF-induced 
mitogenesis of 3T3 and HUVE cells. The ability of the carboxyl-reduced 
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heparin (CR-heparin) to bind aFGF but not to potentiate aFGF activity as well 
as native heparin, suggests that potentiation is not simply due to the ability of 
heparin to bind with high affinity to the growth factor. Based on these 
observations, experiments presented in this chapter are directed towards 
testing the hypothesis that potentiation of aFGF activity by heparin is due to 
the crosslinking of the FGFR and a cell surface heparin-specific receptor with 
an aFGF/heparin complex. Models proposed to explain the mechanism of 
potentiation to date, have not considered the possible involvement of cell 
surface heparin receptors in stabilizing the aFGF/heparin complex on the 
FGFR. However, saturable binding sites for heparin and HS have been shown 
to exist on various cell types (Castellot 1985; Vannuchi et al., 1986, 1988; Barzu 
et al., 1986a,b; Redini et al., 1989). Instead, the models have proposed that 
potentiation by heparin is due to heparin's ability to protect aFGF from 
proteolysis by degradative enzymes, thereby extending its half-life (Damon et 
al., 1989) and/or its ability upon binding to aFGF to produce a conformational 
change in the growth factor, resulting in its increased affinity for the FGFR 
(Schreiber et al., 1985; Kaplow et al., 1990; Vayon et al., 1991 ). A detailed 
discussion of these models is presented in section 1.8 of this thesis. This 
chapter describes a detailed comparison of the effects of native and CR-
heparin on aFGF action and provides evidence that the failure of CR-heparin 
to potentiate aFGF activity is probably due to its reduced ability to bind to 
heparin binding sites either on the FGFR or on adjacent heparin binding 
molecules on the cell surface. 
4.2. Results 
4.2.1. General Properties of Carboxyl-Reduced Heparin 
The procedure used routinely to prepare carboxyl-reduced preparations of 
heparin (Taylor et al., 1976) only reduces a proportion of the carboxyl groups of 
the molecule. In our hands, a single reductive treatment resulted in 35-40°/o of 
I 
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the heparin carboxyl groups remaining in the non-reduced form whereas two 
and three rounds of reduction resulted in 25°/o and 17°/o, respectively, of the 
carboxyl groups being non-reduced (Table 4.1 ). However, when these three 
CR-heparin preparations were compared for their ability to compete for the 
binding of aFGF to heparin coupled agarose beads, the CR-heparin with 35-
400/o carboxyl groups remaining, competed almost as effectively as native 
heparin whereas the more highly reduced preparations were much less 
effective competitors (Table 4.1 ). These differences in competitve activity were 
not due to differences in sulfate content as the CR-heparin preparations were 
indistinguishable from native heparin in their content of sulfate (data not 
shown). 
When tested for their ability to enhance aFGF-induced mitogenesis, the two 
most highly reduced heparin preparations exhibited negligible potentiating 
activity, ie., maximum of 2-3 fold increase in proliferation above aFGF alone 
(Table 4.1 ). Similarly, the CR-heparin with 35-40°/o carboxyl groups remaining 
was a relatively poor potentiator of aFGF mitogenesis compared with native 
heparin (Table 4.1 ), despite apparently binding to aFGF with high affinity. 
These results confirm the earlier findings of Belford et al.,(1992) and also 
demonstrate that the carboxyl group content of heparin plays a critical role in its 
interaction with aFGF. The preparation of CR-heparin with 35-40°/o of carboxyl 
groups remaining was selected for the subsequent studies. 
4.2.2. Potentiation of aFGF Activity by Heparin and CR-Heparin 
Initial studies compared the ability of heparin and CR-heparin to potentiate 
aFGF mitogenic activity in more detail. The ability of heparin and CR-heparin 
to potentiate aFGF-induced mitogenesis of BALB/c 3T3 fibroblasts over a 
period of four days is shown in Figure 4.1. Potentiation of aFGF activity by 
heparin did not take effect until after the first 24 hours of incubation and peaked 
at the end of the second day, decreasing steadily thereafter, as did aFGF 
Table 4.1: Ability of Different CR-Heparin Preparations to Bind to aFGF and Potentiate aFGF Mitogenic Activity 
Rounds of Carboxyl 
Carboxyl Group 
Group Content 
Reduction ( 0/o untreated) 
Nil 100 
x1 35-40 
x2 25 
x3 17 
Percent 
Inhibition of 
aFGF Binding 
to Heparina 
90 
76 
0 
15 
Potentiation of aFGF Mitogenic Activity 
Concentration 3H-Thym idine Potentiation 
(ug/ml) 
10 
50 
10 
50 
10 
50 
10 
50 
Incorporation 
cpmb 
13,882+562 
44,348+4212 
2,455+270 
9, 144+1293 
4,068+302 
3,473+283 
3,204+813 
1,389+232 
Factorc 
9.9 
31.7 
1.8 
6.5 
2.9 
2.5 
2.3 
1.0 
aPercent inhibition of binding of 1 Oug/ml of aFGF to heparin-agarose beads in the presence of SOOug/ml of each heparin preparation. 
b The data are mean ± SEM of triplicate treatments, [3H]thymidine incorporation being measured 24-48 hours following culture initiation. Acidic FGF was used at a concentration of 
1 Ong/ml and in the absence of heparin gave 1,400 ± 579 cpm. Background mitogenesis occurring in the absence of aFGF and heparin has been subtracted from all values. 
clncrease in [3H]thymidine incorporation over cultures containing 1 Ong/ml of aFGF in the absence of heparin. 
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FIGURE 4.1: Time course showing the proliferative response of BALBI c 
3T3 cells to aFGF (1 Ong/ml) in the presence of heparin (•), CR-heparin 
(.._) or in the absence (e) of heparin. Both forms of heparin were used 
at 50ug/ml and alone gave no background proliferation. [3H]TdR was 
added for the final 24 hours of each time point and its incorporation is 
expressed as cpm. Values represent means + SEM (n=4) of one 
representative experiment. Background cpm, subtracted from each 
time point, were <2700 cpm. 
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activity in the absence of heparin. CR-heparin was virtually inactive at the 
concentration used, showing negligible potentiation of aFGF activity for the 
duration of the time course. Thus this experiment confirms the results of 
Belford et al., ( 1992) who showed that CR-heparin was consistently less potent 
than heparin at augmenting aFGF-induced mitogenesis. 
The effect of a constant concentration of heparin and CR-heparin on the dose 
response curve of aFGF is shown in Figure 4.2. In the absence of heparin, the 
dose response for aFGF resulted in a bell shaped curve, indicating that aFGF 
is unable to induce proliferation at high concentrations (>1 ug/ml). Similarly, in 
the presence of heparin, the dose response to aFGF also resulted in a bell-
shaped curve. However, heparin caused a 2-3 fold shift of the dose response 
curve to the left. Thus in the presence of heparin, aFGF mitogenic activity 
peaked at 20-40ng/ml whereas mitogenic activity resulting from aFGF alone, 
peaked at 40-160ng/ml. CR-heparin was less effective at potentiating aFGF 
activity., only inducing a marginal shift in the dose response curve to the left. 
The maximal response induced by aFGF in the presence of CR-heparin was 
slightly higher than that seen with heparin but this was not a consistent 
observation in other experiments. In agreement with the results of the time 
course experiment (Fig. 4.1.), the activity of aFGF when used at a 
concentration of 0.01 ug/ml was not potentiated by CR-heparin but was 
potentiated by heparin. Although in this experiment both heparins were used at 
Sug/ml, similar dose response curves were obtained when heparin and CR-
heparin were used at concentrations as high as 50ug/ml. This data is also 
consistent with earlier studies by Belford et al.,(1992) using CR-heparin. 
4.2.3. Binding Affinities of Heparin and CR-Heparin for Acidic and Basic 
FGF 
Figure 4.3 shows the relative abilities of heparin and CR-heparin to bind to 
bFGF (A) and aFGF (8). Scatchard analysis of the binding data found heparin 
and CR-heparin to have similar binding affinities for bFGF although CR-
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FIGURE 4.2: Proliferative response of BALB/c 3T3 cells to varying 
concentrations of aFGF in the presence of a constant concentration 
(5ug/ml) of heparin (•), CR-heparin (•) or in the absence (e) of 
heparin. Incubation was for 48 hours and [3H]TdR was added for the 
second 24 hours of the incubation. Heparin and CR-heparin alone 
gave no proliferation above the background of 1700cpm. Values 
represent means + SEM (n=4) of one representative experiment. 
FIGURE 4.3: Comparison of the ability of 1251-heparin (•) and 
12s1-CR-heparin (.A.) to bind to immobilized A) bFGF and 8) 
aFGF. Data points represent specific binding and are the means 
of quadruplicate treatments. Non-specific binding in the 
presence of a 100 fold excess of unlabeled heparin was <10°/o. 
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heparin's affinity may be marginally lower than that of heparin. Two sites on 
heparin exhibiting differing affinities for bFGF were detected, a high affinity site 
with Kd 9±2nM and a site of lower affinity with Kd 90+9nM. Similarly, on CR-
heparin binding sites of high and low affinity were detected and their Kds 
calculated as 19+4 and 119+11, respectively. 
Mach et al.,(1993) also proposed the existence of sites with high and low 
affinity for aFGF on heparin, with the number of low affinity sites being even 
more frequent on HS. In my system, only one binding site for aFGF was 
detected on heparin and CR-heparin. Heparin and CR-heparin also exhibited 
identical binding affinity for aFGF, their Kds both being determined as 35+5nM. 
These dissociation constants are in good agreement with those determined by 
Moscatelli (1987), Walicke et al.,(1989) and Lee & Lander (1991) who 
determined the Kds for aFGF and bFGF binding to heparin to be in the range of 
60-90nM and 2-3nM, respectively. My results also confirm their finding that 
aFGF binds to heparin with a lower affinity than does bFGF. 
4.2.4. Protection of aFGF from Trypsin Digestion by Heparin 
One of the mechanisms by which heparin has been proposed to potentiate the 
activity of aFGF involves its ability to bind to and induce a conformational 
change in aFGF which stabilizes it against degradation by proteases (Damon et 
al., 1989). Thus in order to determine whether CR-heparin's lack of potentiating 
ability is due to an inability to provide aFGF with protection against proteases, 
its ability to protect aFGF from degradation by trypsin was tested. Figure 4.4. 
shows the ability of heparin and several modified heparins including CR-
heparin, to protect aFGF against digestion by trypsin. In agreement with CR-
heparin and native heparin interacting with aFGF with comparable high affinity, 
both of these heparins completely protected aFGF from digestion by trypsin. In 
contrast, N-desu lfated/ acetylated heparin, N-desu lfated/acetoacetylated 
heparin and N-desulfated heparin offered only a small degree of protection 
FIGURE 4.4: Ability of native heparin and several chemically 
modified heparins (1 mg/ml) to protect 1251-aFGF (1.Bng) from 
digestion by trypsin (96ug/ml). Mixtures were incubated overnight 
at 370c and then run on a 11 °/o SOS-PAGE gel and radiolabeled 
aFG F detected by autoradiography. 
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while N- & 0-desulfated/N-resulfated heparin and N-& 0-desulfated heparin 
gave no protection. This is largely in agreement with the ability of these 
heparins to bind aFGF as it has been shown previously (Belford et al., 1992) 
that N-desulfated, N- & 0-desulfated/N-resulfated, and N-& 0-desulfated 
heparins do not bind aFGF while N-desulfated/acetylated heparin and N-
desulfated/acetoacetylated heparin exhibit some affinity for aFGF. These 
results suggest that the ability of heparin to potentiate aFGF activity cannot be 
fully explained by its ability to protect aFGF from proteolysis. 
4.2.5. Binding of Radiolabeled aFGF to Heparinase Treated Cells 
It has also been suggested that heparin potentiates aFGF-induced activity by 
inducing aFGF to assume a conformation with increased affinity for its receptor 
(Schreiber et al., 1985; Kaplow et al., 1990). Thus, in the next series of 
experiments, the ability of either heparin or CR-heparin to enhance the binding 
of aFGF to its receptor was tested. In order to examine FGFR binding of aFGF 
without the participation of cell surface HSPGs, BALB/c 3T3 cells were 
pretreated with heparinase to remove surface HSPGs. Figure 4.5 shows the 
effect of different concentrations of heparin and CR-heparin on the binding of 
1251-aFGF to heparinase treated cells. Heparin at concentrations ranging 
between 1 ng/ml and 1 OOug/ml significantly enhanced the binding of 1251-aFGF 
to the FGFR. However, at high concentrations (1 mg/ml), heparin inhibited the 
binding of aFGF to its receptor. CR-heparin also significantly enhanced aFGF 
binding to the FGFR but to a much lesser· extent than did heparin and over a 
narrower concentration range, namely, between 1 ng/ml and 1 ug/ml. 
Concentrations of CR-heparin greater than 1 Oug/ml inhibited aFGF binding. 
These data indicate that CR-heparin is a poor potentiator of aFGF binding to 
FGFR compared with heparin. 
4.2.6. Binding of Heparin and CR-Heparin to Cell Surface Receptors 
If heparin enhances the binding of aFGF to its receptor by forming a complex 
with aFGF and crosslinking both an FGFR and a heparin receptor then it is 
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FIGURE 4.5: Effect of different concentrations of heparin (•) and CR-
heparin (.A.) on the binding of 12s1-aFGF (20ng/ml) to heparinase treated 
BALB/c 3T3 cells. Values represent means + SEM (n=4) of one 
representative experiment. Similar results were obtained on 3 separate 
occasions. Values represent specific binding. Non-specific binding in 
the presence of an excess of unlabeled aFGF (50ug/ml) was routinely 
between 5 and 10°/o of cpm bound. 
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conceivable that the poor potentiating activity of CR-heparin may be the result 
of an inability to interact with heparin receptors on the cell surface. Figure 4.6 
demonstrates that both heparin and CR-heparin bind to the surface of BALB/c 
3T3 cells in a specific and saturable manner. Scatchard analysis of the 
experimental data indicates that heparin and CR-heparin bind to a single class 
of receptors with the same affinity, both having a Kd of 1.8+0.2nM. However, 
heparin binds to three-fold more receptors on the cell surface than does CR-
heparin, namely, 25x106 compared with 8x106. Cross-blocking experiments 
were then performed to determine whether there was a subset of heparin 
receptors on 3T3 cells which failed to interact with CR-heparin. Figure 4.7A 
compares the ability of unlabeled heparin and CR-heparin to inhibit the binding 
of 1251-heparin to the cell surface. It was found that CR-heparin could only 
partially (30-40°/o) inhibit 1251-heparin binding even when added at a 50 fold 
excess. On the other hand, CR-heparin was a more effective inhibitor of the 
binding of 1251-CR-heparin to 3T3 cells (Fig. 4. 78), producing 80°/o inhibition at 
the highest concentration tested. However, heparin was a more potent inhibitor 
of 1251-CR-heparin binding than CR-heparin, the 50°/o inhibition values for 
heparin and CR-heparin being 0.1 mg/ml and 1.2mg/ml, respectively. These 
results demonstrate that CR-heparin only binds to a subset of cell surface 
receptors specific for native heparin and is not recognized by a specific subset 
of cell surface receptors which do not interact with heparin. Thus, the poor 
ability of CR-heparin to potentiate aFGF-induced activity may be related to its 
inability to bind to certain heparin receptors on the cell surface. 
4.2.7. Effect of Heparin and CR-Heparin on the Binding of aFGF and bFGF 
to Soluble FGFR 
To further clarify the effect of heparin and CR-heparin on the binding of aFGF 
to the FGFR, some experiments were performed in collaboration with Dr David 
Ornitz, St Louis, MO, using a soluble recombinant form of murine FGF receptor 
(FR1 AP). Figure 4.8 compares the ability of heparin and CR-heparin to 
enhance the binding of aFGF to this receptor in the absence of other cell-
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FIGURE 4.6: (A) Specific binding of 1251-heparin ( • ) and 1251-CR-
heparin ( • ) to BALB/c 3T3 cells. Nonspecific binding (20°/o) was 
determined in the presence of a 50-fold excess of unlabeled heparin and 
subtracted from the total binding. Values represent means + SEM (n=4) 
of one representative experiment. (B) Scatchard plot of experimental 
· data. 
FIGURE 4. 7: Comparison of the ability of unlabeled heparin (•) and 
CR-heparin (.._) to inhibit the binding of a constant concentration 
(1 OOug/ml) of either 1251-heparin (A) or 12s1-CR-heparin (8) to BALB/c 
3T3 cells. Values represent means + SEM (n=3) and are given as 
percent of labeled heparin/CR-heparin which was bound in the absence 
of cold competitor . 
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FIGURE 4.8: The effect of different concentrations of heparin and 
CR-heparin on the binding of 1251-aFGF to a soluble form of 
FGFR 1. Each bar represents the mean + SD of cpm bound. 
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associated molecules. In the absence of heparin or CR-heparin, very little 
specific binding of aFGF to FR1AP was observed. The binding of 1251-aFGF 
to FR1 AP was significantly enhanced by heparin at concentrations of 0.2ug/ml, 
2.0ug/ml and 20ug/ml with maximal binding occurring at 2.0ug/ml and 
remaining unchanged when the heparin concentration was increased to 
20ug/ml. CR-heparin was dramatically less effective at enhancing the binding 
of 1251-aFGF to soluble FR1 AP. The highest binding of aFGF to FR1 AP 
achieved in the presence of 20ug/ml of CR-heparin was only one-third of that 
observed with heparin. To determine whether CR-heparin could compete with 
heparin for the binding of aFGF, a competition assay was performed where 
CR-heparin was added in excess of heparin. CR-heparin at concentrations in 
excess of heparin by 10- and 100-fold, was a poor competitor, binding not 
being significantly effected. 
In a similar experiment, Figure 4.9A compares the ability of heparin and CR-
heparin to enhance the binding of bFGF to soluble FR1 AP. As has previously 
been reported (Ornitz & Leder 1992), like aFGF, bFGF binding to FR1 AP is 
heparin-dependent. However, the binding of bFGF to FR 1 AP was enhanced 
by heparin concentrations significantly lower than those required to enhance 
aFGF binding to the same receptor. Basic FGF binding was increased 4-fold in 
the presence of only 1 ng/ml of heparin, 5-fold in the presence of 18ng/ml and 
the maximal increase observed, almost ?-fold, occurred in the presence of 
164ng/ml heparin. In contrast, CR-heparin was unable to enhance the binding 
of bFGF to FR1 AP at concentrations up to 164ng/ml. Figure 4.9.B shows the 
effect of a 10-fold and 100-fold excess of CR-heparin over heparin on the 
binding of bFG F to FR 1 AP. A 10-fold excess of CR-heparin resulted in 
approximately 18°/o inhibition of bFGF binding whereas a 100-fold excess 
resulted in approximately 7 4°/o inhibition of heparin-induced binding. 
Interestingly, CR-heparin is much less effective at enhancing the binding of 
bFGF to FR1 AP than it is at enhancing aFGF binding, but it inhibits bFGF 
FIGURE 4.9: The effect of different concentrations of heparin and 
CR-heparin on the binding of bFGF to a soluble form of FGFR 1. 
Figure 4.9.(A) shows the effect of different concentrations of either 
heparin or CR-heparin on the binding of 1251-bFGF to FGFR 1 
while, B) shows the combined effects of heparin and CR-heparin on 
1251-bFGF binding when CR-heparin is at a 10- and 100-fold higher 
concentration than heparin. Each bar represents the mean + SD of 
cpm bound. 
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binding in a mixed competition assay more effectively than it does aFGF 
binding. 
4.3. Discussion 
In this chapter, I have attempted to explain why CR-heparin fails to potentiate 
the mitogenic activity of aFGF despite binding to aFGF as effectively as native 
heparin. An explanation of this intriguing observation promised to shed light on 
the mechanism by which heparin potentiates aFGF activity. 
Initially I confirmed (Belford et al 1992) that heparin which has had 
approximately 60°/o of its carboxyl groups reduced, is able to bind aFGF with 
the same affinity as does native heparin (Kd 35+5nM, Fig. 4.3) but is much less 
effective at potentiating aFGF-induced BALB/c 3T3 cell mitogenesis than is 
native heparin (Table 4.1, Figs 4.1 & 4.2). Furthermore, CR-heparin was 
shown to protect 1251-aFGF from digestion by trypsin equally as effectively as 
does heparin while other chemically modified heparins with little or no binding 
affinity for aFGF were unable to do so (Fig. 4.4). Therefore, CR-heparin 1s 
reduced ability to potentiate aFGF activity is not due to an inability to protect 
aFGF from proteolysis. It has been proposed that potentiation of aFGF activity 
by heparin is due to heparin 1s ability to induce a conformational change in the 
growth factor (Schreiber et al., 1985) thereby making it resistant to proteolysis 
and increasing its biological half-life (Damon et al., 1989). However, bFGF 
activity is also protected from proteolysis in the presence of heparin 
(Gospodarowicz & Cheng 1986) and yet when given to cells expressing normal 
levels of endogenous HSPGs, bFGF activity is not potentiated to anywhere 
near the same extent as is aFGF activity. This, taken together with the 
observation that CR-heparin also protects aFGF from proteolysis, strongly 
suggests that potentiation of aFGF activity by heparin is not due to heparin 1s 
ability to protect aFGF from proteolytic degradation. 
q 
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On the other hand, heparin and CR-heparin differed in their ability to enhance 
the binding of aFGF to the FGFR on cells lacking cell surface HSPGs (Fig. 4.5). 
At low concentrations, heparin significantly enhanced the binding of aFGF to 
the FGFR on heparinase-treated cells while CR-heparin induced only a small 
enhancement. Similarly, the soluble FGFR assay demonstrated that CR-
heparin is substantially less effective than heparin at enhancing the binding of 
aFGF to mFR1 (Fig. 4.8). Thus, the data suggest that CR-heparin's poor ability 
to potentiate aFGF-induced mitogenic activity is due to its failure to effectively 
enhance the binding of aFGF to its cell surface receptor. I will now discuss 
possible reasons why this is so. 
There appear to be two ways by which CR-heparin may prevent aFGF from 
forming a stable interaction with its receptor. First, CR-heparin may fail to 
produce the correct conformational change in the growth factor which is 
thought to be necessary for FGF binding to its receptor, or second, it may not 
allow the formation of a stable ternary complex between aFGF and its receptor. 
The ability of CR-heparin to bind aFGF equally as well as does heparin and to 
protect aFGF from digestion by trypsin, makes it unlikely that CR-heparin is 
unable to induce a conformational change in the molecule, although this cannot 
be totally ruled out (Fig. 1.8) It seems more plausible that CR-heparin fails to 
enable the formation of a stable ternary complex. A ternary complex could 
result from an aFGF/heparin complex either crosslinking a cell surface receptor 
specific for heparin with the FGFR or crosslinking heparin-binding and aFGF-
binding sites on the same FGFR (Fig. 1.9). This latter possibility has become 
an interesting alternative following the recent demonstration that human 
FGFR 1 possesses a heparin-binding site which is essential for FGF binding to 
FGFR1 (Kan et al., 1993). 
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The demonstration that CR-heparin is only able to bind to 1 /3 the number of 
heparin receptors on the cell surface to which heparin binds (Figs 4.6 & 4.7) 
suggests that CR-heparin may be less able to form ternary complexes with 
aFGF, FGFR and heparin receptors as can occur with heparin. It is possible 
that there are specific heparin receptors to which CR-heparin does not bind that 
may be critical for the formation of such ternary complexes with FGFR. 
Furthermore, the reduced ability of CR-heparin to enhance the binding of aFGF 
to FGFR, both on heparinase-treated cells and in the soluble receptor binding 
assay, suggests that CR-heparin may have a low binding affinity for the 
proposed heparin-binding domain on the FGFR. This would prevent the 
formation of stable ternary complexes between an aFGF-heparin complex and 
the FGF and heparin-binding sites on the FGFR. 
Preliminary results from Dr Ornitz's laboratory (personal communication) do 
indeed suggest that CR-heparin has a considerably lower affinity than heparin 
for the heparin binding site on FGFR. In the absence of FGF, CR-heparin was 
at least 10 fold less able to bind to the soluble form of murine FGFR 1 and 
approximately 25 fold less able to bind to FGFR3, compared with heparin. 
Interestingly, while CR-heparin is partially able to enhance the binding of aFGF 
to FGFR 1 in the soluble receptor binding assay, it is totally unable to enhance 
the binding of bFGF to the same receptor. Since CR-heparin was found to bind 
aFGF and bFGF equally as well as does native heparin, this inactivity is not 
due to an inability to bind the growth factors. Furthermore, CR-heparin when in 
excess of heparin by 100-fold was able to inhibit heparin-induced bFGF binding 
by approximately 80°/o whereas it was a much poorer competitor for aFGF 
binding. These results suggest that acidic and basic FGF have different 
requirements for binding to FGFR1. 
In order to explain the soluble FGFR data two assumptions must be made. 
First, in order for aFGF to bind to FGFR1 it must undergo a heparin-induced 
I 
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conformational change whereas with bFGF no such conformational change is 
required. The second assumption made is that CR-heparin does not bind to 
the heparin-binding site of the FGFR and this is supported by preliminary data 
outlined above. Thus, it can be proposed that for optimal binding of aFGF to 
the FGFR to occur, not only must aFGF bind to heparin and undergo a 
conformational change which allows it to bind to the receptor binding site on 
FGFR but the aFGF/heparin complex must also form a ternary complex with 
the heparin- and FGF-binding sites of FGFR to ensure that a stable receptor-
ligand interaction occurs. In contrast, in order for bFGF to bind to FGFR it must 
form a ternary complex with heparin, the heparin-binding site on FGFR and the 
growth factor-binding site on the FGFR. It does not, however, require a 
heparin-induced conformational change in order to bind to the FGFR. The low 
level of aFGF binding to the FGFR seen in the presence of CR-heparin may be 
due to the ability of CR-heparin to induce a partial conformational change in 
aFGF which enables some weak binding to the FGFR. In contrast, the 
absence of any binding of bFGF to the FGFR is due to CR-heparin's inability to 
bind to the heparin-binding site of the FGFR and form a ternary complex with it 
and the growth factor. The relative balance of conformational change versus 
ternary complex formation may vary with each FGFR and between FGFs with 
each FGFR. In summary, in order to explain my experimental results it is 
proposed that for optimal binding of aFGF to FGFR 1 to occur, a heparin 
induced conformational change in aFGF must be followed by the formation of a 
ternary complex, whereas for the binding of bFGF to FGFR 1, only the 
formation of a ternary complex is required. 
Preliminary results from David Ornitz's laboratory (personal communication) 
using BAF3 cells transfected with mFR1, show that CR-heparin does result in 
some enhancement of bFGF-induced mitogenesis but not as much as with 
native heparin which indicates that other cell surface molecules may be 
involved in the formation of ternary complexes. It is plausible that CR-heparin, 
r 
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although unable to bind to the heparin-binding site on FGFRs, may utilize cell-
surface heparin receptors in the formation of a ternary complex between FGF 
and FGFR. 
An interesting additional observation was that high concentrations of both 
heparin and CR-heparin inhibited the binding of aFGF to FGFR on heparinase-
treated cells. Similar observations have been reported by others (Barzu et 
al., 1989; Ornitz et al. , 1992; Nurcombe et al., 1993). There was however, 
generally no inhibition of aFGF-induced mitogenic activity by high 
concentrations of heparin even when cell surface HSPGs were removed by 
culturing the cells in chlorate (results not shown). This phenomenon remains 
largely unexplained. Ornitz et al.,(1992) have suggested that high 
concentrations of heparin may inhibit the dimerization of FGF which they 
suggest is necessary for receptor oligomerization and activation. Alternatively, 
it is possible that at high concentrations, heparin free of aFGF masks heparin 
binding sites on the cell surface or on FGFR and thereby inhibits ternary 
complex formation. 
A second interesting observation which deserves comment was that heparin-
mediated potentiation of aFGF-induced mitogenesis did not take effect until 
after the first 24 hours of culture, peaking at the end of the second day. This 
suggests that, initially, while there is sufficient aFGF to form productive 
complexes between FGFRs and endogenous HSPGs, heparin cannot enhance 
receptor activation. As the aFGF is internalized (or degraded), the proportion 
of unsuccessful complexes increases, due to aFGF's low affinity for cell surface 
HSPGs (see chapter 3). The presence of heparin enables lower 
concentrations of aFGF to be utilized more efficiently by increasing the number 
of productive ternary complexes formed and thereby enabling receptor 
activation to occur. 
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4.4 Summary 
Recently it was reported (Belford et al., 1992) that carboxyl-reduced heparin 
(CR-heparin), despite binding aFGF as effectively as native heparin, was much 
less potent at augmenting aFGF-induced mitogenesis. This chapter describes 
experiments which examined this phenomenon in more detail in the hope that it 
would shed light on the mechanism by which heparin potentiates aFGF activity. 
Initial studies confirmed that heparin with 60°/o of its carboxyl groups reduced, 
although binding aFGF with the same affinity as native heparin (Kd 35+5nM), 
was a poor potentiator of aFGF induced mitogenic activity. Proteolysis 
protection experiments also revealed that CR-heparin was as effective as 
native heparin at protecting aFGF from proteolytic degradation. In contrast, 
CR-heparin was considerably less effective than native heparin at enhancing 
the binding of aFGF to either the FGFR on 3T3 cells or to a soluble form of 
recomb.inant murine FGFR1. Furthermore, CR-heparin only bound to a subset 
(approx. 1 /3) of heparin receptors on 3T3 cells and bound weakly to a heparin 
binding site on FGFR 1. Since CR-heaprin protected aFGF from proteolysis 
and bound aFGF with high affinity it appeared unlikely that the inability of CR-
heparin to enhance aFGF binding to the FGFR was due to its failure to induce 
a conformational change in aFGF essential for FGFR binding. In contrast, the 
reduced ability of CR-heparin to interact with heparin binding sites suggests 
that it is much less efficient than heparin at facilitating the formation of a ternary 
complex between aFGF and the FGFR. Such a ternary complex would require 
a heparin-FGF complex to crosslink the FGFR with a heparin binding site either 
on the FGFR itself or on adjacent molecules on the cell surface. 
Additional studies demonstrated that CR-heparin interacted with bFGF with a 
binding affinity comparable to native heparin. Nevertheless, unlike native 
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heparin, CR-heparin was completely unable to restore binding of bFGF to 
soluble recombinant FGFR 1. However, CR-heparin was quite an effective 
inhibitor of native heparin-induced binding of bFGF to FGFR 1. Such results 
were not obtained with aFGF. These observations suggest that acidic and 
basic FGF have different requirements for binding to FGFR 1 and a model has 
been proposed to explain these differences. 
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Chapter 5 
Histidine-Rich Glycoprotein and Platelet Factor 4 Mask Heparan 
Sulfate Proteoglycans Recognized by Acidic and Basic 
Fibroblast Growth Factor 
5.1. Introduction 
In addition to the heparin-binding growth factors, there are three other well 
characterized heparin-binding proteins present in plasma. These are histidine-
rich glycoprotein (HRG), platelet factor 4 (PF4) and antithrombin Ill (ATIII). 
Since recent studies have shown that FGFs need to interact with cell surface 
HSPGs in order to bind to and activate the FGFR (Vayon et al., 1991 ), I have 
attempted in this chapter to investigate whether HRG, PF4 or ATIII are able to 
act as modulators of FGF activity in vivo. If able to compete with FGFs for 
binding to cell-surface HSPGs, it is proposed that these molecules may be able 
to maintain an equilibrium in which FGFs are only able to access their 
receptors when their activity is specifically required. 
Histidine-rich glycoprotein, with a molecular weight of 75kDa, is a maJor 
heparin-binding protein present in plasma (Haupt & Heimburger 1972; Lijnen et 
al., 1983b), being present in mammalian plasma at concentrations as high as 
1 OOug/ml (Lijnen et al., 1983a). As is suggested by its name, HRG contains a 
remarkably high content of histidine and praline residues, these residues 
comprising approximately 20°/o of its amino acids (Heimburger et al 1972; 
Lijnen et al., 1980; Koide et al., 1985). Although little is known about HRG, data 
suggests that it binds to unique HS sequences and that its heparin/HS binding 
domain probably lies within the histidine-rich region (Burch et al., 1987). It also 
binds to plasminogen (Lijnen et al., 1980; Ichinose et al., 1984), fibrinogen 
(Ichinose et al., 1984) and thrombospondin (Leung., 1986). Some of the 
functions that have been assigned to HRG to date are the neutralization of 
heparin's anticoagulant activity in plasma (Lijnen et al., 1983b), the 
,· 
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neutralization of heparin's ability to inhibit smooth muscle cell proliferation 
(Hajjar et al.,1987), inhibition of cell adhesion (Rylatt et al.,1981; Silverstein et 
al., 1985), immunosuppression (Shatsky et al., 1989), retardation of fibrinolysis 
by plasmin, and by binding to fibrinogen, retardation of the conversion of 
fibrinogen to fibrin by thrombin (Leung 1986). 
Platelet factor 4 exists as a high molecular weight complex of a tetramer of PF4 
polypeptide and chondroitin sulfate (Barber et al., 1972; Moore et al., 1975) in 
the a granules of platelets. It also has a high affinity for heparin (Maione et 
al., 1990), eluting from heparin-Sepharose with 1.5M NaCl (Niewiarowsky et 
al., 1976). Although normally found in human plasma at concentrations as low 
as 1 Ong/ml, concentrations as high as 25ug/ml are thought to be obtained at 
sites of vascular injury where platelets aggregate and the a-granules are 
released (Files et al., 1981 ). The physiological significance of PF4 is uncertain 
although it does reverse immunosuppression (Katz et al., 1986), has 
chemotactic activity for neutrophils, monocytes, and fibroblasts (Deuel et 
al., 1981; Senior et al 1983) inhibits bone resorption (Horton .et al., 1980) and 
inhibits angiogenesis (Taylor & Folkman 1982). In addition to its anti-
angiogenic activity, Sharpe et al.,(1990) have shown that PF4 specifically 
inhibits endothelial cell proliferation and migration in vitro and the active part of 
the molecule has been identified as the heparin-binding region. However, the 
systemic administration of hrPF4 has not been shown to inhibit tumour growth 
possibly due to its rapid inactivation or clearance (Folkman & Brem 1992). The 
demonstration by Maione et al.,(1990) that inhibition of HUVE cell proliferation 
in vitro by rhPF4 could be reversed by addition of fresh medium containing 
growth factor and heparin, suggested that PF4-induced inhibition was due to 
suppression of growth factor activity. However, the observation that PF4 did 
not inhibit bFGF-induced proliferation of human dermal fibroblasts or 
keratinocytes led them to conclude that rhPF4 inhibition of HUVE cell 
proliferation was not due to binding and sequestering of soluble bFGF. 
/1 
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Antithrombin Ill, present in human plasma at concentrations of 150ug/ml 
(Murano et al., 1980), is the major inhibitor of the activated serine proteases of 
the blood coagulation cascade. ATIII binds to the serine proteases and forms a 
stable and inactive complex with them (Rosenberg & Damus 1973; Owen 
1975). The binding of heparin to ATIII greatly facilitates the inactivation of the 
enzymes involved in the coagulation process (Bjork & Nordenman 1976; 
Kowalski & Finlay 1979; Holmer et al., 1979). Heparin is thought to induce a 
conformational change in either ATI 11 or the serine protease facilitating the 
formation of the inhibitor-protease complex (Rosenberg & Damus 1973; Li et 
al., 1976). While it is not known to which heparin/HS sequences HAG and PF4 
bind, ATIII is known to bind specifically to a particular pentasaccharide in 
heparin and HS of which the 3-0-sulfate group of the internal glucosamine 
residue is essential for high affinity binding (Petitou et al., 1988). 
In the following section, I have outlined studies conducted to determine whether 
chicken and human HAG, human ATIII and human PF4 interact with the same 
HSPGs on the 3T3 cell surface and in the ECM as do acidic and basic FGF. 
The study also compares the relative binding affinities of these heparin-binding 
molecules for HSPGs and compares their abilities to inhibit the binding of 1251-
aFGF and 1251-bFGF to the 3T3 cell surface and to the ECM. 
5.2. Results 
5.2.1. Binding of HRGs to Cell Surface HSPGs 
In chapter 3 an assay was developed for detecting the binding of acidic and 
basic FGF to cell surface HSPGs on BALB/c 3T3 cells. The assay entailed 
immobilizing the growth factors in PVC plastic wells and quantifying cell 
adhesion to the growth factors using the vital stain Rose Bengal. In the case of 
HAG, preparations from human (hHRG) and chicken (cHRG) plasma were 
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prepared by phosphocellulose ion exchange chromatography (Aylatt et 
al., 1981) and used in subsequent experiments. The purity of the two HAG 
preparations was demonstrated by SOS-PAGE, in each case a single 
Coomassie Blue stained band being detected (Fig. 5.1 ). Human HAG has a 
molecular weight of approximately 75kDa whereas chicken HAG is a somewhat 
larger molecule with a molecular weight of approximately 135kDa. 
In initial experiments the optimum concentration of chicken and human HAG for 
coating PVC plates for use in the adhesion assay was determined (Fig. 5.2). It 
was found that both HAGs could mediate BALB/c 3T3 cell adhesion when 
immobilized to plastic, although lower coating concentrations of cHAG than 
hHAG were required for maximum binding. In subsequent assays, cHAG was 
used at 1 Oug/ml and hHAG at 5ug/ml to coat the plates. 
An interesting feature of this adhesion assay was that plastic immobilized HAG 
is able to act as a spreading factor for BALB/c 3T3 cells in the absence of fetal 
calf serum. Figure 5.3 shows that after two hours incubation at 370c, cells 
added to an HAG-coated dish had attached quite firmly to the HAG substrate 
and had changed from a rounded to a more spread out morphology. In 
contrast, cells seeded on an uncoated dish remained rounded and showed no 
inclination to attach to the plastic surface. 
The next series of experiments examined whether binding of BALB/c 3T3 cells 
to immobilized HAG was heparin inhibitable as was shown to be the case for 
immobilized acidic and basic FGF (chapter 3). Eleven GAGs were tested at a 
single concentration (1 OOug/ml) for their ability to inhibit the binding of BALB/c 
3T3 cells to either chicken or human HAG-coated wells. As was found for the 
FGFs, only heparin, fast moving HS and bovine intestinal HS were able to 
inhibit HAG binding. Figure 5.4 depicts the complete inhibition curves for 
heparin, fast moving HS and bovine intestinal HS. Heparin was the most 
FIGURE 5.1: SOS-PAGE analysis of preparations of chicken and 
human HAG. Samples (1 Oug) were run on a 10°/o gel and stained 
with Coomassie Blue. Molecular weight standards are marked in 
kDa. 
200-
116 
-
66-
FIGURE 5.3: Ability of cHRG to promote the attachment and 
spreading of BALB/c 3T3 cells. Bacteriological petri dishes were 
coated with PBS (A) or with cHRG (1 Oug/ml) in PBS (B) and non 
specific binding sites blocked with Hanks BSS/0.1 °/o BSA pH 7.0 
before the addition of 10ml of a BALB/c 3T3 cell suspension 
(0.6x1 o5 cells/ml) to each dish. The cells were left to adhere to the 
dishes for 2 hours at 370c before being examined under a light 
m 1croscope. 

FIGURE 5.4: Comparison of the ability of heparin (•), fast moving 
heparan sulfate (e) and bovine intestinal heparan sulfate (A) to 
inhibit the binding of BALB/c 3T3 cells to immobilized (A) cHRG 
(1 Oug/ml) and to (8) hHRG (5ug/ml) . Heparin and heparan sulfates 
were incubated with immobilized HRG for 1 hour on ice before 
adding cells (2.5x1 oscells/well) for 1 hour at 37°C, 100°/o binding 
representing that occurring in the absence of inhibitor. Values 
represent the means of triplicate treatments. Standard errors of the 
mean were < 10°/o. 
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potent competitor for both cHRG and hHRG binding, with virtually complete 
inhibition of binding occurring at concentrations > 0.8ug/ml. Fast moving HS 
and bovine intestinal HS were much less effective, requiring concentrations as 
high as 100-300ug/ml to completely inhibit cells from binding to the immobilized 
HRGs. These data indicate that binding of BALB/c 3T3 cells to both 
immobilized HRGs is dependent upon heparin/HS recognition. The lower 
inhibitory activity of the two HSs for human and chicken HRG may be because 
the particular HS motifs on the HS chain with which the HRGs interact, occur 
p less frequently in these heparan sulfates than they do in heparin. 
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5.2.2. Inhibition of Binding of Heparin Binding Proteins to Cell Surface 
HSPGs 
A series of cross blocking studies were carried out using the plate binding 
assay to determine whether the FGFs and the heparin/HS binding proteins, 
HRG, ATIII and PF4 bind to similar or different HS structures on the surface of 
BALB/c 3T3 cells. Chicken and human HRG, acidic and basic FGF, and PF4 
were found to totally block 3T3 cell binding to each of the HRGs and FGFs 
immobilized on the plate (Figs 5.5 & 5.6). These data suggest that the HRGs, 
FGFs and PF4 interact with either the same HS sequence or with closely 
associated HS sequences on the 3T3 cell surface, although based on the 
inhibition curves, each factor exhibits a different affinity for 3T3 HSPGs. 
Table 5.1 compares the concentration of each heparin binding factor required 
to inhibit 3T3 cell binding by 50°/o and may only be compared within each data 
column due to different concentrations of factor used to coat the plates. ATIII 
was completely unable to inhibit 3T3 cells from binding to immobilized FGFs, or 
HRGs. This result indicates that the FGFs and HRGs interact with HS 
structures on 3T3 cells which differ from the particular pentasaccharide 
sequence in heparin and HS with which ATIII is known to bind. Based on the 
inhibition data presented in Table 5.1 the overall hierarchy of inhibition for the 
five inhibitory factors was PF4 > bFGF > aFGF = cHRG > hHRG. This 
Table 5.1 
Ability Of Different Heparin Binding Molecules To Inhibit Binding of FGFs and HRGs to 3T3 Cells 
Inhibitor 
PF4 
bFGF 
aFGF 
cHRG 
hHRG 
ATIII 
bFGF 
54a 
34 
125 
148 
2667 
>16000 
Molecule Bound to Plate 
aFGF 
42 
200 
1875 
815 
5333 
>16000 
cHRG 
33 
114 
500 
940 
2400 
>16000 
hHRG 
21 
200 
625 
407 
2000 
>16000 
a Values represent the concentration (nM) required to inhibit BALB/c 3T3 cell binding by 50°/o, based on 
molecular weights of inhibitors being 31.2kDa for PF4, 17.SkDa for bFGF, 16kDa for aFGF, 135kDa for cHRG, 
75kDa for hHRG and 62.3 kDa for ATIII. 
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FIGURE 5.5: Comparison of the ability of soluble PF4 (•), bFGF 
(0), aFGF (e), cHRG (•) and hHRG (D) to inhibit the binding of 
BALB/c 3T3 cells to immobilized (A) cHRG (1 Oug/ml) and to (B) 
hHRG (5ug/ml). Cells and inhibitors were incubated together for 2 
hours on ice before being added to HAG-coated wells for a further 
1 hour incubation at 37°C, 100°/o binding representing that 
occurring in the absence of inhibitor. Values represent the mean 
of triplicate treatments. Standard errors of means were < 20°/o. 
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FIGURE 5.6: Comparison of the ability of soluble bFGF ( o ), PF4 
(I), aFGF ( e ), cHRG ( A) and hHRG ( D) to inhibit the binding of 
BALB/c 3T3 cells to immobilized (A) bFGF (0.313ug/ml) and to (B) 
aFGF (2.5ug/ml). Assay conditions and datapresentation as 
described in legend for Figure 5.5. 
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hierarchy was generally maintained irrespective of the heparin binding protein 
immobilized on the plate. Thus, the general trend suggests that PF4 and bFGF 
bind cell surface HSPGs with the highest affinity while cHRG generally exhibits 
a lower affinity but always an affinity greater than that exhibited by hHRG. 
Direct comparisons of aFGF and cHRG showed some variation as to which 
was the more potent inhibitor, but aFGF always bound HSPGs with lower 
affinity than did bFGF and PF4. 
Since all of the inhibition assays described above were performed at 370c with 
plastic immobilized heparin binding molecules, it was important to determine 
whether similar results could be obtained at 40c with heparin binding 
molecules in solution. Such studies were performed with soluble FITC 
conjugated cHRG and cell binding detected by fluorescence cytometry. Figure 
5.7 shows that the binding of soluble FITC-cHRG to 3T3 cells at 40c is both 
saturable and heparin inhibitable. This confirms the result seen in the plate 
assay where heparin was a potent inhibitor of 3T3 cell binding to immobilized 
cHRG at 370c (Fig. 5.4). Binding-inhibition experiments with soluble FITC-
cHRG (Fig. 5.8) showed that FGFs and HRGs totally block FITC-cHRG binding 
to 3T3 cells with a hierarchy of inhibition, (ie., bFGF > aFGF = cHRG > hHRG), 
similar to that observed with the plate binding assay. An additional experiment 
also demonstrated that PF4 totally inhibited FITC-cHRG binding (data not 
shown). 
The inhibition of binding of soluble radiolabeled acidic and basic FGF to 3T3 
cell surface HSPGs was also examined. This assay had the advantage that 
physiologically relevant concentrations (1 Ong/ml) of the FGFs were used with 
physiologically relevant concentrations (ie.,uM) of the HRGs, ATIII and PF4 
which were added as inhibitors. Figure 5.9 compares the ability of bFGF, 
aFGF, cHRG, hHRG and ATIII to inhibit the binding of 10ng/ml of 1251-bFGF to 
the 3T3 cell surface. The results are in agreement with those obtained with the 
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FIGURE 5. 7: Ability of FITC-cHRG to bind to BALB/c 3T3 cells in 
the presence and absence of heparin (200ug/ml). FITC-cHRG 
and heparin were incubated together for 30min on ice before 
being added to cells and incubated for a further 30min on ice. 
After washing, the FITC-cHRG remaining bound to the cells in 
the presence and absence of heparin was determined by a 
FACScan. Amount of FITC-cHRG bound to cells is given in 
fluorescence intensity units (FIU). 
FIGURE 5.8: Ability of different concentrations of (A) cHRG ( • ) and 
hHRG ( o) and (B) aFGF (e ) and bFGF ( o ) to inhibit the binding of 
FITC-cHRG (SOug/ml) to BALB/c 3T3 cells. cHRG, hHRG, aFGF or 
bFGF were incubated with BALB/c 3T3 cells for 30min on ice before 
FITC-cHRG was added to each sample and incubated for a further 1 
hour on ice. After washing, the FITC-cHRG remaining bound to the 
cells in the presence and absence of inhibitor was determined by a 
FACScan. The amount of FITC-cHRG bound to cells is expressed as a 
percent of control binding, ie., that occurring in the absence of inhibitor. 
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FIGURE 5.9: Ability of heparin, bFGF, aFGF, cHRG, hHRG and 
ATIII to inhibit the binding of 1251-bFGF (1 Ong/ml; 0.57nM) to 
BALB/c 3T3 cells. Cells were incubated with the inhibitors for 1 
hour on ice before the addition of 1251-bFGF and a further 2 hours 
incubation on ice. After washing away unbound 1251-bFGF, the 
amount of cell-associated radioactivity was determined by a 
gamma counter. 1251-bFGF binding to the cell surface is 
presented as percent control binding, ie., 1251-bFGF binding 
occurring in the absence of inhibitor. Each value represents the 
mean of triplicate treatments+ SEM· 
Inhibitor Concentration 
(uM) 
heparin 42 
bFGF 5.7 
aFGF 6.3 
cHRG 3.7 
hHRG 6.7 
ATIII 1.1 
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Rose Bengal plate assays (Table 5.1 ). Basic FGF was the most potent 
inhibitor of 1251-bFGF binding, reducing binding to <25°/o of that observed in 
the absence of inhibitor. Acidic FGF, cHRG and hHRG were somewhat less 
effective inhibitors reducing binding to approximately 40-60°/o of the control. In 
agreement with the Rose Bengal plate assay, ATIII was unable to significantly 
inhibit the binding of 1251-bFGF to the 3T3 cell surface. The ability of heparin 
to inhibit 1251-bFGF binding by >80°/o indicates the heparin/HS dependence of 
the binding being observed. Similar inhibition results were obtained with 1251-
aFGF (Fig. 5.10). Heparin, the FGFs and HRGs as well as PF4 significantly 
inhibited the binding of 1251-aFGF to 3T3 cells, whereas ATIII was again 
inactive. These data confirm that all of the heparin binding molecules, except 
ATIII, interact with the same species of HSPG on the 3T3 cell surface and very 
likely with the same or adjacent HS sequences. 
5.2.3. Inhibition of Binding of Heparin Binding Proteins to HSPGs on the 
ECM 
Since FGFs have been shown to be associated with ECM HSPGs in vivo 
(Jeanny et al., 1987; Folkman et al., 1988) it was of interest to assess whether 
the different heparin binding proteins could inhibit the binding of radiolabeled 
FGFs to the ECM. Initial experiments examined the binding of radiolabeled 
FGFs and HRG to bovine corneal endothelial cell ECM in the presence and 
absence of a high concentration of heparin. With 1251-aFGF, binding is clearly 
heparin-dependent and at 50ug/ml of aFGF, binding has still not reached 
saturation (Fig. 5.11 A). Scatchard analysis of the experimental data found 
heparin-inhibitable binding of 1251-aFGF to the ECM to have a dissociation 
constant of 2.7±0.SuM. A similar experiment was performed with 1251-bFGF 
and its Kd determined as 1.7±0.2uM (results not shown). Figure 5.11 B 
demonstrates that 1251-cHRG can also bind to the ECM 1n a heparin-
dependent and saturable manner. Its dissociation constant for heparin-
inhibitable binding sites was determined as 146+37nM. At concentrations of 
1251-cHRG above those indicated, binding could not be inhibited by heparin 
FIGURE 5.10: Ability of bFGF, heparin, aFGF, PF4, cHRG, hHRG 
and ATIII to inhibit the binding of 1251-aFGF (1 Ong/ml; 0.63nM) to 
BALB/c 3T3 cells. Assay conditions and data presentation as 
described in the legend of Figure 5.9. 
Inhibitor Concentration 
(uM) 
heparin 42 
bFGF 5.7 
PF4 0.5 
hHRG 6.7 
aFGF 6.3 
cHRG 3.7 
ATIit 1.1 
0 20 40 60 80 100 
0/o Control Binding 
FIGURE 5.11: Ability of 1251-aFGF (A) and 1251-cHRG (8) to bind to bovine 
corneal endothelial cell extracellular matrix in the presence and absence of 
heparin (250ug/ml). Different concentrations of 12s1-aFGF or 1251-cHRG 
were incubated in the presence and absence of heparin for 1 hour on ice, 
before being added to ECM-coated wells of a 96-well plate. After a further 2 
hour incubation on ice, ECMs were washed free of unbound radioactivity and 
the EC Ms detached by incubation with 4M guanidine-HCI/ 2°/o Triton X-100, 
overnight at 4 't. The amount of 1251-aFGF or 1251-cHRG bound to the 
ECM was determined and values represent the means of triplicates 
treatments. Standard errors of means were < 10 o/o. 
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which may indicate that at high concentrations cHRG binds to low affinity, non-
HSPG, sites in the ECM. Thus the reason for HRG's relatively high binding 
affinity compared with the FGFs, may be due to it binding cooperatively to 
HSPG and non-HSPG sites in the ECM. Such a dual interaction may not occur 
at the cell surface. 
In order to determine whether physiological concentrations of molecules such 
as PF4 and HRG could act as in vivo regulators of FGF activity by modulating 
FGF uptake and release from the ECM, their ability to inhibit the binding of 
physiologically relevant concentrations of 1251-bFGF and 1251-aFGF to the 
ECM was determined. Figures 5.12 and 5.13 show that bFGF, aFGF, PF4, 
cHRG and hHRG are all effective inhibitors of 1251-bFGF and 1251-aFGF 
binding to the ECM, reducing binding by 60-90°/o. As observed in other assays 
ATIII showed no inhibitory activity. The high degree of inhibition by heparin 
(70°/o with bFGF and 95°!o with aFGF) demonstrated the heparin/HS 
dependence of the binding assay. These results show that HRG and PF4, at 
concentrations approaching the physiological level, are able to substantially 
reduce the binding of 1251-aFGF (40ng/ml) and 1251-bFGF (2ng/ml) to the 
ECM. 
5.2.4. Inhibition of FGF Induced Mitogenesis by HRG 
Many attempts were made to determine whether cHRG could inhibit aFGF-
induced 3T3 cell mitogenesis but unfortunately no inhibition of mitogenesis was 
observed. Subsequent binding inhibition studies with cHRG revealed that 
DMEM totally blocked cHRG binding to BALB/c 3T3 cells (Fig. 5.14 & Table 
5.2). The inability of cHRG to bind to cells cultured in DMEM meant that 
mitogenic assays could not be performed in DMEM, the medium to which the 
3T3 cells were accustomed. Furthermore, the cells were unable to proliferate 
and support aFGF-induced mitogenesis in the absence of fetal calf serum when 
cultured in F15, RPMI, and Medium 199, media which were less inhibitory to 
FIGURE 5.12: Ability of bFGF, aFGF, heparin , PF4, hHRG, cHRG 
and ATIII to inhibit the binding of 1251-bFGF (2ng/ml; 0.11 nM) to 
bovine corneal endothelial cell ECM. ECMs were incubated with 
inhibitors for 1 hour on ice before the addition of 1251-bFGF which 
was followed by 2 hours incubation on ice. After washing away 
unbound 1251-bFGF, bound growth factor was released from the 
ECM by incubation with 4M guanidine HCI/ 2°/o Triton X-100 
overnight at 40c. The amount of 1251-bFGF released was 
determined and is presented as percent control binding, ie., 1251-
bFGF binding to ECM in the absence of inhibitor. Each value 
represents the mean of triplicate treatments+ SEM. 
Inhibitor Concentration 
(uM) 
bFGF 5.7 
heparin 8.3 
aFGF 6.3 
PF4 1.0 
cHRG 0.7 
hHRG 1.3 
ATIII 1.1 
0 20 40 60 80 100 120 
0/o Control Binding 
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FIGURE 5.13: Ability of heparin, bFGF, PF4, hHRG, aFGF, cHRG 
and ATIII to inhibit the binding of 1251-aFGF (40ng/ml; 2.5nM) to 
bovine corneal endothelial cell ECM. Assay conditions and data 
presentation as described in the legend of Figure 5.12. 
Inhibitor 
bFGF 
aFGF 
heparin 
PF4 
hHRG 
cHRG 
ATIII 
Concentration 
(uM) 
5.7 
6.3 
8.3 
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1.3 
0.7 
1 .1 
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HAG binding (Table 5.2). Until the inhibitory component in DMEM is identified 
and removed we are unable to determine whether HAG can act as an anti-
proliferative agent. 
Table 5.2: Effect of various media on the binding of cHAG to BALB/c 3T3 
cellsa 
Medium Median FIU Percent Control Binding 
Hanks BSS 365 100 
DMEM 7 2 
199 93 25 
F15 60 16 
RPMI 1640 90 25 
a Control binding represents HAG binding to cells in Hanks BSS/0.1 °/oBSA. 
Background binding in the absence of HRG was 1 °/o of control binding. 
Chicken HRG binding to the BALB/c 3T3 cells was detected by indirect 
immunofluorescence using an anti-cHAG antibody and FITC-Protein A. 
Fluorescence was quantified by a FACScan and the median fluorescence 
intensity of each peak determined as fluorescence intensity units (FIU). 
FIGURE 5.14: FACScan profile showing the effect of DMEM on the 
binding of cHRG to 3T3 cells as measured by indirect 
immunofluorescence. The red line represents background binding, 
the blue line represents cHRG binding in the presence of DMEM 
and the green line represents control cHRG binding in Hanks 
BSS/0.1 °/oBSA. 
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5.3. Discussion 
The major finding to result from this study is that aFGF, bFGF, cHRG , hHRG 
and PF4 all interact with the same HSPG species on the 3T3 cell surface. It 
appears likely that they either bind to the same or to adjacent saccharide 
sequences on the cell surface HS chains. In contrast, ATIII fails to bind to the 
HS structure recognized by these molecules. This conclusion was based on 
data obtained from three separate binding assays, namely inhibition of the 
interaction of immobilized HRG and FGFs, soluble fluoresceinated cHRG and 
soluble radiolabeled FGFs, with 3T3 HSPGs. Cell surface HSPGs have been 
previously shown to be of critical importance in FGFR activation by FGFs 
(Vayon et al., 1991; Rapraeger et al., 1991; Olwin & Rapraeger 1992) and the 
ability of molecules such as HRG and PF4 to compete with FGFs for binding to 
the same HSPGs suggests that HRG and PF4 may play a fundamental role in 
regulating FGF activity. Support for this idea comes from the observation that 
HRG and PF4 are very effective inhibitors of the binding of physiological 
concentrations of radiolabeled acidic and basic FGF to cell surface HSPGs. 
The continuous presence of HRG in plasma at concentrations as high as 
1 OOug/ml and its ability to substantially inhibit the binding of aFGF and bFGF to 
HSPGs on the 3T3 cell surface makes it a prime candidate as a regulator of 
FGF activity. It is envisioned that by binding to HSPGs on the cell surface, 
HRG would prevent acidic and basic FGF from constitutively stimulating 
FGFRs. Unfortunately, attempts to determine whether HRG can inhibit FGF-
induced proliferation were thwarted by the discovery that HRG was unable to 
interact with HSPGs in the medium in which the fibroblasts were cultured 
(Table 5.2). 
PF4's distribution is highly localized, being released from blood platelets at 
sites of vascular injury, and is therefore less likely than HRG to act as a general 
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modulator of FGF activity. In addition PF4 has a very low plasma concentration 
(Lane et al., 1984), although, FGFs do play an important role in wound repair 
and, like PF4, are released at sites of vascular injury. At such sites PF4 may, 
on the one hand, aid the displacement of FGFs from the ECM, thus enabling 
the FGFs to bind to the cell surface and activate FGFRs and on the other hand, 
inhibit FGF-induced proliferation by masking cell surface HSPGs required for 
FGF action. PF4 has already been reported to have antiangiogenic properties, 
possibly as a result of its ability to inhibit endothelial cell proliferation (Taylor & 
Folkman 1982; Sharpe et al., 1990). The ability of PF4 to potently inhibit the 
binding of acidic and basic FGF to HSPGs on the fibroblast cell surface 
suggests that when added exogenously, PF4 inhibits FGF-induced proliferation 
by successfully competing with the FGFs for cell surface HSPGs. Although 
Maione et al.,(1990) found that PF4 can inhibit FGF-induced HUVE cell 
·proliferation but not FGF-induced fibroblast proliferation, my results would tend 
to suggest that PF4 would be able to inhibit fibroblast proliferation by inhibiting 
FGF binding to the cell surface. Unfortunately I did not have sufficient supplies 
of PF4 to test its antiproliferative capacities. Nevertheless, these results do 
reinforce the idea that PF4's antiproliferative and antiangiogenic activities are 
due to its ability to inhibit FGFs from binding to the cell surface and activating 
their receptors. 
Although the FGFs, HRGs and PF4 all interact with the same HSPG species, 
they differ in their affinities for them. Basic FGF and PF4 have the highest 
binding affinity, followed by cHRG and aFGF which appear to exhibit 
approximately equal affinity, and hHRG has the lowest affinity. The inhibition 
data presented in this chapter, using three different binding assays, confirmed 
that aFGF has a substantially lower affinity (approx. 5 fold) for 3T3 cell surface 
HSPG than bFGF (see section 3.2.1 ). The data is also in agreement with D.A. 
Lane's observation (unpublished) that HRG is eluted from immobilized heparin 
with lower concentrations of NaCl than PF4 suggesting that PF4 has a higher 
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affinity for heparin than HAG. This may be due to PF4's tetrameric structure 
and its ability to form a complex with up to four heparin-like molecules 
simultaneously (Marshall et al., 1984) while human HAG probably has only one 
heparin binding site per molecule (Burch et al., 1987). Cross blocking studies 
also indicated that ATIII did not interact with the HS sequences on 3T3 cells 
recognized by the FGFs and HAGs. Lane et al.,(1986) also found that both 
PF4 and HAG interact with HS sequences in addition to the pentasaccharide 
sequence with which ATIII binds. 
Acidic and basic FGF are known to be localized to basement membranes (BM), 
both growth factors having been identified in ECMs deposited by cultured 
myoblasts (Weiner & Swain 1989) and endothelial cells (Baird & Ling 1987; 
Vlodavsky et al., 1987a). Basic FGF is also present in BMs of rat fetus 
(Gonzalez et al., 1990), bovine cornea (Folkman et al., 1988) and human blood 
' 
vessels (Cordon-Cardo et al., 1990). Scatchard analysis of heparin-inhibitable 
binding of acidic and basic FGF to the ECM suggests that both FGFs bind to 
HSPG in the ECM with considerably lower affinity (Kds of 2.7 + 0.5uM and 1.7 
+ 0.2uM, respectively) than they are thought to bind to HSPGs on the cell 
surface (Kd 2-1 OnM) (Moscatelli 1987). Thus, FGFs may be able to pass from 
low affinity receptors in the ECM to relatively higher affinity HSPGs on the cell 
surface according to kinetic equilibrium. The ability of HAG to also bind to the 
ECM in a heparin-inhibitable manner suggests that HAG may also be able to 
modulate FGF activity by regulating its release from the matrix. 
Although matrix bound FGF is known to be biologically active, the presence of 
FGF in BMs in vivo does not appear to stimulate the overlying endothelial and 
epithelial cells to proliferate (D'Amore 1990a). It has therefore been suggested 
that while bound to HSs in the ECM/BM, FGFs are not accessible to their cell 
surface receptors. Indeed, the ECM/BM has been proposed to act as a 
physiological reservoir for growth factors holding them in a stable and protected 
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form until they are required to bind to and activate FGFRs on the cell surface. 
This would also explain how FGFs are prevented from acting on and 
stimulating vascular endothelium continuously. It is not clear though, how 
FGFs are released from the ECM when they are required to stimulate cell 
proliferation. Current hypotheses suggest that HS-bound matrix-associated 
FGFs might be released by locally high concentrations of specific HS-
degrading enzymes (heparanases) (Flaumenhaft et al., 1989) or by locally high 
concentrations of heparin which may originate from degranulating mast cells 
(Jansson et al., 1975; Yurt et al., 1977). In support of the former possibility, 
lshai-Michaeli et al., (1990) have demonstrated the release of active bFGF 
from the ECM by intact platelets, neutrophils and lymphoma cells, all of which 
express heparanase activity. It has also been proposed that physical damage 
to the matrix occurring during injury, or damage occurring during tissue 
remodeling, could result in the release of FGFs from their storage sites 
(Folkman et al., 1988). The data presented in this chapter suggest that an 
alternative means by which FGFs could be released from the ECM would be if 
HRG or PF4 were to displace them from their HSPG binding sites in the ECM, 
making FGF available for binding to HSPGs on the cell surface. 
In conclusion, studies described in this chapter have demonstrated that PF4 
and HRG are potentially important regulators of FGF action by competing for 
the same or closely associated HS motifs on HSPGs. These molecules could 
regulate FGF action in both a positive and negative sense, on the one hand by 
displacing FGF from ECM/BM and making these FGFs available to responsive 
cells, and on the other hand by masking HSPGs on responsive cells and 
preventing FGFR activation. 
115 
5.4. Summary 
Recent studies have shown that FGFs need to interact with cell surface HSPG 
in order to bind to and activate FGFR. In this chapter, three major heparin-
binding proteins, histidine-rich glycoprotein (HAG), antithrombin Ill (ATIII) and 
platelet factor 4 (PF4) were tested for their ability to act as modulators of FGF 
activity by competing with the FGFs for cell surface HSPGs. HRG and ATIII 
are present at high concentrations in plasma whereas PF4 is released locally at 
high concentrations by degranulating platelets. HAG from both chicken and 
human, and human PF4 were demonstrated to compete with each other and 
with acidic and basic FGF for binding to BALB/c 3T3 cell surface HSPGs, 
whereas ATIII did not compete. Thus HAG, PF4, aFGF and bFGF all interact 
with the same HS chains on the 3T3 cell surface, either binding to the same or 
to adjacent saccharide sequences on the chains. In terms of their relative 
binding affinity for cell surface HSPGs, the hierarchy was shown to be PF4 > 
bFGF > aFGF = cHRG > hHRG. HAG was also shown to bind to ECMs, 
originating from bovine corneal endothelial cells, ,n a heparin-inhibitable 
manner. Indeed both HAG and PF4 were shown to effectively inhibit the 
binding of 1251-aFGF and 1251-bFGF to ECMs, at concentrations thought to 
occur in vivo. Based on these findings, it is proposed that HAG and PF4 may 
act as positive regulators of FGF activity by displacing FGF from the ECM or 
BM and making FGF available to responsive cells. Alternatively, they could act 
as negative regulators by masking HSPGs on responsive cells and preventing 
FG FR activation. 
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Chapter 6 
Final Discussion 
In this thesis several aspects of the roles of soluble heparin and cell surface 
HSPGs in the functioning of acidic and basic FGF were examined. The 
experimental results obtained may be divided into the three sections, 
considered below. 
6.1. Role of Cell Surface HSPGs in Binding of FGFs to the FGFR 
It is now clear that the binding of FGF to heparin or HSPG is an essential 
requirement for activation of the FGF receptor by FGFs (Vayon et al 1991; 
Rapraeger et al., 1991; Olwin & Rapraeger 1992) and the experimental work 
presented in this thesis confirms and expands upon this finding. Two models 
have been proposed to explain the role of HSPG/heparin in the interaction of 
bFGF with the FGFR. Vayon et al.,(1991) have proposed that the interaction of 
HSPG or heparin with bFGF produces a conformational change in bFGF which 
allows it to interact with the FGFR (Fig. 1.8). In contrast, Nugent & Edelman 
(1992) have proposed that the formation of a ternary complex either between 
bFGF, FGFR and HSPG or between bFGF, FGFR, heparin and heparin binding 
sites on the cell surface, is required to produce an interaction of sufficiently high 
avidity for receptor activation to occur (Fig. 1.9). In the light of a recent finding 
by Kan et al.,(1993) that FGFR1 possesses a heparin binding site which is 
essential for FGF binding to FGFR 1, a ternary complex could also result from 
an FGF/heparin complex crosslinking heparin- and FGF-binding sites on the 
same FGFR. 
In this thesis, evidence has been presented which suggests that both a 
heparin/HSPG-induced conformational change in the growth factor and the 
formation of a ternary complex may be required for the interaction of FGF with 
the FGFR. Furthermore, I have obtained evidence to suggest that aFGF and 
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bFGF have different requirements for binding to FGFR 1 which may have 
implications for understanding how cells and tissues can selectively respond to 
individual members of the FGF family. I will now summarize the evidence I 
have obtained which supports the ternary complex model of FGFR activation. 
Firstly, in chapter 3, bFGF was shown to dissociate from the FGFR at least 20-
fold slower in the presence of HSPGs than in their absence which confirms the 
finding of Nugent & Edelman (1992) and suggests that HSPGs are an essential 
requirement for "high avidity" binding of bFGF to FGFR. It cannot be assumed 
that the rate of FGF dissociation from the FGFR would change as a result of an 
increase in affinity of FGF for its receptor, arising from a conformational change 
in the growth factor. In fact, there is considerable evidence showing that the 
affinity constant of a receptor for a ligand applies only at equilibrium and is 
independent of the dissociation and association rate of the receptor-ligand 
interaction (Williams 1991 ). Thus, the formation of a ternary complex as a 
result of crosslinking of the FGFR and HSPG by FGF is more likely to stabilize 
the binding of the growth factor to its receptor and prolong the period that it is 
bound to the FGFR, ie., decrease the dissociation rate. Secondly, it was 
shown that aFGF, in the presence of cell surface HSPGs, dissociates from the 
FGFR at least 10-fold faster than does bFGF. This result, together with the 
demonstration that aFGF has an approximately 5-fold lower affinity for cell 
surface HSPGs than bFGF, suggests that at low concentrations, aFGF is not 
able to utilize 3T3 cell surface HSPGs to form ternary complexes as effectively 
as does bFGF. 
Further support for the ternary complex model comes from comparative studies 
performed with heparin and CR-heparin in chapter 4 which showed that CR-
heparin was much less effective than native heparin at enabling aFGF to form a 
stable interaction with the FGFR. The ability of CR-heparin to bind aFGF 
equally as well as does heparin and to protect aFGF from digestion by trypsin, 
makes it unlikely that CR-heparin is unable to induce a conformational change 
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in the molecule. It seems more plausible that CR-heparin fails to enable the 
formation of a stable ternary complex. In addition, the demonstration that CR-
heparin is only able to bind to 1/3 the number of heparin receptors on the cell 
surface to which heparin binds, suggests that CR-heparin may be less able to 
form ternary complexes with FGF, FGFR and heparin binding sites, as can 
occur with heparin. There may in fact be specific heparin binding receptors on 
the cell surface to which CR-heparin does not bind which are critical for the 
formation of such ternary complexes with the FGFRs. 
Furthermore, preliminary data from the laboratory of David Ornitz suggests that 
CR-heparin has a considerably lower affinity than heparin for the heparin 
binding site on the FGFR. In the absence of FGF, CR-heparin was at least 10-
fold less able than heparin to bind to the soluble form of murine FGFR1 and 
approximately 25-fold less able to bind to the soluble form of murine FGFR3. 
One would predict that CR-heparin's poor ability to interact with the heparin 
binding site on FGFR1 would prevent the formation of stable ternary complexes 
between FGF and the FGFR. Indeed, in chapter 4, CR-heparin was observed 
to have a reduced ability to enhance the binding of aFGF to the FGFR on 
heparinase treated cells. Moreover, in the soluble receptor binding assay, CR-
heparin was totally unable to enhance the binding of bFGF to FGFR1 and only 
partially able to restore the binding of aFGF to FGFR1. 
Finally, although CR-heparin was completely unable to enhance the binding of 
bFGF to FGFR1 in the soluble receptor assay, preliminary results from David 
Ornitz's laboratory using BAF3 cells transfected with mFR1, show that CR-
heparin does result in some enhancement of bFGF-induced mitogenesis but 
not as much as with native heparin which indicates that other cell surface 
molecules (ie., heparin binding molecules) may be involved in the formation of 
ternary complexes. 
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The strongest evidence obtained in favour of heparin inducing a 
conformational change in FGF comes from my observation that heparin 
increased the net amount of acidic and basic FGF bound to the FGFR on 
heparinase treated cells without affecting FGF association or dissociation rates 
(see chapter 3). If heparin was replacing the role of HSPGs in the formation of 
a ternary complex, one would have expected heparin to produce a decrease in 
the dissociation rate of FGF from the FGFR. However, the increase in the net 
amount of FGF bound to the FGFR in the presence of heparin, suggests that 
heparin may have induced a conformational change in the growth factor which 
increased its affinity for the FGFR, thereby enabling more receptors to be 
engaged. 
Further evidence in favour of a conformational change occurring in aFGF, but 
not bFGF, comes from the results of the soluble receptor assay (see chapter 4) 
in which CR-heparin partially restored the binding of aFGF to FGFR 1 but totally 
failed to enhance the binding of bFGF to the same receptor. Since CR-heparin 
was found to bind to acidic and basic FGF equally as well as native heparin, 
this inactivity is not due to an inability to bind the growth factors. It may indicate 
though, that CR-heparin was able to induce a conformational change in aFGF, 
but not facilitate the formation of a ternary complex, thus allowing some 
binding of aFGF to its receptor. In contrast, CR-heparin was unable to induce 
either a conformational change or the formation of a ternary complex with 
bFGF. 
In conclusion, it appears that HSPGs and heparin are able to mediate both a 
conformational change in the growth factor and the formation of a ternary 
complex and that both are important in the interaction of FGF with FGFR 1. It is 
highly likely that the relative balance of conformational change versus ternary 
complex formation may vary with each FGFR and between FGFs and a given 
FGFR. In the case of FGFR 1, I propose that for optimal binding of aFGF to 
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FGFR1 to occur, a heparin-induced conformational change in aFGF must be 
followed by the formation of a ternary complex, whereas for the binding of 
bFGF to FGFR1, only the formation of a ternary complex is required. 
6.2. Mode of Potentiation of aFGF Induced Mitogenic Activity by Heparin 
For the last ten years it has been known that heparin potentiates the biological 
activity of aFGF in vitro (Thornton et al., 1983; Orlidge & D'Amore 1986; 
Schreiber et al., 1985), although the mechanism by which it does so is not fully 
understood. In chapter 3 of this thesis, I have confirmed that heparin 
potentiates aFGF-induced mitogenesis on BALB/c 3T3 cells and HUVE cells to 
a significantly greater extent than it does bFGF-induced mitogenesis. 
Moreover, in the absence of exogenously added heparin, aFGF's potency as a 
mitogen in vitro is markedly less than that of bFGF. It is not until heparin is 
added into the culture with aFGF that aFGF's potency increases to levels 
comparable with that of bFGF. 
From my data, it appears that the difference in potency of aFGF and bFGF is 
due to the relative lower binding affinity of aFGF for the 3T3 cell surface 
HSPGs, ie., approximately a 5 fold difference based on my measurements. By 
having a higher affinity for cell surface HSPGs, bFGF is able to activate FGFRs 
at much lower concentrations than aFGF. On the other hand, aFGF very likely 
has a higher affinity for heparin than it does for 3T3 HSPGs and is thus able to 
utilize heparin more effectively in interacting with the FGFR (whether a 
conformational change or ternary complex is required). Thus heparin 
increases the number of productive complexes formed between aFGF and its 
FGFR at limiting concentrations of aFGF, resulting in a potentiation of aFGF's 
mitogenic activity. Therefore, providing that the correct FGFR is expressed on 
the cell surface, FGF induced mitogenic activity appears to be directly related 
to the affinity of the growth factor for cell surface HSPGs. Indeed, FGF activity 
during murine neural precursor cell development in vivo has been shown to be 
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regulated in part, by the affinity of aFGF and bFGF for a particular species of 
endogenous HSPG (Nurcombe et al., 1993). HSPGs from E9 which bind bFGF 
at least four times better than aFGF were approximately seven times better at 
stimulating neural epithelial cell division with bFGF than with aFGF whereas the 
E11 HSPGs which bind aFGF better, were four times better at stimulating cell 
division with aFGF than with bFGF. 
6.3. Inhibition of Binding of FGFs to Cell Surface HSPGs by Heparin 
Binding Proteins 
Acidic and basic FGF are known to have a role in various pathological 
processes. For example, FGFs have been isolated from cultured tumour cells 
and from tumour tissue (reviewed by Gospodarowicz 1987b) and are thought to 
stimulate tumour cell growth as autocrine growth factors and as tumour 
angiogenic factors (Gospodarowicz et al., 1987b; Schweigerer et al. , 1987b; 
Folkman & Klagsbrun 1987; Burgess & Maciag 1989; Nagao & Nishikawa 
1989). In addition, FGFs may promote solid tumour growth by vascularizing 
the invading tissue (Folkman & Klagsbrun 1987), promote arthritis by 
stimulating the invasion of new capillary blood vessels into joints, and in 
diabetes, stimulate capillaries in the retina to invade the vitreous, resulting in 
blindness (Folkman 1987). Compounds which can selectively inhibit the 
activation of FGFAs by FGFs could be important in the prevention of such 
angiogenesis-related pathologies. Most attempts at developing inhibitors have 
focussed on inhibiting the interaction of FGF with the FGFA. An alternative 
means of inhibiting activation of the FGFA would be by inhibiting the interaction 
between FGF and cell surface HSPGs. 
In chapter 5, I have examined several naturally occurring heparin binding 
proteins, namely HAG, PF4 and ATIII, for their ability to disrupt the interaction 
between FGFs and HSPGs. Interestingly, it was found that HAG and PF4, but 
not ATIII, interact with the same HSPG species on the 3T3 cell surface as do 
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acidic and basic FGF. Acidic and basic FGF also interact with the same 
HSPGs as each other. However, it is not clear whether aFGF, bFGF, cHRG, 
hHRG and PF4 all bind to the same, or to adjacent saccharide sequences on 
the HS chains. Furthermore, HRG and PF4 were found to be very effective 
inhibitors of the binding of radiolabeled acidic and basic FGF, at physiological 
concentrations, to HSPGs situated both on the 3T3 cell surface and in bovine 
corneal endothelial cell ECMs. Unfortunately technical problems prevented me 
from testing HRG and PF4 for their ability to inhibit FGF-induced proliferation. 
However, the observations described above, suggest that HRG and PF4 may 
actually play a role in regulating FGF activity in vivo. It is proposed that HRG, 
which is present in plasma continuously and at concentrations as high as 
1 OOug/ml, by binding to HSPGs on the cell surface would prevent acidic and 
basic FGF from constitutively stimulating FGFAs. Very little is currently known 
about how FGFs are kept in abeyance until they are required to activate their 
receptors. On the other hand, PF4 tends to be localized at sites of vascular 
injury. However, at such sites it may be able to aid the displacement of FGFs 
from the ECM, thus enabling them to bind to cell surface HSPGs and activate 
the FGFA. A similar situation may apply for HAG. Alternatively, PF4 may act 
as an inhibitor of FGF-induced proliferation by masking cell surface HSPGs 
required for FGF action. 
6.4. Future Work 
A number of interesting experiments need to be performed to clarify some of 
the observations reported upon in this thesis. Of particular importance is the 
identity and action of the component in DMEM which is inhibitory to HAG 
action. Once identified, this component could be removed from the culture 
medium and HAG tested for its ability to act as an antiproliferative agent. A 
related study would be to test the ability of HAG to bind to the two forms of 
differentially glycosylated HSPG, isolated by Nurcombe et al.,(1993) which 
exhibit specific affinities for aFGF or bFGF. If HAG does bind to these, it would 
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be of interest to test the ability of cHRG to displace FGFs from these HSPGs 
which should give some indication as to whether HAG could actually displace 
FGFs from cell surface HSPGs in vivo. In addition, experiments could be 
attempted to determine whether HAG has the ability to inhibit the binding of 
heparin/HSPG to the heparin binding site on FGFR 1 and FGFR3 in the soluble 
receptor binding assay. If so, it would suggest that HAG has the potential to 
act as an inhibitor of FGFR activation. Eventually, it would be interesting to 
determine the particular saccharide sequence on heparin/HSPG with which 
HAG interacts and compare it to that with which the FGFs bind (Turnbull et al 
1992; Habuchi et al 1992). 
Further work with CR-heparin and its fragments, in collaboration with Dr Ornitz, 
may help to clarify the different requirements that acidic and basic FGF appear 
to have for binding to FGFR 1, in the soluble receptor binding assay. It would 
also be interesting to compare the requirements of the two growth factors for 
binding to some of the other FGFRs with a view to understanding the role of 
conformational change versus ternary complex formation in determining the 
specificity of the receptor/ligand interaction obtained. 
A longer term study would be the examination of the role of FGFs and other 
growth factors, and the expression of their receptors, during angiogenesis. 
Many of the pathologies in which FGFs have been implicated appear to be 
related to stimulation of blood vessel growth and therefore, an area of 
considerable potential is the development of inhibitors of angiogenesis and 
application of them to inhibition of tumour growth. One strategy would be to 
develop and screen for, sugar fragments able to inhibit angiogenesis. Sugar 
fragments unable to bind FGFs but able to bind to and block the heparin 
binding site on the FGFR would be expected to inhibit FGF activation of the 
FGFR as would sugar fragments able to bind FGFs, but unable to interact with 
the heparin binding site on the FGFR. Whatever the outcome of the studies 
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outlined briefly above, it is clear from my work and the work of other 
laboratories that HSPGs play a key role in the functioning of many heparin-
binding growth factors. 
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